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KANSREKENING 
 
Kop of munt, bekend geleuter, 
dat is een probleem van niks, 
Kans een half, dat weet een kleuter, 
op het hoofd van Beatrix. 
 
Maar hoe groot zijn onze kansen 
in de levensloterij? 
Valt de prijs en gaan we dansen? 
Of gaat hij je neus voorbij? 
 
Hoe gaan dochters eerste stapjes? 
Valt ze om of houdt ze moed? 
En die dubieuze grapjes, 
vallen ze verkeerd of goed? 
 
Valt het tuinfeest in het water? 
Valt de voordeur in het slot? 
Valt de schemering wat later? 
Valt het mee of valt het schot? 
 
Zekerheid bestaat voor allen 
enkel op de levensvraag, 
hoe je brood met jam zal vallen: 
Altijd met de jam omlaag. 
 
 
MARJOLEIN KOOL 
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Chapter 1 
 11  
Cystic fibrosis (CF) is a common hereditary, multisystem disease leading to significant 
morbidity and early death. For many autosomal recessive diseases, such as CF, it is possible to 
investigate whether a person is an unaffected carrier. If both partners are carriers, each child 
has a 1-in-4 risk of having CF. Population screening for CF carriers is possible because there is 
a suitable test available, and it merits evaluation because CF is a common, serious disease, for 
which there is no satisfactory treatment. Furthermore, reproductive options are available for 
carrier couples. A CF carrier screening programme enables the participants to determine their 
risk of having an affected child, and to take a decision on the basis of that knowledge. In most 
countries, population screening for CF carriers is not included in standard medical care, and the 
debate centres on the question of whether it is, indeed, desirable. This thesis addresses issues 
related to the desirability and feasibility of offering preconceptional CF carrier couple 
screening in the Netherlands.  
This Chapter first provides some background information about the disease itself and 
different aspects of CF carrier screening. A description of the objectives and outline of the 
thesis will follow this. 
 
1.1 The disease cystic fibrosis 
 
Clinical background 
Cystic fibrosis (CF, mucoviscidosis) is one of the most common autosomal recessive disorders 
affecting people of European descent. The disease is characterised by severe chronic respiratory 
infections and gastrointestinal problems (pancreas insufficiency, meconium ileus), caused by the 
accumulation of thick mucus. Other characteristics are growth problems, high sweat sodium 
concentrations, and male infertility.1 2 The clinical severity and course of CF is variable. 
 Most patients with CF are diagnosed within the first two years of life, although there is 
substantial variability in the age at onset of CF symptoms.3 Confirmation of the diagnosis is 
usually obtained from a sweat test and, more recently, DNA mutation analysis. The aim of 
treatment for CF is to prevent or reduce the progressive decline in pulmonary function, and to 
improve nutritional status and physical condition. Treatment is best managed by a 
multidisciplinary team.2 4 5 Most patients need spray therapy and physiotherapy, a high-energy diet 
and daily medication, such as antibiotics, anti-inflammatory drugs and pancreatic enzyme 
replacement. Advances in treatment have considerably improved the prognosis for patients with 
CF. However, as more CF patients are surviving into adulthood, the frequency of other 
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complications increases such as CF related diabetes mellitus6 and digestive tract cancer.7 
Moreover, issues concerning reproductive health and pregnancy management are also arising.8  
 CF patients usually die as a result of respiratory failure caused by damage to the lungs. 
Lung transplantation may prolong the life of an end-stage sufferer.9 Gene therapy is currently 
being investigated, but does not yet seem to be readily available in the near future.10 Current 
treatment for CF is very intensive, and demands a great deal of support from the family, friends 
and health care system.11 It also affects the patient’s quality of life.12 Although the medical care 
provided has greatly improved over the years, CF is still a disease that is incurable. In general, 
during the course of the disease, the symptoms get worse, reducing life expectancy. Newborns 
now have a median life expectancy of approximately 30 to 40 years.13 14 
 
Genetic background  
The gene responsible for CF is located on chromosome 7, and was identified in 1989.15-17 The 
gene encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and its 
principle function is transmembrane transfer of chloride ions. In CF, absence or dysfunction of 
the protein, caused by mutations in the CF gene, results in an abnormal salt transport, thereby 
increasing the viscosity of mucus in organs throughout the body. Since the identification of the 
gene, almost 1000 mutations have been found, most of which are very rare 
(http://www.genet.sickkids.on.ca/cftr/). The most common mutation, the delta F508 deletion, 
accounts for approximately 70% of the total number of mutations in populations worldwide.18 
On the basis of DNA-testing, it is difficult to predict the clinical phenotype from the genotype. 
There is a correlation between genotype and phenotype with regard to pancreatic 
insufficiency,19 but this correlation is less clear for pulmonary manifestations.20 
 
Epidemiological background  
There are regional differences in the frequencies and distribution of CFTR mutations,21 but the 
greatest variation occurs across ethnical and racial groups.22 23 The occurrence is most frequent 
in individuals with Northern/Western European ancestry, with a birth prevalence of CF of 
approximately 1 in 2500-4000. In the Netherlands, the birth prevalence is 1 in 3600.24 This 
means that with a population of 16 million people, approximately 50 children with CF are born 
each year. The total number of CF patients in the Netherlands is now estimated to be 
approximately 1200 (J. Noordhoek, personal communication), and this number will arise with 
the increasing life expectancy. 
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Carriers of CF 
In populations that are of Northern/Western European origin, approximately 1 in 25-30 
individuals is a carrier of a CFTR-gene mutation (1 in 30 in the Netherlands24 25). As far as we 
know, there is no health problem for carriers due to their status. In fact, to explain the high 
frequency of the gene, heterozygote advantage has been suggested.26 If both partners in a 
couple are carriers, they have a 1-in-4 risk of having a child with CF. Most carriers do not 
know that they are a carrier, so they are not aware of their risk and, in most cases, the diagnosis 
of a child with CF is highly unexpected. Over 80% of the patients are born in families with no 
history of CF,27 and it has therefore been suggested that CF carrier screening in the general 
population is warranted.28-30  
 
1.2 Cystic fibrosis carrier screening 
 
The purpose of carrier screening 
Population-based carrier screening programmes aimed at the identification of CF carrier status in 
couples before the birth or conception of a child, make it possible to inform these couples about 
their risk of having a child with CF. The purpose of CF carrier screening then is to offer these 
couples the opportunity to anticipate on this increased risk, and to make informed reproductive 
decisions.3 Possible reproductive options for carrier couples include avoiding pregnancy, 
adoption, acceptance of the risk of having a child with CF, prenatal diagnosis and selective 
termination of the pregnancy, preparation for a child with CF, pre-implantation genetic diagnosis 
to select unaffected zygotes, or a pregnancy induced either by means of artificial insemination 
with sperm or egg-cell donation from a screened donor.  
Although one of the consequences of screening may be a reduction in the number of births 
of children with CF, or a reduction in the costs of health care, such reductions are not a purpose of 
the screening.31 32 A screening programme that results in a strong reduction in the number of 
children born with CF, but does not enable participants to make an autonomous informed 
decision, fails completely.33 
 
Target groups for carrier screening 
Carrier screening can be considered for different target groups, including pregnant women and 
their partners (pregnancy or prenatal screening), individuals or couples before pregnancy 
(preconceptional screening), high school students (school screening), and newborns (neonatal 
screening). Each approach has its own pros and cons.34 35 The advantage of neonatal screening 
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is that it can be added to the existing newborn screening programmes. If a newborn turns out to 
be carrier, the parents can be tested, and if both are carriers they can use this information to 
make decisions on future reproductive options. Neonatal screening has the disadvantage that 
those tested cannot decide for themselves whether or not they want to know if they are a 
carrier.30 High school screening has the advantage that it can be coupled with a formal 
educational component. Acceptance of school screening for CF was high in young 
adolescents,36 37 but it has been suggested that it has psychological disadvantages, such as 
stigmatisation or peer pressure when testing occurs in a group.38 39 Furthermore, the time-
interval between knowing the test-results and using the information is long. Screening all 
individuals of reproductive age is unlikely to be systematic, as many people will not consider 
testing to be relevant,27 40 although a recent pilot study among individuals in primary care 
suggests otherwise.41 When weighing all benefits and drawbacks, pregnancy screening and 
preconceptional couple screening seem to be the best options for carrier screening in the 
general population. Pregnancy screening has a practical advantage because of existing 
facilities, and since most pregnant women contact their general practitioner or visit antenatal 
clinics, the target group is easy to reach. A disadvantage is that this type of screening leaves 
limited reproductive options if both partners are carriers, and might impose a time constraint 
when decisions about prenatal diagnosis have to be made. Preconceptional screening provides 
a maximum number of reproductive options and a minimum of (time) constraint.42 However, 
one disadvantage of preconceptional screening is the absence, in most countries, of a 
preconceptional consultation system, and therefore considerable effort must be made to reach 
the target population, i.e. those contemplating pregnancy.  
In view of (a) current legislation, (b) the high percentage (85%) of planned 
pregnancies,43 and (c) the relative late stage in which pregnant women contact a health care 
worker, the preconceptional approach would seem to be the most suitable way of CF carrier 
screening in the Netherlands.  
 
Methodological issues in pregnancy screening and preconceptional screening 
One of the main technical problems with CF carrier screening is that the test to identify carriers 
is not 100% sensitive, because not all mutations are known. In most populations that are of 
European origin, approximately 90% of CF mutations can be detected.3 This means that for 
couples in which a mutation is detected in one of the partners, while the other is negative 
tested, there will still be a chance that they are a carrier couple. Consequently, these so-called 
+/– couples might be more anxious because they will have a residual risk of having a child 
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with CF while they cannot be offered clear options, such as prenatal diagnosis. Special 
attention must be paid to this imperfect test-sensitivity in the education and counselling 
provided when screening is offered. Apart from laboratory and clerical errors, the specificity of 
the CF carrier test is 100%, which means that none of the non-carriers will have a positive test-
result (false-positive cases). 
In the screening, carriers are detected by means of direct mutation analyses after DNA 
is extracted from buccal scrapes, blood cells or mouthwashes.25 In general, the collection of 
samples by the buccal scraping and mouthwash methods, which are non-invasive and painless, 
are found to be most acceptable by the target group.44-46 
Samples from couples during or before pregnancy can be collected (a) from one partner 
first, and the second only if the first is tested positive (single sampling), or (b) from both 
partners at the same time (double sampling). One advantage of double sampling, compared to 
single sampling, is that it prevents the unnecessary anxiety and need for counselling that might 
arise when one partner is tested positive and the other partner is asked to provide a sample.47 
Costs of double sampling and storage of both samples are minimal, especially when collecting 
mouthwashes. Another advantage of double sampling is that when both partners receive the 
same genetic information at first hand, they share the responsibility, preventing stigmatisation 
of one of the partners. A precondition for double sampling is that both partners are available 
and consent to testing.  
There are two types of couple screening when both samples are available: (a) testing the 
sample of one partner first, and the other only if the first one is found to be carrier (single- 
entry testing), and (b) testing both samples at the same time (double-entry testing). Comparing 
these methods, double-entry incurs higher costs than the single-entry method, because almost 
twice as many people are screened. It is clearly cheaper and easier to test the second partner 
only if the first is found to be a carrier, because only 1 in 25-30 partners require CF screening. 
Another drawback of double-entry testing is the problem of finding twice as many +/– couples. 
Taking into account that the primary purpose of screening is to inform carrier couples about 
their status, it seems unnecessary to test both partners at the same time.  
When analysing the DNA samples, the number of screening steps may vary. One could 
test (a) with the same sensitivity in both partners (one-step testing) or (b) with higher 
sensitivity in the partners of identified carriers (two-step testing). For double-entry testing, the 
partners of identified carriers, who themselves are not carriers in the first step, are tested for a 
larger number of mutations in the second step.48 Ten Kate et al49 showed that with regard to the 
residual risk in couples who were not identified as carriers, it is far more beneficial to test both 
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partners for as many mutations as possible than to start with a first step with a lower sensitivity 
and proceed to a second step with a higher sensitivity. In practice, most screening programmes 
opt for testing with the same sensitivity for both steps. 
 
Disclosure of test-results 
Wald50 proposed a method of couple-based CF screening, in which only those couples in which 
both partners are found to be carriers (+/+ couples) are informed of their carrier status; 
otherwise couples are designated as “screen negative”. In this way, the possible anxiety and 
need for counselling in a +/– couple is circumvented. A disadvantage of non-disclosure of a 
+/– result is that information is withheld from carriers who might wish to take advantage of it 
in the future (with a new partner), or whose families might wish to be tested. The advantages 
and disadvantages of disclosure or non-disclosure of +/– results have generated many debates. 
Some have favoured the strategy proposed by Wald,51 52 although it remains controversial.53 54 
 
The current situation in the Netherlands 
Currently, it is standard practice to offer CF carrier testing to adult individuals who have a 
positive family history of CF, to partners and relatives of identified carriers, and to partners of 
people with CF. In this way, only a minority of carrier couples will be identified, since 80% of 
babies with CF are born to couples with no previous family history of the disease. Furthermore, 
only a minority of relatives in high-risk families request carrier testing.55 Holloway and 
Brock56 have shown that only 8%-24% of all carrier couples would be detected if testing the 
relatives of CF patients was restricted to the second cousin level and closer. 
 Since most parents of children with CF report that they wish they had known their risk 
beforehand, an increase in the number of prospectively identified carrier couples seems 
desirable. Carrier screening in the general population is suggested to be the most favourable 
approach, coupled with testing the relatives of carriers.28 40 An earlier study carried out by Ten 
Kate and Tijmstra57 reported a positive attitude towards carrier screening that would be offered 
to prospective parents among different groups of the population in the Netherlands. 
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Potential harm of genetic screening 
An important criterion that is applied to genetic screening programmes is that they should only 
be considered if the beneficial aspects outweigh the harmful aspects in screening. The 
introduction of genetic carrier screening programmes in the general population raises many 
psychosocial, ethical, legal and economic issues and concerns. The possible adverse effects of 
screening include anxiety caused by information which cannot be used to make positive 
personal choices; undue pressure on individual choice; social stigmatisation of individuals who 
might decline an offer of screening; misuse of the information, and discrimination based on 
test-results after disclosure to third parties such as insurers or employers.58 59 Screening also 
has implications for families, since it not only involves the individual being tested, but also 
other family members who have not consented to testing. Carrier detection has also raised the 
question of whether the option of terminating an affected pregnancy devalues the lives of CF 
patients or impedes the search for a cure.60 Furthermore, questions related to the wide clinical 
and ethnic variability, and the changing prognosis of the disease have been raised, including a 
huge anticipated burden that it would impose on genetic counselling resources.61 
 
Screening and legislation 
The Population Screening Act (WBO) protects the physical and mental health of the Dutch 
population against the possible dangers of screening activities. Thereby, certain screening 
programmes, determined by the scope of the Act, are subject to licensing before they can be 
implemented.62 Licences will be granted only on the conditions that the benefits of the 
proposed screening outweigh the risks for those involved, and that it will be implemented 
correctly and expertly. The Health Council of the Netherlands also formulated criteria 
specifically applied to genetic screening to ensure systematic assessment of screening 
programmes before they are introduced into the community.32 In theory, preconceptional CF 
carrier screening appears to meet most of these criteria.63 
 In 1996, it was not clear to the Health Committee of the Population Screening Act 
whether preconceptional carrier screening would be subject to licensing. Nevertheless, the 
preconceptional CF carrier screening research project was positively evaluated, as if it was 
subject to licensing.64 
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Recommendations for screening in other countries  
In most countries, routine CF carrier screening is not included in standard care. Worldwide, 
recommendations for CF carrier screening are diverse. In 1997, a Consensus Development 
Conference convened by the US National Institutes of Health recommended that “Genetic 
testing for CF should be offered to adults with a positive family history of CF, to partners of 
people with CF, to couples currently planning a pregnancy, and to couples seeking prenatal 
care”.3 Recently, the Subcommittee on Cystic Fibrosis Carrier Screening, established by the 
American College of Medical Genetics, published recommendations and guidelines for optimal 
laboratory testing, interpretation, and counselling.61 In the United Kingdom, the National 
Screening Committee (NSC) decided not to endorse countrywide antenatal carrier screening 
after having considered the Health Technology Assessment (HTA) report by Murray et al.65 
The Antenatal Screening Subgroup of the NSC is keeping the question under review 
(http://www.nsc.nhs.uk/). Preconceptional screening is not discussed in the United Kingdom, 
although the HTA report concluded that evidence supports the availability of preconceptional 
genetic screening for couples who request it.65 
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1.3 Objectives and outline of the thesis 
 
The main objective of this study was to evaluate the desirability and feasibility of a 
preconceptional CF carrier screening programme in the Netherlands. In addition to the 
evaluation of a screening study, carried out between 1997 and 2000, various other aspects of 
CF carrier screening in the general population were investigated by: 
1) reviewing the evaluation of carrier screening programmes described in the literature,  
2) investigating the attitudes among CF parents and patients with CF, and  
3) describing the experiences and reproductive decisions of CF carrier couples who were 
 identified before the birth of a child with CF.  
 
The following research questions were addressed: 
- How are CF carrier screening programmes evaluated in published reports, and do they meet 
certain important screening criteria applied to these programmes? (Chapter 2)  
- What are the attitudes towards reproductive issues and carrier testing among adult CF 
patients and parents of children with CF? (Chapter 3) 
- What are the experiences with genetic carrier testing among carrier couples identified by 
testing in CF families before the birth of an affected child, and what is the influence of the 
prospective risk of CF carrier couples on their reproductive decisions? (Chapter 4)  
- What experiences have been gained from offering CF carrier screening to couples who are 
planning to have children, and what were the attendance rates in four different ways of 
offering screening? (results from the screening study; Chapter 5) 
- Which factors are associated with participation in CF carrier screening among couples who 
are planning to have children? (results from the screening study; Chapter 6) 
- What is the impact of participation in preconceptional CF carrier screening? (results from 
the screening study; Chapter 7) 
- What do couples themselves prefer with regard to the disclosure of test-results? (results 
from the screening study; Chapter 8) 
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Abstract 
The aim of this study was to discuss pilot studies for cystic fibrosis (CF) carrier screening 
before and during pregnancy in the light of important genetic screening criteria. Overall, CF 
carrier screening meets the prerequisites that justify screening. However, more specific criteria 
for the development of screening programmes were not always taken into consideration. Most 
project leaders concentrated on uptake as an important outcome, and less on informed decision-
making. To further investigate the long-term psychological and social effects of genetic 
screening, continuous monitoring of screening projects is recommended. 
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Introduction and purpose 
Genetic screening programmes should meet certain criteria before they can be introduced into 
the community. In the evaluation of a specific screening programme a distinction can be made 
between 1) a conceptual approach to determine whether the subject of the screening would 
meet the criteria if introduced, and 2) a pilot phase.1 The results of the pilot phase serve as a 
basis for a final decision on whether or not to proceed with the introduction of a genetic 
screening programme, and how best to offer and implement this programme. Until now, a 
range of pilot programmes for cystic fibrosis (CF) carrier screening in the general population 
have been developed and completed.2 The project leaders drew certain conclusions from these 
studies, but the question remains as to the extent to which these were evaluated according to 
the genetic screening criteria applied to these programmes. 
The purpose of this study was 1) to determine how project leaders of pilot studies for 
CF carrier screening evaluated their programmes, and 2) to discuss these pilot studies in the 
light of criteria applied to genetic screening, in order to define how they could best be 
evaluated.  
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Selection of pilot studies  
This paper discusses CF carrier screening, as recommended by the National Institutes of Health 
(NIH), that is screening for couples who are currently planning a pregnancy and for couples 
seeking prenatal care.3 Screening programmes aimed at individuals of reproductive age are also 
considered, since these were designed to screen before conception.  
Screening offered during pregnancy, compared to preconceptional screening, has the 
advantage that this target group is highly receptive to the idea of screening and easy to reach, 
since most women contact their general practitioner (GP) or visit an antenatal clinic. However, 
this method of screening leaves limited reproductive options open for a carrier couple, and 
there is little time for counselling and reflection before decisions about a prenatal diagnosis 
have to be made, in contrast to screening outside pregnancy.  
Since the identification of the gene in 1989, a series of pilot studies focusing on CF 
carrier screening have been conducted and evaluated in the United States, Australia and various 
European countries. This review is based on a literature search in the electronic reference 
database of MEDLINE (1990-2001) for peer-reviewed published literature describing these 
pilot studies. Only the results published in these articles and reported by Henneman et al (this 
thesis) are discussed. No additional information was requested from the project leaders. 
Furthermore, pilot studies were not included if CF carrier screening was offered in combination 
with screening for other diseases. In total, 13 studies on carrier screening during pregnancy and 
7 studies on screening programmes aimed at individuals of reproductive age or couples 
planning to have a pregnancy were selected (Table 1a/1b). 
 
Selection of screening criteria 
It is now possible to use genetic screening for an increasing number of disorders. Therefore, 
standards relating to the introduction and organisation of genetic screening programmes have 
been developed. In the past ten years, various reports on genetic screening criteria have been 
published by different committees, such as the Nuffield Council on Bioethics in the United 
Kingdom,4 the Health Council of the Netherlands,5 the Public and Professional Policy 
Committee of the European Society of Human Genetics,1 and the US National Academy of 
Sciences.6 In the United States, general guidelines for the development of genetic tests have 
been issued by the NIH Task Force on Genetic Testing.7 Recently, the American College of 
Medical Genetics Subcommittee on Cystic Fibrosis Screening published laboratory standards 
and guidelines for population-based CF carrier screening.8 
  
Table 1a — CF carrier screening programmes during pregnancy 
 
First author Setting Target group  Method of approach Pre-education Sampling Method of 
testinga 
Report of 
test-resultsb 
Mennie19 37 41 51 
 
Hospital c  
 
Women n=4,348 
<18 wk pregnant  
Leaflet sent home after booking  
Immediate testing offered at visit 
Leaflet 
Counselling if needed 
Women n=3,165 Seq Full 
Schwartz59 
 
Hospital  
 
Women n=7,400 
Pregnant 
Leaflet sent home after booking  
Immediate testing offered at visit  
Leaflet 
Questions answered  
Women n=6,599 Seq Full 
Jung60 
 
Hospital   Women n=638 
<16 wk pregnant  
Immediate testing offered at visit 
 
Leaflet 
Questions answered 
Women n=637 Seq Full 
Livingstone42 
 
Hospital c  Women n=8,536  
<18 wk pregnant  
Leaflet sent home after booking 
Testing offered at visit  
Immediate testing or return visit  
Leaflet 
Counselling if needed 
Couples n=5,922 Seq Combined 
Wald52 61 
 
Hospital  Women n=810 
<19 wk pregnant  
Testing offered at visit 
Return partner’s sample by mail 
Leaflet  Couples n=543 Seq Combined 
Miedzybrodzka43 
 
Hospital  Women n=2,002 
<17 wk pregnant  
Testing offered at visit 
Immediate testing or return visit  
(with partner’s sample) 
Leaflet  
Counselling  
Women n=1,475 
Couples n=321 
Seq Full and 
combined 
Harris62 
Hartley25 
 
General 
practice 
Women n=623 
<14 wk pregnant  
Testing offered at visit 
Immediate testing or return visit  
(with partner’s sample) 
Leaflet  
Counselling  
Women n=267 
Couples n=262 
Seq  
Sim 
Full  
Witt29 
 
Primary 
prenatal care 
Women n=6,617 
<17 wk pregnant  
Immediate testing offered at  
routine prenatal class 
Video and brochure Women n=5,161 Seq Full 
Loader20 
 
Hospital  
 
Women  
Pregnant (90%)   
Immediate testing offered at visit Leaflet  
Questions answered  
Occasional counselling 
Women n=4,879 Seq Full 
Doherty53 
 
Primary 
prenatal care  
Women  
<18 wk pregnant  
Testing offered at visit 
Return partner’s sample 
Leaflet  
Questions answered 
Couples n=1,682 Seq Combined 
Cuckle26 
 
 
Hospital  
General 
practice  
Women n=6,071 
<18 wk pregnant  
 
Leaflet sent home after booking  
or given on arrival 
Immediate testing offered at visit  
or after confirmation pregnancy 
Leaflet  
Face-to-face explanation 
Women n=3,773 
 
Seq 
 
Full 
Grody22 
 
Prenatal clinics 
  
Women n=4,739 
<19 wk pregnant  
Immediate testing offered at visit Video or brochure  
Questions answered  
Women n=3,192 Seq Full 
Delvaux28 
 
Hospital Couples n=1,156 
<21 wk pregnant 
Immediate testing offered at visit  Counselling Couples n=314 Seq Full 
 
a Seq=sequential testing: second partner is tested only if the first is positive; Sim=simultaneous testing: both partners are tested at the same time; b Full: participants are 
fully informed about the test-results, Combined: only those couples in which both partners are found to be carriers are informed about their carrier status; c In 1994, the 
pilot study was integrated into routine prenatal care.58 
 
 
  
 
Table 1b — CF carrier screening programmes outside pregnancy 
 
First author Setting Target group  Method of approacha Pre-education Sampling Method of 
testingb 
Report of 
test-resultsc 
Watson30 36 
 
General practice  
Family planning 
clinic 
Individuals 
n=1,796 
16-44 years  
Letter + leaflet 
Active-opportunistic 
Immediate testing  
Leaflet  
Counselling 
Individuals n=801 Seq Full 
Bekker31 46 
 
 
General practice Individuals 
n=5,529 
18-45 years  
 
Letter + leaflet  
Active-opportunistic 
Passive-opportunistic 
Immediate testing or return visit 
Leaflet  
Counselling 
Individuals n=957  Seq Full 
Tambor32 
 
 
Primary care  Individuals 
n=3,321 
18-44 years  
Letter + leaflet 
Active-opportunistic  
Immediate testing 
Leaflet  
Individual education 
session 
Individuals n=244 Seq Full 
Clayton21 48 
 
Various settings Individuals  
 
Posters and take-away letters  
Return with partner’s sample 
Videotape or brochure Couples n=179 Seq Full 
Payne24 
 
 
General practice Individuals 
n=3,057 
16-45 years  
Letter + leaflet 
Active-opportunistic  
Immediate testing or return visit 
Leaflet  
Counselling  
 
Individuals n=481 
Couples n=31 
Seq 
 
Full and 
combined 
Honnor35 
 
 
General practice 
Family planning 
clinic 
Individuals 
n=5,102 
18-50 years  
Passive-opportunistic 
Immediate testing 
Leaflet  
Counselling if needed   
Individuals n=2,220 Seq Full 
Henneman33 
 
General practice 
Municipal Health 
Services 
Individuals 
n=38,114 
20-35 years  
Letter + leaflet Leaflet  
Group education session 
or GP consultation 
Couples n=559 Seq Full 
 
a Active opportunistic: testing offered personally by a health professional. Passive opportunistic: testing offered by handing out a leaflet; b Seq=sequential testing: the 
second partner is tested only if the first is positive (single-entry testing); c Full report: participants are fully informed about the test-results; Combined report: only those 
couples in which both partners are found to be carriers are informed about their carrier status. 
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Criteria for the evaluation of screening for diseases in the general population are not new. 
Famous and traditionally accepted are the criteria formulated in 1968 by Wilson and Jungner at 
the request of the World Health Organisation (WHO).9 However, genetic screening is 
distinguished from other types of medical screening by the genetic nature of the disorder. 
There is also a shift from the aim of treating, preventing and alleviating disease - an important 
goal of any screening programme - to the aim of offering the individual certain options. 
Therefore these criteria are not entirely suitable for genetic screening, but may have served as 
the basis for many of the reports on genetic screening. 
To evaluate the various different pilot studies on CF carrier screening according to 
genetic screening guidelines, the criteria that were considered most important were selected 
(Table 2). These criteria are listed in all of the above-mentioned reports on genetic screening 
criteria. The cost-effectiveness of screening programmes has been studied extensively,2 
however this is not taken into consideration in this review. Firstly, although some maintain that 
cost-effectiveness is an important consideration in the debate over which target groups should 
be offered CF carrier testing,8 10 it is generally acknowledged that there is something 
problematic about cost saving through termination of affected fetuses as the primary aim of 
screening.5 11 Therefore, costs considerations should only play a limited part in decisions 
concerning genetic screening. Secondly, and an earlier research has already indicated that cost 
considerations need not be an important barrier.12 Thirdly, the costs and available resources 
will differ between countries.  
 
Table 2 — General criteria and specific criteria to be met by genetic screening programmes 
 
General criteria  
1. The disease is an important health problem  
2. There is an effective intervention or a decision to be taken by the person screened 
3. There is a suitable test with known predictive value 
 
Specific criteria  
4. Participation is voluntary, with time allowed for consideration and based on consent  
5. The target group is provided with good quality, comprehensible and balanced information 
6. There is enough evidence that psychological harm caused by the offer and/or participation is 
negligible 
7. There is enough evidence that social harm caused by the offer and/or participation is negligible 
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Genetic screening criteria can be sub-divided into general criteria and specific criteria. General 
criteria relate to the prerequisites for starting a community-wide carrier screening for a genetic 
disease, as outlined by the WHO.13 To justify screening, a screening programme has to meet 
these general criteria, before pilot studies investigating the more specific criteria can be 
developed.  
 
General criteria for genetic screening  
In general, the authors of the published pilot studies seemed to agree that CF carrier screening 
is justified because it meets most of the general criteria. 
 
1. The disease is an important health problem 
YES. CF is a serious, well-characterised, incurable disorder. The disease is characterised by 
severe, relapsing respiratory and gastrointestinal problems due to the accumulation of sticky 
mucus.14 The symptoms and course of CF are variable.3 In general, during the course of the 
disease the symptoms worsen. The median life expectancy for CF is now approximately 30 to 
40 years, and it is projected that in newborns it will become more than 40 years.15 CF is one of 
the most common autosomal recessive disorders found in Caucasians, with a birth prevalence 
of approximately 1 in 2500-4000. In populations that are of European origin, approximately 1 
in 25-30 individuals is a healthy CF carrier. If both partners in a couple are carriers, each child 
they have has a 1-in-4 risk of having CF.  
 
2. There is an effective intervention or a decision to be taken by the person screened  
YES. The purpose of CF carrier screening is to enable participants to find out whether they are 
a carrier, and to take a decision based on that information. Carrier screening during pregnancy 
offers carrier couples the possibility of prenatal testing and, subsequently, the termination of a 
pregnancy. Screening before pregnancy offers couples a greater range of reproductive options, 
such as deciding not to have children, adoption, prenatal testing, pre-implantation genetic 
diagnosis, or pregnancy by means of artificial insemination with sperm from a screened donor 
or egg-cell donation. 
 
3. There is a suitable test with known predictive value 
YES, PROBABLY. CF is caused by mutations in the gene encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein. The gene was identified in 198916-18 
and, to date, over 900 mutations have been identified (http://www.genet.sickkids.on.ca/cftr). In 
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some of the pilot studies, the test-sensitivity was found to be 85% or less, which was 
considered to be less than ideal for a screening test.19-22 Nowadays, in most screening centres, 
the sensitivity of the test is at least 85-90% in Caucasians.3 The test-specificity is 
approximately 100% (no false positives), if stringent quality assurance guidelines are adhered 
to, as specified, for example, in the report of the NIH-DOE Task Force on Genetic Testing7 or 
issued by the Steering Committee of the European Concerted Action on Cystic Fibrosis.23 
Direct mutation analyses can be applied after collecting samples by buccal scraping, the 
mouthwash method, or blood-sampling. In general, buccal scraping and the mouthwash 
method, which are non-invasive and painless, are considered by the target group to be the most 
acceptable methods of testing.21 22 24 
 
Specific criteria for genetic screening programmes  
Outcome measures described in each CF carrier screening pilot study, relevant to this review, 
are listed in Table 3a/3b. To determine whether these studies meet the specific criteria for 
genetic screening programmes, the outcome measures are discussed according to each 
individual criterion for genetic screening programmes. 
 
4. Participation is voluntary, with time allowed for consideration and based on consent  
Carrier screening in pregnancy has mainly been offered to women during routine visits to 
antenatal clinics or, alternatively, to save time, when a pregnancy is first confirmed by a GP. 
High uptake rates of 53%-99% have been reported, and many project leaders have therefore 
suggested that there is considerable interest in screening in a target group that is highly 
receptive to the idea of screening. However, reasons for participation were not always asked, 
but when assessed it was sometimes found that important reasons for women to accept 
screening were that they felt that all tests are important during pregnancy,25 26 that they could 
not refuse,27 that the doctor told them to participate,20 or that the test was easy to carry out.28 
Witt et al29 reported that among the 259 women who had the test, almost 26% accepted the test 
because a blood sample had already been taken. These data suggest that carrier testing during 
pregnancy is sometimes accepted just because it is offered, and the easy way in which it can be 
carried out, and not because of any perceived benefits of the testing.  
Carrier screening outside pregnancy in the general population has been offered through 
primary health care services, such as general practices, family planning clinics, and other 
(health-related) community centres. Several studies concluded that uptake rates were mainly 
determined by the method of invitation.21 24 30-32 Uptake was approximately 10% when 
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invitations were sent by letter, and increased to 24-87% with active opportunistic testing, i.e. a 
personal approach and immediate testing. This influence of the mode of invitation on uptake 
has been interpreted as a lack of motivation in an unreceptive target group to participate in the 
test.24 31 32 
On the one hand, it could be argued that the high uptake rate achieved in opportunistic 
testing is the result of a supply push rather than a demand from the population31 This was 
demonstrated in some studies by the sizeable number of individuals who decided to have the 
test, even though they were not planning to have (any more) children.24 30 32 On the other hand, 
the low uptake rate achieved by mailed invitations might be due to other reasons, such as lack 
of knowledge and inconvenience of the time or location, even though the non-respondents were 
interested in testing. Lack of time to attend an educational session was reported by 53% of non-
pregnant couples as the main reason for not participating in a study carried out by Henneman et 
al,33 whereas half of these couples perceived high benefits of screening. Furthermore, uptake 
increased after a second invitation (this thesis, Chapter 5), suggesting that some people are not 
prepared for the initial offer of screening, and that they might attend if the subsequent offer of 
screening is more convenient.  
Time to decide whether or not to have the test is important and necessary to prevent 
people from regretting their decision later on. It also gives participants the opportunity to make 
a decision based on the conviction that screening is to their benefit, and not just because it is 
offered or strongly recommended, as was argued in connection with opportunistic screening 
programmes.34 In most studies, consent for testing was asked directly, but participants were 
only occasionally asked whether they were satisfied with the amount of time they were allowed 
to consider participation. Honnor et al35 showed that when a consent form was signed 
immediately after testing was offered, 4.8% of participants and 15.5% of those who had not 
been tested felt that they would have liked to have had more time to decide. 
Satisfaction was evaluated in most studies, by asking participants whether they had any 
regrets about their decision, whether they were satisfied with testing, and whether they would 
recommend testing to others. Overall, the participants were satisfied, although some studies 
reported that carriers were less satisfied than those who tested negative.27 29 36 37 Remarkably, 
one pilot study showed that although the participants were satisfied with the test, they did not 
advise others to have it.28 
  
Table 3a — Outcome measures mentioned in CF carrier screening studies during pregnancy  
 
Studies Uptake rate  Reasons to 
accept 
Reasons to 
decline 
Time to decide Satisfaction Understanding  Psychological 
impact 
Social 
 impact 
Mennie19 37 41 51 
Edinburgh, UK X X X X X X X X 
Schwartz59 
Denmark X X   X X X X 
Jung60 
Germany X  X    X  
Livingstone42 
Edinburgh, UK X X X   X X  
Wald52 61 
Oxford, UK X  X      
Miedzybrodzka43 
Aberdeen, UK X     X X X 
Harris62 Hartley25 
Manchester, UK X X  X X X X  
Witt29 
San José, USA X X X  X X X X 
Loader20 
Rochester, USA X X X  X X X  
Doherty53 
Maine, USA     X    
Cuckle26 
Leeds,UK X X X      
Grody22 
Los Angeles, USA X  X  X X X X 
Delvaux28 
Belgium  X   X X X X 
 
 
  
 
Table 3b — Outcome measures mentioned in CF carrier screening studies outside pregnancy 
 
Studies Uptake rate  Reasons to 
accept 
Reasons to 
decline 
Time to decide Satisfaction Understanding  Psychological 
impact 
Social 
 impact 
Watson30 36 
Hertfordshire,UK X    X X X X 
Bekker31 46 
London, UK X     X X X 
Tambor32 
Baltimore, USA X     X   
Clayton21 48 
Nashville, USA  X X   X   
Payne24 
South Wales, UK X  X   X X X 
Honnor35 
Perth, Australia X   X  X X  
Henneman33 
the Netherlands X X X  X X X X 
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5. The target group is provided with good quality, comprehensible and balanced information 
Educating people about carrier screening is complicated, due to the limited knowledge about 
genetics in the general population,38 and a test-sensitivity of less than 100%, causing a residual 
risk to individuals who are not found to be a carrier. The content of the written information 
provided in most pilot studies was evaluated in an earlier study carried out by Loeben et al.39 It 
was concluded that the wide variation in the information about CF and reproductive options 
contained in the pamphlets did not seem to meet the recommendations for balanced 
information. The impact of (unbalanced) information on decisions was not investigated, but it 
was, however, suggested that interest in CF testing might be influenced by the nature of the 
information that is presented.34 40 Furthermore, there was some evidence that uptake as part of a 
routine visit was based on poorer knowledge than when it required a separate visit.32 
The effectiveness of the information provided has been measured by assessing 
knowledge of the clinical and genetic aspects of CF (testing), recall of test-results and 
understanding of the residual risk. Some studies showed that the level of knowledge increased 
after pre-test information had been provided, thus supporting informed choice.29 31 After 
testing, however, it was demonstrated that a sizeable percentage of those who received a 
screen-negative result believed that they were definitely not carriers,22 24 25 27 35 36 41-43 and 
accurate recall of risk of having a child with CF decreased after a few months.24 31 After three 
years, a sub-set of 466 negative-tested individuals selected from six pilot studies showed that 
81% correctly remembered the results they had received. However, 50% incorrectly believed 
that they were definitively not carriers.44 Also of concern are the test-positive individuals who 
believed that they were only likely to be carriers.24 31 35 36 41 Furthermore, in two studies it was 
shown that some carriers believed there was a 1-in-4 risk of having a child with CF if one 
partner was a carrier.24 36 Personal counselling after receiving positive test-results did not 
necessarily increase understanding.35 
It has been suggested that a psychological inclination to process and recall information 
in a way that minimises risk underlies the inaccurate recall that has been reported in previous 
studies.44 This may be a useful psychological defence mechanism.45 However, misunder-
standing might also have arisen because people were not motivated to undergo testing in the 
first place.46 In addition, differences in presentation, content, emphasis on information, and 
time spent on counselling have been suggested as possible influences on understanding of the 
test-results.41 47 Henneman et al (this thesis, Chapter 7) showed that the predictors of a correct 
understanding of test-results in preconceptional couples after six months were a positive test-
Evaluation of carrier screening programmes 
 
 36 
result, a high level of knowledge about CF, a high level of education, attending at an 
educational session, and previously heard of CF.  
Only a few studies aimed at the best way of providing the information in order to 
optimise understanding. Written materials and videos were shown to be equally effective 
methods of educating most people about carrier screening.22 48 However, these methods were 
found to be less effective for those people with a low educational background.48 49 Higher 
scores on a knowledge test were achieved by those who had received personal education during 
an educational session,50 (Chapter 7, this thesis) compared with those educated only by printed 
materials, suggesting that face-to-face verbal information might be needed, in particular to 
inform couples with a low level of education about screening.  
 
6. There is enough evidence that psychological harm caused by the offer and/or 
participation is negligible 
Anxiety levels were assessed in most screening studies. In stepwise screening, in which one 
partner is sampled and tested first and the second only if the first partner tested positive, it was 
often found that women who were identified as a carrier were more anxious while waiting for 
the partner’s result. However these feelings of anxiety seemed to be short-lived and 
disappeared once their partners were tested negative.22 27 43 51 In a study in which it was found 
that women experienced no anxiety while awaiting their partner’s result, it was suggested that 
this was because of the high quality of the pre-test education.29 
Couple-based screening, in which both partners are sampled at the same time and only 
those couples in which both partners are found to be carriers were informed about their carrier 
status, while all others are told that they have no marked increased risk (non-disclosure of test-
results), was proposed by Wald52 and evaluated in several studies.42 43 53 One reason for the 
introduction of this method was avoidance of the unnecessary anxiety and need for counselling 
that might arise when one partner is tested positive and the other partner is asked to provide a 
sample. It was, indeed, shown that there was no peak in anxiety after couple-based testing, 
compared to stepwise testing when positive results were received.42 43 Long-term follow-up 
showed no differences in anxiety between the two different methods of screening.47 There have 
been many debates on the introduction of Wald’s proposal of couple-based screening. 
Recently, it has been stated that the introduction of this couple-based screening is not 
recommended, among other things because the non-disclosure of test-results deprives the 
positive-tested partner of the positive-negative couple the opportunity to inform their family of 
their increased risk.8 In addition, non-disclosure also seemed to be less well accepted by the 
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target population, as was found in a couple-screening study carried out by Henneman et al 
(Chapter 8, this thesis).  
Long-term psychological effects have been assessed, and it was found that 16% of 280 
identified carriers selected from six pilot studies remained worried after three years of follow-
up.44 There were no differences in reproductive behaviours or intentions between carriers and 
those tested negative. 
Three studies, all using a general health questionnaire, found no impact of screening on 
health perceptions at the initial time of testing or after receiving (positive) test-results,24 27 46 
although in carriers there was a small negative effect on how they perceived their current 
health at three years follow-up.44 
 
7. There is enough evidence that social harm caused by the offer and/of participation is 
negligible 
Evaluations of social harm were mainly limited to asking identified carriers whether they 
shared the information with their partner, family and friends. In a study carried out by Watson 
et al,36 over 90% of the carriers discussed the results with their partner or family, and brought 
their partner or close relatives for testing within six months, indicating that there is little 
perceived stigma associated with the diagnosis. Witt et al29 found that among 76 female 
carriers only 3% felt that people would look at them differently if they knew they were carriers.  
The misuse of information, and discrimination based on test-results after disclosure to 
third parties such as insures and employers was hardly ever assessed. Furthermore, the social 
stigmatisation of a person who declines screening was not investigated.  
 
Discussion  
In this review, pilot studies for CF carrier screening before and during pregnancy were 
discussed in the light of important genetic screening criteria, and it was investigated whether 
the project leaders evaluated their studies on the basis of these criteria. Conceptually, since CF 
carrier screening meets the general criteria, the development of genetic screening programmes 
is justified, and this was mainly addressed in the introduction of the reviewed articles. The 
outcome measures used in the evaluation of pilot studies did not always comply with the 
specific criteria for genetic screening programmes. Most project leaders concentrated on uptake 
in the screening as an important outcome, and less on consent based decision-making. 
Knowledge of CF, understanding of test-results before and after testing, and the anxiety and 
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satisfaction of participants have been studied extensively, but less attention has been paid to the 
long-term psychological and social effects of screening. 
 
Participation is voluntary  
Most pilot studies focussed primarily on the rate of uptake as a measure of interest in 
participation. The degree of interest in screening appeared to be influenced by the setting and 
the way in which it was offered, i.e. opportunistically or passively, and the ease with which 
testing can be accomplished. In genetic screening, uptake is not important, unless for economic 
reasons. Determining what motivates some individuals to participate in a carrier screening 
programme, while others decline, provides greater insight into the desirability and acceptability 
of screening than the uptake itself.  
 
Information is of good quality, comprehensible and balanced 
Participants’ knowledge of CF before testing was measured in some pilot studies, but there was 
less information about the level of knowledge of those who did not participate. However, to 
enable informed decisions to be made, it is important to demonstrate that the individual has 
fully understood the options and implications of screening.3 In order to present ‘balanced’ 
information, it has been suggested that a relatively equal percentage of the negative as well as 
the positive aspects of testing should be highlighted, alongside the neutral ones.39 Cho et al54 
described ten critical elements that are needed to evaluate the content of informational 
materials, and these might well be used in the development of educational material about CF 
carrier screening. By whom and how the information should be provided is a matter that needs 
further serious consideration, as has also been suggested by Mennuti et al.55  
Understanding the consequences of the test-results was discussed in most pilot studies. 
The results suggest that, on the one hand, incorrect understanding seems to be a way of coping 
with risk information, rather than poor understanding. On the other hand, there are factors 
associated with understanding, such as the method of education and counselling, and 
participant characteristics, such as level of education and motivation, that could be taken into 
account to improve the understanding of test-results. 
 
Psychological and social harm is negligible 
Although the psychological and social effects of being tested received various levels of  
attention, research on the anxiety caused by the invitation to undergo screening was limited. 
More information should be gained about the psychological effects and the social 
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stigmatisation of persons who might decline an offer of screening, and also on the long-term 
social implications for carriers, such as potential discrimination and denial of insurance.40 
Additional attention should be paid to the implications for the family, because not only the 
individual undergoing the test is involved, but also other family members who have not 
consented to testing.  
 
Limitations of the study 
There are some limitations in this review. First, there was no personal contact with the project 
leaders who carried out the pilot studies; data was gathered only by searching the electronic 
reference database of MEDLINE. Therefore, elements that were lacking in the studies might 
have been evaluated without peer-reviewed publication. Furthermore, it may be possible that 
the results of some studies are still being evaluated. Secondly, there are other screening criteria 
that must be met, in addition to those that were selected for this review, e.g. relating to the 
provision of quality assurance, and organisational aspects. However, the criteria addressed in 
this review were mentioned in all the reports on genetic screening criteria, and were therefore 
considered to be the most important. 
 
Evaluation of pilot studies in general 
The pilot studies on CF carrier screening did not evaluate all aspects of the selected genetic 
screening criteria. One reason for this may be that some project leaders were not fully aware of 
the criteria that specifically apply to genetic screening. Screening has traditionally been mainly 
viewed as a public health activity, aimed at reducing the prevalence of disease, and in which a 
high uptake is essential if the screening is to be effective. Another reason could be difficulty in 
evaluating specific outcomes. Some issues are relatively easy to evaluate, because certain 
outcome measures have been developed and validated, such as the short form of the 
Spielberger state-trait anxiety inventory.56 However, few resources are available for the 
evaluation of other outcome measures, for example, the concept of informed decision-making 
and the social consequences of screening. Recently, Marteau et al57 developed a method to 
measure informed-choice, which might be useful for further studies on genetic screening. On 
the one hand, the use of various outcome measures does not necessarily mean that a study has 
been well designed. On the other hand, lack of evaluation measures does not mean that the 
study itself is unsuitable. 
The evaluation of any screening programme must include an assessment of how 
decisions are made after the individual has received information, and appropriate outcome 
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measures that reflect the quality of this decision-making process are needed. Such research has 
predominantly concentrated on patient satisfaction, psychological well being, anxiety and 
distress, but it is also important to know the impact of screening results and risk interpretation 
on the choices participants make with regard to life-style and behaviour. Much more is known 
about reproductive behavioural choices in prenatal CF carrier screening compared to screening 
outside pregnancy.2 11 58 Only a very few carrier couples have been identified outside 
pregnancy,2 and samples sizes are too small to warrant valid conclusions. Information on 
subsequent reproductive decisions is limited in both target groups, and research on long-term 
reproductive behaviour is worthwhile. 
The evaluation of pilot studies are a prerequisite to address the question of whether CF 
carrier screening should be implemented in the general population, and how this could best be 
done. Until now, considerable research has been carried out, but in order to further investigate 
the outcome measures with regard to psychological and social aspects, continuous monitoring 
of (pilot) screening is recommended, in participants as well as in non-participants. Suggestions 
for outcome measures in the evaluation of screening programmes are given in Table 4. This 
paper provides a framework for information to support the interpretation of outcome measures 
in pilot studies not only investigating CF, but also other genetic disorders.  
 
Table 4 — Suggestions for outcome measures preferably measured in the evaluation of genetic 
screening programmes 
 
Outcome measures in genetic screening programmesa: 
1. Informed decision: time to decide, motivation, informed choiceb 
2. Cognitive aspects: level of knowledge, ability to recall test-results, understanding test-
results/information 
3. Psychological aspects: anxiety, perception of health, regret about the decision, satisfaction 
4. Social aspects: stigmatisation, discrimination, sharing of information 
5. Behavioural aspects: reproductive and life-style decisions  
 
a For all outcome measures there should be short-term and long-term evaluation; b Informed choice as a 
combination of knowledge, behaviour and attitude.57 
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Abstract 
Assessing the reproductive choices of parents of children with cystic fibrosis (CF) is important 
in getting a greater insight into the possible needs for counselling of carrier couples in the 
reproductive decision-making process. Also, parents’ reproductive attitudes might indicate 
critical issues for the discussion with regard to introducing general population screening 
programmes. Data were available from two groups of subjects: 287 adult patients with CF 
(mean age 27.5 years) and 288 parents of a child with CF (mean age of child 7.7 years) who 
participated in a Dutch national survey. Attitudes towards reproductive issues and carrier 
screening and parents’ reproductive behaviour were analysed in terms of responses to 
questionnaires. To avoid having another child with CF, most parents decided against further 
pregnancies or used other reproductive options. Prenatal diagnosis was used by 72% of parents, 
whereas 76% of parents planning more children intended using this option. Intention to use 
prenatal diagnosis was associated with the strength of religious conviction, and was not 
associated with perceived severity of CF, health of the child, or future therapeutic possibilities. 
Respondents demonstrated difficulties in deciding to abort for CF. A majority of parents and 
adult patients supported carrier couple identification within CF families. The results suggest 
that those most involved with CF will accept the reproductive choices of carrier couples 
identified in population screening programmes.  
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Introduction 
Parents of children diagnosed with Cystic Fibrosis (CF) have a 1-in-4 risk of having another 
affected child. Several reproductive options for subsequent family planning are available for 
these parents. Parents can choose to have no more children, opt for prenatal diagnosis and 
selective termination of pregnancy, or use alternatives, such as artificial insemination or 
adoption. Most parents believe that prenatal diagnosis is an important reproductive option for 
families at risk.1-4 Actual utilisation of prenatal diagnosis is, however, generally lower than was 
expected from earlier studies when this option was not available.2 5-7 It has been suggested that 
perceptions of raising a child with CF and future expectations of improvement in duration and 
quality of life may contribute to the complexity in reproductive decision-making of CF 
parents.2 4 6 7 Assessment of the choices and factors influencing reproductive decisions of 
parents at risk is important to provide a greater insight into the possible requirement for 
counselling of carrier couples in the reproductive decision-making process. Also, parents’ 
reproductive decisions might give an indication of critical issues in the reproductive choices 
and needs of CF carrier couples identified in general population screening programmes. 
Because of their personal experiences and familiarity with coping with the disease, the 
opinions of both CF parents and patients with CF are important in any discussion about the 
introduction of such a screening programme. 
The present paper reports on these issues, as reflected in the response to a Dutch national 
survey on the medical, psychological and social impacts of CF. Data were available to study the 
following research questions: 
1. What are the attitudes of parents of children with CF towards usage of prenatal diagnosis? 
(This question was not asked to adult patients) 
2. What are the attitudes of adult patients and parents of children with CF towards abortion 
for CF? 
3. Are there any variables associated with the intention to use prenatal diagnosis and the 
willingness to consider abortion?  
4. What is the influence of the diagnosis of CF in a child on subsequent family planning? 
5. What is the reproductive behaviour of parents of children with CF? 
6. What are the attitudes of adult patients and parents towards population CF carrier screening 
and carrier testing within CF families? 
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Participants and methods 
All the participants of a Dutch national study in 1997 on the impact of CF on medical, 
psychological and social aspects of life were included in our analyses. The national survey 
considered two groups of subjects: adult patients with CF (age >16 years) and CF children (age 
<16 years). Two questionnaires comprising 124 items were designed: one for adult patients and 
one for children with CF. The children’s questionnaire (one per child) was completed either by 
one of the parents or both parents together. Starting in May 1997, questionnaires were sent to 
health care providers to distribute to their adult patients or parents. In addition, questionnaires 
were mailed directly to all patients and parents who were members of the Dutch Cystic 
Fibrosis Foundation (NCFS). Questionnaires from 287 adult patients and 312 children with CF 
were returned by mail. Twenty-one parents had two or more children with CF, giving a 
response of 288 parents. In the Netherlands, there are about 1000 patients with CF, 
approximately 41% are aged 16 years or older.8 Based on these results, the response was 
assumed to represent 70% (287/410) of adult patients and 53% (312/590) of CF children 
younger than 16 years. 
To answer the research questions presented in this paper, all relevant questions from the 
national study were selected. These questions queried the attitudes of parents of children with CF 
towards prenatal diagnosis and pregnancy termination, reproductive intentions, the impact of CF 
on family planning and reproductive behaviour. In addition, attitudes of adult patients with CF 
towards pregnancy termination were queried. Answers to the questions were both open-ended and 
in multiple choice format. Furthermore, sociodemographic characteristics of patients, age at 
diagnosis, perception of severity of CF (on a five-point scale) and perceived health status of the 
patient (on a five-point scale) were assessed. Parents’ perceived problems with the treatment of 
their child with CF were assessed on a four-point scale. Asking parents whether the impact of CF 
on their own daily activities was merely negative or positive assessed the perceived burden of 
raising a CF child. The perceived influence of (future) possibilities of gene therapy, lung 
transplants, new antibiotics and home care on the outcome for CF was queried. In addition to these 
questions, five-point Likert scales were used to describe the attitudes towards population CF 
carrier screening and carrier testing within CF families. 
 
Statistical analysis 
Questionnaire data were entered into the Statistical Package for the Social Sciences 
(SPSS/Windows). Five-point Likert scales were reduced to three categories to avoid empty or 
small cells, by combining the responses ‘Fully agree’ with ‘Agree’, and ‘Fully disagree’ with 
Chapter 3 
 49 
‘Disagree’, to form ‘Agree’ and ‘Disagree’. The third category was ‘Neither agree nor 
disagree’. Perceived severity of CF, perception of health and parents’ perceived problems with 
treatment were reduced to dichotomous outcome variables, respectively ‘High severity’ (very 
serious, serious, rather serious) and ‘Low severity’ (not serious, not serious at all);  ‘Bad’ (bad, 
sometimes good and sometimes bad) and ‘Good’ (fair, good, very good); ‘No problems’ (no 
problems at all, hardly any problems) and ‘Problems’ (some problems, a lot of problems). 
Furthermore, religion was reduced to a dichotomous variable ‘Religious conviction’ (religious 
and attending church >1 month); ‘Lack of religious conviction’ (not religious or religious and 
attending church <1 month). Adult patients’ and parents’ responses were compared using chi-
square tests for categorical data and t-tests for continuous data.  
 Univariate analyses were conducted for all patients and disease-related characteristics, and 
(1) parents’ intention to use prenatal diagnosis, and (2) parents’ consideration to abort for CF. 
Significant variables in the univariate analysis were entered into a stepwise multiple logistic 
regression in order to identify the most relevant predictors in the model. The same procedure was 
followed for the adult patients’ consideration to abort for CF. Values for p<0.05 were accepted as 
significant.  
 For the data relating to reproductive issues and attitudes, the answers of parents with more 
than one child with CF were counted only once and the questionnaires considering the youngest 
child were taken.  
 
Results 
Patient characteristics are given in Table 1. Adult patients ranged in age from 16 to 56 years, 
with a mean age of 27.5 years. The CF children’s mean age was 7.7 years (range 0-15 years). 
Of adult patients 46% were female, of children 51% were female. Twenty-two percent of CF 
adults were married. In many families, the patient was the first to be diagnosed with CF. Sixty-
one percent of adult patients and 74% of children were the only CF patient in their family. 
Relatives had been tested for CF carrier status for a majority of adults and children, 
respectively 60 and 67%. Mean ages at diagnosis were 6.2 (range 0-42) years old for the adult 
patients and 1.2 (range 0-10) years old for the children with CF. About half of the adults and 
83% of the children were diagnosed by two years of age. More parents of children with CF 
than adult patients reported that the burden of disease was ‘High’. Health was perceived as 
‘Bad’ by 23% of parents and by 22% of adult patients, compared to 3% (age 0-19 years) and 
5% (age 20-44 years) of the Dutch population.9 ‘Bad’ perceived health significantly correlated 
with lung problems (r=0.50) and gastrointestinal problems (r=0.24). Most patients were not 
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religious or were religious but practised sporadically. Only 13% of adult patients and 18% of 
children, according to their parents, practised their religion on regular basis. The questionnaire 
for children younger than 16 years was completed in 57% of the cases by the mother of the 
child, in 4% by the father of the child, in 33% by both parents together, and in 5% by the 
parents and child together.  
 
Table 1 — Characteristics of adult patients and children with CF (reported by parents)  
 
 Adults with CF              Children with CF  
(n=287)                          (n=312) 
 
Age, mean (range) in years 
Gender, % female (n) 
Marital status, % married (n) 
Residential situation, % (n) 
  Residing with parents 
  Residing alone 
  Residing with partner (and child) 
  Other 
First-diagnosed CF-child in familya, % Yes (n) 
Only CF patient in family, % Yes (n) 
Family CF carrier tested, % Yes (n) 
Age at diagnosis, mean (range) in years 
Perceived severity of disease, % High (n) 
Perceived health of patient, % Bad (n) 
Religion, % Religious conviction (n) 
27.5  (16-56)   7.7  (0.5-15) 
46  (132)  51  (158) 
22  (64)  NA 
 
40  (114)  96  (308) 
17  (49)  NA 
39  (113)  NA 
  4  (11)    4  (4)  
73  (209)  80  (251)  
61  (175)  74  (231)  
60  (172)  67  (210) 
6.2  (0-42)  1.2  (0-10)  
41  (119)  86  (267)  
22  (62)  23  (71) 
13  (38)  18  (55) 
 
NA=not applicable; a Eight CF children were diagnosed at the same time as their sibling and both were 
assigned as first-diagnosed patient in the family;  Adults with CF compared to children with CF, p<0.05. 
 
Attitudes towards prenatal diagnosis  
Of all parents, 59% (169/288) certainly would have used prenatal diagnosis if they had known 
beforehand that they were a CF carrier couple, 12% would not have used it and 29% were 
unsure. To get more insight into the influence of the child’s CF on childbearing decisions, 
parents planning more children were queried about their reproduction intentions. At the time of 
the study, 59 parents (20%) were determined to have more children and 38 parents (13%) were 
unsure about this. Table 2 shows that of these 97 parents, 76% thought that they would use 
prenatal diagnosis in the future, 18% answered that they would certainly not use it. Of the 97 
parents, 36 had used prenatal diagnosis previously and 35 intended to use it again. Parents who 
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were unsure about having more children were significantly more indecisive about using 
prenatal diagnosis.  
 
Table 2 — Reproductive intentions of parents of children with CF planning (n=59) or unsure 
about planning (n=38) more children 
 
 Yes 
%  (n) 
No 
%  (n) 
Don’t know  
%  (n) 
 
Would use prenatal diagnosis  
All parents (n=97) 
  Parents planning more children (n=59) 
  Parents unsure about more children (n=38) 
 
Would consider using other methodsa 
All parents (n=97) 
  Parents planning more children (n=59) 
  Parents unsure about more children (n=38) 
 
76  (74) 18  (17)   6  (6) 
81  (48) 19  (11)   0 
68  (26) 16    (6) 16  (6) 
 
 
18  (17) 65  (63) 17  (17) 
24  (14) 64  (38) 12  (7) 
  8  (3)  66  (25) 26  (10) 
 
 
 
 
 
 
 
 
 
 
 
a Other methods of having a child such as artificial insemination, adoption, pre-implantation genetic diagnosis;  
 Parents planning more children to parents unsure about planning more children, overall chi-square test p<0.05. 
 
Of all parents planning more children, 18% would consider using other methods to have a 
child, such as adoption, artificial insemination or pre-implantation genetic diagnosis, and 65% 
would not use these methods. Parents who were unsure about further pregnancies were less 
often in favour of using these other methods to have a child, than parents who were certain 
about having more children (8% v. 24%). The results of characteristics significantly (p<0.05) 
and not significantly associated with the acceptance of prenatal diagnosis in univariate analyses 
are shown in Table 3.  
 
Table 3 — Characteristics related to the intention to use prenatal diagnosis and the consideration 
to abort for CF: univariate analyses in 97 parents of children with CF 
 
 Would use prenatal 
diagnosis  
(p-value) 
Would consider 
abortion  
(p-value)  
First-diagnosed CF-child in family 
Family CF carrier tested 
Serious perceived severity of disease 
Bad perceived health of patient 
Lack of religious conviction 
Would consider abortion for CF 
High perceived problems with treatment 
Negative impact on daily activities 
High expectations of future possibilitiesa 
0.024    0.062 
0.040    0.007  
0.090   0.007  
0.147   0.040  
0.001    0.003  
0.001    NA 
0.314   0.268 
0.230   0.003  
>0.5   >0.5 
 
NA=not applicable; a High expectations of gene therapy, lung transplants, new antibiotics, home care;  p<0.05. 
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Logistic regression analysis revealed only one unique predictor for parents’ intention to use 
prenatal diagnosis for subsequent pregnancies. Those parents with lack of religious conviction 
would make use of prenatal diagnosis 10.6 (95%CI 3.1-36.2) times more than would parents 
with religious conviction.  
 
Attitudes towards abortion  
To assess the acceptance of abortion of an affected child, the attitudes of adult patients and parents 
with reproductive plans towards termination of pregnancy were queried (Table 4). A higher 
proportion of parents than adult patients would consider abortion, respectively 57% and 30%. All 
respondents were less decisive about actually terminating a pregnancy, with adult patients being 
more indecisive than parents. Fifty-one percent of adult patients and 26% of parents did not know 
if they would actually abort the CF child.  
 
Table 4 — Intention of adult patients (n=160) and parents of children with CF (n=97) to terminate 
affected pregnanciesa 
 
 Yes  
%  (n) 
No 
%  (n) 
Don’t know 
%  (n) 
 
Would consider aborting if child has CF 
Adult patients (n=160) 
Parents (n=97) 
 
Would decide to abort if child has CF 
Adult patients (n=160)   
Parents (n=97) 
 
30  (48) 34  (55) 36  (57)  
57  (55) 30  (29) 13  (13)  
 
 
14  (22) 35  (57) 51  (81)  
45  (44) 29  (28) 26  (25)  
 
 
 
 
 
 
 
 
a Respondents not planning any children or any more children were excluded from the analyses;  Overall chi-
square test, comparing adults patients to parents, p<0.05. 
 
The results of characteristics significantly (p<0.05) and not significantly associated with the 
consideration of parents to abort for CF in univariate analyses are shown in Table 3. The final 
multiple logistic model obtained from the stepwise procedure included four unique predictors for 
CF parents’ consideration to abort: (1) lack of religious conviction (OR=8.9, 95%CI 1.9-40.9), (2) 
negative impact of CF on daily activities (OR=9.7, 95%CI 1.6-57.6), (3) high perceived severity of 
CF (OR=4.4, 95%CI 1.1-18.9), and (4) carrier testing of CF relatives (OR=3.9, 95%CI 1.3-12.1). 
How parents perceived the health of the patient was significantly related to the consideration to 
abort in univariate analysis, but was not a significant predictive factor in the logistic regression. 
This variable was, however, correlated with parents’ perceived impact of CF on daily activities 
(r=0.36).  
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Two characteristics were significant in univariate analyses and were also predictors in patients’ 
willingness to abort for CF. Female patients were 2.2 (95%CI 1.1-4.6) times more willing than 
male patients to abort for CF. Patients with lack of religious conviction were 7.5 (95%CI 1.3-
10.0) times more than patients with religious conviction willing to consider termination of 
pregnancy. 
 
Perceived influence of CF diagnosis on subsequent family planning  
Fifty-three percent of the parents (154/288) indicated that the diagnosis of their CF child had 
influenced their plans for subsequent pregnancies, 40% said it had not influenced their 
reproductive plans, and 7% did not know. Parents were requested to describe in their own 
words why they think the diagnosis had or had not influenced their actual reproductive 
decisions. Table 5 shows that a majority (70%) of the parents who reported that the diagnosis 
had influenced their decisions gave as a reason that they did not want to have another child 
with CF. Thirty-two of these 108 parents had children after the diagnosis of CF, and another 18 
had reproductive plans, suggesting that most of them used or planned to use reproductive 
options to have a healthy child. 
 
Table 5 — Reasons given by parents as to why they feel the diagnosis of their CF child 
had an influence (n=154) or no influence (n=114) on subsequent family planning  
 
 %  (n)a  
Influence, because 
  Do not want to have another child with CF 
  Undecided about further pregnancies   
  Easier to decide not to have any more children  
  No reason given 
  Other 
 
No influence, because 
  Family was completed 
  Want to have another child anyway 
  No reason given 
  Other 
  Was pregnant at the time of diagnosis  
53  (154) 
 
 
 
 
 
 
40  (114) 
 
70  (108) 
14  (21) 
  8  (13) 
  7  (10) 
  1  (2) 
 
 
50  (57) 
25  (29) 
18  (20) 
  4  (4) 
  4  (4) 
 
a Twenty parents (7%) did not know if the diagnosis had an influence on their plans.  
 
Of those parents who reported that the diagnosis of the CF-child had no influence on 
reproductive planning, 57 (50%) already had their initially planned number of children at the 
time of CF diagnosis (Table 5). Twenty-nine parents (25%) planned another child, with 23 
reporting that they planned to use or had already been using prenatal diagnosis.  
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Actual reproductive behaviour of CF parents 
So far we have described the perceived impact of CF diagnosis on subsequent family planning 
and reproductive intentions. Next we assessed the actual effect of the birth of a CF child on 
family planning as reported by the parents. Of all parents, 63% (181) had no further children 
after the diagnosis of their child with CF (Table 6). Of these parents, 33% felt their family was 
complete at the time of the diagnosis and 32% stated that they refrained from having further 
children due to the diagnosis of their child with CF. In addition, 28% were still planning more 
children, and 3% had a different or no partner.  
 
Table 6 — Actual reproductive choices of parents after the diagnosis of CF in a child 
 
 %  (n) 
Had no further children after diagnosis of probanda 
  Family complete 
  Wanted to avoid having another affected child  
  Subsequent pregnancies planned 
  Reason not clear from data 
  Different partner or no partner  
 
Was pregnant at time of diagnosis 
 
Had further children after diagnosis of proband 
  Used prenatal diagnosis 
  Termination of pregnancy 
  Risk of an affected child accepted 
  Had an unaffected child by other meansc 
63  (181) 
 
 
 
 
 
 
  4  (11) 
 
33  (96) 
  
33  (59) 
32  (58) 
28  (50) 
  5  (9) 
  3  (5) 
 
 
 
 
72  (69) 
21  (20)b 
25  (24) 
  5  (5) 
 
a At the time the questionnaire was completed; b Equivalent to 29% of parents who used prenatal 
diagnosis; c Artificial insemination (n=3), pre-implantation genetic diagnosis (n=1), adoption (n=1). 
 
A third of the parents (96/288) had more children after the diagnosis; 79% of them had one, 
and 17% had two more children. Eleven couples were pregnant at the time of diagnosis. Table 
6 shows the actual utilisation of prenatal diagnosis, termination of pregnancy and other options 
used by parents with subsequent pregnancies. The majority of parents who had more children 
(69/96) had one or more pregnancies monitored with prenatal diagnosis and 29% of them had 
at least one affected pregnancy terminated. One couple continued two pregnancies in which the 
child was diagnosed with CF at prenatal diagnosis. Twenty-four parents (25%) stated that they 
had accepted the 1-in-4 risk of having another child with CF. Five of these parents had more 
children with CF. Five parents (5%) had used other methods to have a healthy child. 
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Attitudes towards CF carrier screening and testing  
Table 7 shows the attitudes of adult patients and parents towards the statements in the survey 
concerned with population CF carrier screening and carrier testing. Nineteen percent of both 
adult patients and parents stated that all persons planning children should be screened for their 
CF carrier status. In contrast, 60% of adult patients and 56% of parents did not agree to this 
statement. A higher percentage of adult patients and parents supported the view that persons 
with a family history of CF should be carrier tested, with parents significantly more in favour 
than adult patients. If carriers know their status, 63% of adult patients and 69% of parents 
thought that they should have their partner tested when planning children. In addition, parents 
agreed more often than adult patients did with the statement that carriers should inform their 
family about their carrier status. 
 
Table 7 — Attitudes of adult patients and parents of children with CF (<16 years) toward 
statements about CF carrier screening and testing 
   
 Adult patients                Parents  
(n=287) %                     (n=288) % 
 
All persons planning a pregnancy should be 
screened for CF carrier status 
  Agree 
  Disagree 
  Neither agree nor disagree 
 
All persons with a family history of CF planning  
children should have themselves and, if necessary, 
their partner tested for CF carrier status. 
  Agree 
  Disagree 
  Neither agree nor disagree 
 
Carriers should have their partners tested  
before planning a pregnancy. 
  Agree 
  Disagree 
  Neither agree nor disagree 
 
Carriers should inform their family about 
their CF carrier status 
  Agree 
  Disagree 
  Neither agree nor disagree 
 
 
19   19 
60   56 
21   25 
 
 
 
 
56   66 
26   17 
17   17 
 
 
 
63   69 
24   17 
12   13 
 
 
 
56   80 
30   11 
14     8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Overall significant chi-square test,  p<0.05. 
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Discussion 
In the present study, the attitudes towards reproductive issues and carrier testing among those 
most closely involved with CF were considered. Also, the subsequent reproductive behaviour 
of parents who have had a previous child with CF was investigated. The results show that 
prenatal diagnosis is an important reproductive option for parents of children with CF. Most 
parents having or planning to have more children after the diagnosis of CF in a child used or 
intended to use prenatal diagnosis. Abortion for CF, however, was less acceptable for 
respondents when asked about their own intentions. The results also show that 66% of parents 
and 56% of adult patients supported carrier identification within CF families, and a majority of 
respondents supported testing of spouses of a CF carrier.  
We are aware of the limitations of our study. First, due to privacy aspects, we were not 
able to do a non-response research. Therefore we are not sure how representative the data are. 
Nevertheless, the responses can be assumed to represent 70% of adult patients, which is a 
sufficiently high response. The response to the questionnaires of CF children was assumed to 
represent 53% of children younger than 16 years in the Netherlands. However, the study only 
considered parents with one or more living CF children. Parents of a child who died from CF 
were not questioned. Second, the data analysed for this study originated from responses to 
questions that were developed as part of a unique national enquiry on the impact of CF on the 
quality of life. Therefore, we were limited to the data available. No information was available 
on actual family size, birth-rank of child with CF, contraceptive behaviour, and sociodemo-
graphic characteristics of parents. The data, however, gave us clear information about the CF 
parents’ reproductive intentions and behaviour. 
CF is a disease with highly variable clinical characteristics and increasing possibilities 
for treatment, which has extended life expectancy and improved quality of life over the past 
decades. Median survival in the Netherlands now exceeds 30 years. Nevertheless, our results 
show that prenatal diagnosis is considered a very important reproductive option for parents of 
children with CF. Of all parents, 59% said they would have used prenatal diagnosis if they had 
known beforehand about their risk. This result suggests that these parents not only support 
carrier couple identification before the birth of an affected child, but that they also support 
taking further action upon this information, that is, they would have used prenatal diagnosis 
themselves. Of all parents planning children, 76% indicated that they would opt for prenatal 
diagnosis in a subsequent pregnancy, while 72% of parents who had more children after the 
diagnosis of CF in a child had utilised this option. In addition, six parents who did not have any 
more children, due to termination of pregnancy, miscarriage, or because they were pregnant at 
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the time of the study, and therefore excluded from the analyses, also had their pregnancy 
monitored by prenatal diagnosis. This suggests that the use of prenatal diagnosis is actually 
somewhat higher than 72%.  
We compared our data with the results of other studies. Comparison has its limitations, 
however, in view of probable cultural differences in the population at study. Nevertheless, 
actual use of prenatal diagnosis in our study is more or less consistent with the studies of Wertz 
et al2 and Dudding et al,10 in which respectively 77% and 70% had had or were considering 
prenatal diagnosis. However, other studies showed lower interest in prenatal diagnosis, and 
infrequent use of it. In an earlier study in California,11  before prenatal tests became available, 
78% of all parents felt that prenatal diagnosis would provide an important option for families at 
risk. However, only 32% indicated that the availability would have changed their own 
reproductive plans. In a study of Jedlicka-Köhler et al,6 51% were interested in prenatal 
diagnosis and only 28% (5/18) of the parents finally agreed to prenatal diagnosis. A percentage 
of 22% (5/23) was observed in an American study7 on parents of a child with CF identified in a 
neonatal screening programme. The authors of these two more recent studies concluded that 
subsequent conceptions and pregnancies were not influenced by the availability of prenatal 
diagnosis.6 7 Others suggested that differences in attitudes towards the use of prenatal diagnosis 
could be explained by cultural differences in beliefs and attitudes,12 family structures, and 
future prognosis for children with CF.2 5 
In the present study, the intention to use prenatal diagnosis was significantly associated 
with the strength of religious conviction. Those parents who were not religious would make 
use of prenatal diagnosis more than religious parents. This is most likely related to the 
unwillingness to abort of those with a religious conviction. Opinions on elective abortion in 
general, however, were not queried. Attitudes towards prenatal diagnosis were not predicted by 
the child’s health or by the perceived severity of CF. In addition, no influence was found of 
future expectations, such as the development of gene therapy and lung transplants on parents’ 
intention to use prenatal diagnosis. An earlier study11 has shown that the attitudes towards 
availability of prenatal diagnosis were associated with religion, views on abortion, number of 
children, and family income. Others have found that intentions to use prenatal diagnosis were 
associated with attitudes towards abortion, perceived approval of siblings, and absence of listed 
accomplishments by the child with CF, such as having friends or living a normal life,2 but also 
by the presence of healthy children.5 13 
In our study, lack of religious conviction was also among the strongest factors related to 
parents’ consideration to abort a CF affected pregnancy. Other factors in predicting the 
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consideration of abortion were the impact of CF on daily activities, relatives tested for 
carriership, and the perceived severity of CF. The negative effects of CF on daily life and the 
perception of severity of CF possibly reflect the burden of the disease on the family and the 
child. These parents might have experienced great difficulties that accompany CF and therefore 
may not be able or may not want to cope with another sick child. The positive relationship 
between the attitude towards abortion and carrier testing of relatives might be explained by the 
association of a positive family attitude towards carrier identification and reproductive options, 
such as abortion. This is supported by the finding of Wertz et al,14 showing that perceived 
extended family attitudes towards abortion was among the factors most strongly related to 
willingness to abort for CF. 
Adult patients were less in favour than parents to consider terminating an affected 
pregnancy, respectively 29% and 57%. A comparable study in the United Kingdom showed 
that 23% of female patients would abort an affected fetus.4 However, 68% of all patients in that 
study thought that termination of pregnancy was acceptable, suggesting that patients consider 
termination acceptable in general but not for themselves.4 Male patients were less than female 
patients in favour of considering abortion, respectively 22% and 40%. An explanation for this 
may be that most male CF patients are not able to have children themselves due to infertility. 
Although a large majority planned to have their pregnancy monitored by prenatal 
diagnosis, the proportion that would consider aborting an affected fetus was considerably smaller. 
Fifty-seven percent of parents planning children indicated a willingness to consider terminating a 
pregnancy if the fetus was found to have CF, whereas 76% would use prenatal diagnosis. This was 
also shown in other studies.1-3 15 16 This discrepancy could be partly explained by the fact that 
many parents were unsure about the decision to actually abort (26%). Evers-Kiebooms et al15 had 
already suggested in 1988 that many parents will need psychosocial support in the decision-
making process about prenatal diagnosis. Also, Frets et al17 found that parents who were eligible 
for prenatal diagnosis experienced the decision-making process as more difficult compared with 
those for whom prenatal diagnosis was not available. Although we do not know how many times 
the parents had opted for prenatal diagnosis, 29% of those who had used prenatal diagnosis had 
had an abortion. If we take into account the 25% risk of CF parents of having an affected child, 
these results suggest that most parents with an affected fetus choose to abort it. Different studies 
showed that, among parents of children with CF, actual abortions for CF after positive prenatal 
diagnosis in different studies were 64%-100%.10 18-20 
The intention of parents to use other reproductive methods than prenatal diagnosis 
exceeded the actual use. Eighteen percent reported that they would use other methods, while only 
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one parent had an adopted child, two parents used artificial insemination, and one parent 
succeeded with pre-implantation genetic diagnosis. The results also show that parents who were 
certain about having more children would be more in favour of using these other methods than 
parents who were not certain about having more children. Fifty-eight parents decided to refrain 
from having more children in order to avoid another child with CF, which reflects a further 
reproductive decision besides prenatal diagnosis and other methods of having a healthy child. 
 In common with other studies,3 10 11 15 19 21 parents in the present study reported the 
influence of CF on subsequent reproductive plans. Our findings that 53% of parents reported 
the influence of the diagnosis of the CF child on subsequent family planning closely resembles 
the 48% among families in an earlier survey.11 However, the reasons why the diagnosis 
influenced their decisions were different. In the study of Kaback et al,11 60% had no further 
children, and 36% had fewer children. Before prenatal tests became available, the child with 
CF always tended to be the last child born in the family. In the present study, 70% of parents 
reported that they did not want to have another child with CF, however, half of this group had 
or planned to have more children using the reproductive options available.  
Some parents reported that CF influenced their reproductive decisions because they 
may have to use prenatal diagnosis. Remarkably, other parents reported no influence of CF on 
childbearing decisions because of the availability of prenatal diagnosis. These results suggest 
that the impact of the availability of prenatal diagnosis is being perceived differently among 
parents. 
In order to find out what those most involved with CF think about population CF carrier 
screening and about carrier testing within CF families, we analysed the responses of CF parents 
and adult patients to, admittedly, extremely formulated statements about these concepts. The goal 
of carrier identification for CF is to provide couples, who want it, with information that permits 
them to make informed reproductive decisions. The majority of parents and adult patients 
confirmed that carriers should have their partner tested if they plan to have children. Previous 
studies have shown that the majority of CF parents support population carrier screening.1 4 In 
addition, 63% of adult patients were in favour of screening before pregnancy and 88% supported 
prenatal screening. Only a minority of 10%-22% of parents and patients felt that screening should 
be restricted to families with a family history of CF.4 In the present study, parents more than adult 
patients supported the notion that carriers should inform their family about their carrier status. One 
possible reason for this difference in openness between parents and patients may be that some 
patients do not talk about their illness, because they want to be considered as normal as possible 
and feel uneasy or even guilty when the trait is discussed within the rest of the family. In addition, 
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their parents might want to inform other relatives about the family risk of CF. Parents and patients 
were less often in favour of having all persons in the general population planning children 
screened for CF carrier status. However, this result may be due to the formulation of the statement, 
i.e. ‘all persons planning children should have themselves tested’. This phrase was directed at an 
obligatory screening. If screening is presented as a free choice, a higher percentage of agreement 
can be expected, as has been found in other studies.1 4 Overall, the present results suggest that most 
parents and adult patients support the possibility of carrier couple identification before the birth of 
an affected child, which also suggests that the introduction of carrier couple identification will 
probably not be a controversial issue among those most closely involved with CF. However, their 
opinions should be taken into account more extensively when future implementation is considered. 
In conclusion, the aim of the present study was to consider the attitudes towards 
reproductive issues and CF carrier testing among parents of children with CF and adult patients as 
reflected in the response to a national study. Overall, the results suggest that whereas patients and 
parents will accept the use of reproductive options such as prenatal diagnosis and abortion by 
carrier couples identified in the general population, a personal decision on abortion for CF is not 
such an easy matter. In our opinion, close attention should be given to the counselling and support 
of high-risk couples in the decision-making process regarding reproductive choices. In addition, 
although it is difficult to predict the reproductive behaviour of couples identified in carrier 
screening programmes, the present results suggest that couples with a high risk of having a child 
with CF will make use of the reproductive options available. 
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Abstract 
This qualitative study explores the experiences of cystic fibrosis (CF) carrier couples, 
prospectively identified in CF families, and the impact of the resulting genetic risk on 
reproductive behaviour. Of the 12 couples identified until 1997, seven couples participated in 
semi-structured interviews and two couples filled in a questionnaire, two to eight years after 
receipt of the test-results. After receiving the results, most couples reported that they were 
shocked, because they did not expect to be both carriers. More anxiety was expressed by those 
who were pregnant (n=4) at the time of testing. There were reported difficulties in disclosing 
the results to family members, and the reactions of family members were not always 
supportive. After testing, some couples had problems with reproductive decision-making. All 
viable pregnancies (17 in 8 couples) were monitored by prenatal diagnosis; all affected 
pregnancies were terminated (6 in 4 couples). Couples who have live-born children after 
testing may subsequently have concerns during infancy about the correctness of the results of 
prenatal diagnosis and how to inform their children. Most couples did not regret the testing 
and, in general, the counselling was experienced positively, although some dissatisfaction was 
reported with regard to the psychological support received during pregnancy. Couples 
supported the idea of carrier screening in the general population, although various concerns 
were expressed. The results indicate a preference for testing before pregnancy. These findings 
may be useful in investigating possible dilemmas caused by the introduction of population 
carrier screening. Observations reported here might also apply to other recessively inherited 
disorders. 
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Introduction 
Cystic fibrosis (CF) is one of the most common autosomal recessive genetic disorders among 
Caucasian populations with a birth prevalence of 1 in 2500-4000. Despite advances in 
treatment, there is still no cure for CF. Approximately 1 in 25-32 Caucasians are CF carriers. 
As far as we know, CF carrier status is completely harmless to the carrier’s health. However, if 
two partners are carriers they face a 1-in-4 risk of having a child with CF. Extensive research 
has been carried out to investigate the attitudes and reproductive behaviour of carrier couples, 
but most of the information has been obtained from carrier couples identified after the birth of 
a child with CF. In these couples, the reproductive decisions are predominantly influenced by 
their experiences with CF. There is only little data available on the experiences of carrier 
couples identified before the birth of an affected child, consisting mainly of quantitative data 
on reproductive outcomes obtained from carrier screening programmes.1 2 No study has yet 
reported the personal experiences and attitudes of these carrier couples. 
Since 1989, CF carrier couples can be prospectively identified before the birth of an 
affected child by means of carrier screening programmes, or through knowledge of a family 
history of CF. In most countries, the desirability and feasibility of the introduction of CF 
carrier screening programmes is still being investigated. The study of carrier couples, identified 
as a result of specific carrier testing, provides an opportunity to obtain more data on the 
possible dilemmas caused by the introduction of screening in the general population. In carrier 
couples identified within CF families there is usually one partner with no family history of the 
disease, and their experiences might help in the development of educational and counselling 
strategies for future identified carrier couples where there is no (known) family history of CF.  
The purpose of this qualitative study was therefore to investigate the personal 
experiences of carrier couples identified by testing in CF families before the birth of an 
affected child in order to (1) explore their experiences with genetic carrier testing, (2) explore 
the effects of prospective risk on reproductive plans and family relations, and (3) to assess 
whether improvements are necessary in the provision of genetic counselling and services for 
these couples. 
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Methods 
Procedure 
Until 1997, the DNA Diagnostic Laboratories of Groningen and Rotterdam in the Netherlands 
provided medical records of 12 prospectively identified CF carrier couples. All couples had 
requested DNA testing because of a positive family history. In our request, the couples were 
contacted by their clinical geneticist and asked to participate in the study. The experiences and 
attitudes of the couples were assessed by means of interviews held between 1998 and 1999. 
Partners were interviewed together, at home, by a member of the research team (LH). The 
Medical Ethical Committees of the University Hospitals in Amsterdam, Groningen and 
Rotterdam all approved the study protocol. 
 
Instruments 
A 70-item semi-structured interview protocol was developed, containing questions about: 
family history of CF, perceived burden of CF, factors influencing the decision to have the test, 
experiences with the carrier testing process, disclosure of test-results to family members, the 
impact of positive results on reproductive decisions, and satisfaction with the social support 
and counselling provided. In addition, attitudes towards carrier screening in the general 
population were assessed. The interviews were transcribed verbatim and the responses to 
questions were analysed. The answers given by each partner were evaluated separately.  
 
Subjects 
Of the 12 identified couples approached, nine couples gave their informed consent to 
participate in the study. Seven of them were interviewed. The other two couples only agreed to 
complete a mailed questionnaire containing questions similar to those asked in the interview. 
Table 1 shows some characteristics of the couples. All carrier couples had been identified two 
to eight years before they were contacted to participate in the study. In seven of the couples, 
one partner had a family history of CF, and in two of the couples, both partners had CF in their 
family. At the time of the interview, the women ranged in age from 28–36 years, with a mean 
age of 33.0 years. The mean age of the men was 34.3 years (range 30–38 years). Although 
most respondents reported that they were religious, only one couple went to church regularly 
(once a week).  
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Results 
Familiarity with CF 
All couples were asked about their personal experiences with CF. In three couples, at least one 
partner had experienced the death of a CF patient. Table 1 shows that four couples, although 
tested for CF carrier status on family indication, had had no personal experiences with the disease 
CF. Those with no family history of CF mostly reported that they first learnt about CF when they 
met their partner and his or her family. Most respondents perceived CF as being a serious to very 
serious disease.  
 
Table 1 — Characteristics of CF carrier couples  
 
Couples 
 
Relative with CF in family         
at the time of interview 
Personal experiences 
with CF 
Years between receipt of 
test-results and interview 
01  M 
      F 
02  M 
      F 
03  M 
      F 
04a M 
      F 
05  M 
      F 
06  M 
      F 
07  M 
      F 
08  M 
      F 
09a M 
      F 
Sib†, nephew 
-- 
Sib†, nephew†, 2nd cousin† 
-- 
Two sibs 
-- 
Nephew†, nephew 
Sib† 
2nd Cousin 
Sib† 
-- 
Nephew, cousin 
Sib† 
-- 
-- 
2nd Cousin 
-- 
Sib† 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
8 
 
5 
 
6 
 
8 
 
5 
 
2.5 
 
2 
 
5 
 
M=male; F=female; a Completed questionnaires; † Patient with CF has died. 
 
Information on carrier risk and testing 
The couples were asked how they found out that they were at risk and that they could be tested. 
Of two couples, one of the partners was identified as a carrier after participating in scientific 
research when they were young. Two couples read about carrier testing for families with a 
history of CF in a magazine, after the CF-gene was found in 1989. The other couples were told 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
No 
Yes 
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about testing by relatives (n=3) or by a midwife (n=2). Five couples did not realise that they 
were at risk until they read about it (n=1) or when other people told them (n=4). One man 
found it difficult to share the news with his wife because she was pregnant when he was 
informed about their risk: 
(08) “When she was seven months pregnant, her mother called and told me it was in the 
family. At that moment, I didn’t think it was sensible to put the burden on her, so I didn’t 
tell her. In my opinion, the chances were not very high that I could also be a carrier. A 
few weeks after the baby was born, I thought: he hasn’t got it…he was growing well and 
had passed all the growing curves. Then I decided to tell her.” 
  
Decision to have the test 
All couples reported that their main reason for wanting to be tested was to gain certainty. One 
couple reported that they had the test because the midwife had advised them to do so: 
(07) “The midwife urged us to have the test, but we didn’t really want to. We planned to 
go on holiday two days later. At that moment, we didn’t realise we were at risk. My 
husband’s brother had died of CF, but that didn’t mean my husband was a carrier and 
there wasn’t any CF in my family. We also didn’t want to confront his parents with it, 
because they’d already lost a child with CF.” 
Before having the test, most partners with a family history of CF thought that their risk of 
being a carrier was high. This high perceived risk was often not considered to be a burden, 
because the risk of the other partner was perceived as low. Two couples in which both partners 
had a family history of CF reported a high perceived risk of both being carriers, and felt rather 
anxious. However, the wish to have more certainty overruled these feelings, as one woman 
said: 
(05) “We had a high risk, higher than others. On the one hand, you think it will be okay 
and you hope to hear that everything is all right. On the other hand, there was fear and 
anxiety. However, it wasn’t difficult to make the decision to have the test, because we 
wanted certainty.” 
All but two men talked to their parents about carrier testing, and several couples had discussed 
it with other members of the family. Some received advice, but they all felt it was their own 
decision. Four couples talked to their general practitioner (GP).  
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Two couples reported that members of their family and their GP wondered whether it was 
necessary, as one woman explained: 
(08) “We talked to both our parents and to our GP. The GP was not sure whether we 
should have the test, whether if it was worthwhile. My father also asked whether it was 
necessary. He didn’t want to face it. My mother-in-law also wondered if we should do it. 
It didn’t occur in their family anyway.” 
 
When and how testing took place 
All couples were tested between 1989 and 1995. Six couples were the first to be tested in their 
families. Table 2 shows that four couples had sequential testing, one partner with a family 
history of CF tested first and the other partner tested later. The test-results were received 
between two weeks and five months later. Although most couples were not too worried while 
waiting for their results, this period was perceived as very long for almost everybody. The 
three couples with a pregnancy before testing received their results earlier than the other 
couples.  
 
Table 2 — Ways of carrier couple testing for CF  
 
Couples Way of testing Pregnancy 
during testing 
Weeks between testing (last 
partner) and receipt of results 
01 
02 
03 
04 
05 
06 
07 
08 
09 
Sequential 
Sequential 
Sequential 
Simultaneous 
Sequential 
Simultaneous 
Simultaneous 
Simultaneous 
Simultaneous 
No 
Yesa 
No 
No 
No 
No 
Yes 
Yes 
Yes 
2 
14 
20 
13 
8 
16 
3 
3 
3 
 
a Couple became pregnant while waiting for the results. 
 
Reaction to test-results 
The partners with a family history of CF were not surprised to hear that they were carriers. 
However, to hear that they were both carriers came as a shock for most couples. The shock was 
even greater for the four couples with a pregnancy. In addition, those who received their results 
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by telephone (three couples) were less satisfied with the method of communication than those 
who had an appointment at the Clinical Genetic Centre, as one woman said: 
(08) “The doctor called and said: “you are both carriers”. We had never, never thought 
about it. It was a terrible shock, I cried at home and called my husband at work, but he 
was in a meeting and therefore couldn’t come to the phone. It was a dreadfully unhappy 
situation.” 
Two couples immediately seemed to be able to handle the results quite well. They were 
surprised for a moment, but carried on with their lives, as one woman explained: 
(03) “My first reaction was: how on earth could this happen? However, we accepted it. It 
was unexpected, but that’s the way it is. We’re a carrier couple and that’s it.” 
 
Disclosure of test-results to others 
Most couples immediately told their parents about the results. Three pairs of parents felt very 
bad about it when they heard the news, and now sometimes feel guilty because they had passed 
it on to their children. Two of these pairs of parents had given birth to children with CF, and 
they felt it as a burden that their grandchildren were also at risk. Most couples felt supported by 
their family. In four families with no history of CF, the parents wanted to know which side it 
came from. Two of these couples felt less supported by their parents because of the disbelief 
they expressed. These parents felt it difficult to understand that something was wrong, because 
they had had healthy children themselves. Although for most couples it was self-evident to tell 
other members of the family about the test-results, some couples did not inform them 
immediately for various reasons. The parents of one couple at first discouraged them to tell the 
rest of the family, because they thought it was not necessary. Two couples did not tell family 
members who were not planning to have children at that moment. Two couples had problems 
with talking openly to other people in general and especially about the consequences of testing. 
They expected that most of their family and friends would not support the idea of abortion. 
When told about their risk, most of the relatives in three of our seven families with no history 
of CF ignored the information. They perceived a low risk, as one woman explained:  
(03) “They didn’t pay much attention to it and they still don’t, in my opinion. Maybe 
they put it aside or think the chance is so small. I think it’s further away from them 
because in my family there are no people who had CF.” 
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Reproductive decisions after testing 
All couples were asked if their plans for having children had changed after the test. In two 
couples there were fertility problems. Three couples did not feel that the test-results influenced 
their reproductive plans. Four couples, at one point after testing, reported that they had great 
difficulty in deciding whether to have more children. They felt it difficult to make a decision 
about prenatal diagnosis in a subsequent pregnancy. One of these couples decided to have 
fewer children than originally planned, which they found difficult: 
(02) “We planned to have three or four children. We’re both from a big family. For a 
long time, I still wanted to have more children, but my husband didn’t. Later on he 
wanted to get more information about having children in another way. It was difficult 
and it’s still difficult sometimes.” 
After receiving the test-results, there were 17 viable pregnancies in nine couples (Table 3). All 
pregnancies were monitored by prenatal diagnosis. Six were affected in four couples, and were 
all terminated.  
 
Table 3 — Reproductive outcome in CF carrier couples  
 
Couples Number of children 
before carrier testing 
Viable pregnancies 
after carrier testingc 
Affected pregnancies 
terminatedd 
Total number of 
children 
01a 
02 
03 
04b 
05 
06b 
07a 
08 
09 
 
Total 
- 
1 
- 
- 
- 
- 
- 
1 
- 
 
2 
3 
1 
1 
- 
4 
1 
2 
1 
4 
 
17 
1 
- 
- 
- 
2 
1 
- 
- 
2 
 
6 
1 
2 
1 
- 
2 
- 
1 
2 
2 
 
11 
 
a Pregnant at the time of interview; b Fertility problems; c All pregnancies were monitored with prenatal diagnosis; 
d All affected pregnancies were aborted. 
 
In four couples, the woman was pregnant at the time they received the test-results. They felt 
very anxious when awaiting the results of the prenatal diagnosis that followed. Two couples 
explicitly reported a favour to have carrier testing outside the pregnancy, as one woman said: 
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(07) “I think that if we knew it before the pregnancy, the situation would have been more 
clearer, you would then have already gone through it. You would know what to decide.” 
The couples in which there was a pregnancy after receiving the test-results were prepared, 
although they felt rather reserved during the first few months:  
(03) “We had to wait until I was ten weeks pregnant. You realise you’re pregnant, but 
you also realise that the pregnancy might be terminated and you don’t know what’s going 
to happen.” 
Seven couples had children at the time of the interview. Two couples already had a child when 
they found out that they were carrier couples, and they then had the child tested for CF. Two 
couples (still) had no children because of fertility problems. Both couples had tried to get 
pregnant with in vitro fertilisation (IVF); one succeeded but ended the pregnancy because the 
fetus was affected. Of those who had children after testing, four couples reported that they had 
had some doubts about the accuracy of the results of the prenatal diagnosis after they had heard 
that the child was not affected. These doubts mostly occurred when the child was young and 
when he or she showed symptoms comparable with CF, such as coughing or sweating. For all 
couples, the doubts vanished when the children grew older. One couple had a sweat-test three 
months after the child was born, in addition to the results of prenatal diagnosis, to gain more 
certainty. Two couples sometimes checked the sweat or stool of the child. Reasons not to have 
any doubts sometimes seemed to have to do with decisions that were made, as one woman 
commented: 
(01) “I don’t think about CF when the child is coughing, because that would mean you 
would also have your doubts about the child that was aborted: that it might have been 
healthy.” 
 
Satisfaction with testing 
One man said that he regretted telling the midwife that he had a brother with CF, because if he 
had not done so, they would not have had all the misery during his wife’s pregnancy. 
Nevertheless, afterwards they were very glad they knew about their risk. In total, eight couples 
said that they did not regret the testing. One couple had an induced abortion, but still felt that it 
was a very difficult decision they had to make. They felt that their happiness was 
overshadowed by the affected pregnancy. The woman in this couple sometimes also felt angry 
about meeting her husband because he had confronted her with the disease. 
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Disclosure of test-results to the children 
All couples with children stated that they would tell their child(ren) about carrier testing and 
their (possible) status when they are old enough to understand. Three couples knew the test-
results of their children already, because they had been given to them after prenatal diagnosis. 
Two couples expressed dissatisfaction about not knowing the test-results of their children. Two 
couples felt it would be difficult for them to tell their children about carrier testing, because 
then they might have to tell them about the other decisions they had made, as one woman 
explained: 
(05) “We think that’s very difficult. It means you’ll also have to tell the rest of the story, 
that there were two other children aborted.” 
 
General aspects 
Before testing and after receiving the test-results, all couples received face-to-face genetic 
counselling. All couples understood quite clearly what they had been told, and most couples were 
satisfied with it. One couple felt that the information given to them was too general and not 
tailored to their personal situation. This couple had received a letter summing up all the 
possibilities for carrier couples, starting with the option to refrain from having children. Since the 
woman was already pregnant, and they had a great wish to have children, they did not feel 
emotionally supported. Some couples (n=3) reported that they would like to hear more about other 
couples in a similar position. There was also a need for more information on other ways of 
becoming pregnant, i.e. pre-implementation genetic diagnosis.  
There was some dissatisfaction with the psychological support received during pregnancy. 
Two couples reported that they might have wanted to talk to someone at certain times. The social 
worker visited four couples during or after pregnancy. However, three couples were not 
completely satisfied with the counselling they received. The couple who heard that the pregnancy 
resulting from IVF was affected with CF had a meeting with the clinical geneticist and the social 
worker, and were very dissatisfied with the conversation and the feed-back, although they fully 
realised their unfortunate situation:  
(06) “We had to explain to them whether or not we clearly understood what had become 
known and what we would do about it. We knew that already of course. We came there, 
well…for them it’s difficult too…, we came there to hear that it wasn’t true. That’s what 
you want to hear, but it can’t be.” 
 
Personal experiences of carrier couples 
 74 
Attitude towards carrier testing 
In general, couples supported the idea of screening. However, they also expressed various 
concerns, such as the difficult decisions that would have to be faced, the necessity of receiving 
adequate information, and the fact that CF screening does not guarantee that the child is 
healthy. In addition, one respondent expressed concerns in view of the improved life-
expectancy of CF patients. Another person argued that if you promote screening you might 
give people the impression that handicapped people do not have a right to live. Some couples 
also wondered whether there would be sufficient interest in screening. Most couples (n=7) 
thought that the best way to offer screening was to invite couples or individuals (not at school) 
to participate outside the pregnancy. Moreover, most respondents said that people should 
decide for themselves whether they want to have the test and when. 
 
Discussion 
As far as the authors are aware, this is the first study to address the personal experiences of CF 
carrier couples identified through genetic testing before the birth of an affected child. Caution 
is obviously needed in drawing conclusions from the findings, given that they are based on 
interviews conducted in a small study sample. Moreover, in most cases, the interview took 
place years after the carrier testing was performed (retrospective), and it is likely that there is 
selective retention of information and/or incorrect recall. Follow-up of couples at a regular 
interval after receiving the results would have been better, however, it would have taken years 
to have the data available and, in our opinion, this study has already provided some interesting 
results. Furthermore, more (recent) interviews could have provided additional qualitative data. 
However, this could not practically have been performed because all known prospectively 
identified couples were approached at the start of the study. Nevertheless, the couples were 
rather heterogeneous in their experiences and therefore illustrated a whole range of aspects 
related to the carrier testing process. Another point is that these findings should not be 
generalised without further study to couples identified in genetic screening programmes, but 
with no family history of CF. On the other hand, although they had a family history of CF, half 
of the couples included in this study had no direct experience with the disease.  
The results of the study show that, although in all nine couples there was at least one 
partner with a family history of CF, five couples did not realise that they were at risk until they 
read about it or when other people told them. Consequently, in four couples the woman was 
already pregnant when they had the test. A possible explanation for the lack of information 
about the risk and carrier testing is the limited dissemination of information throughout the 
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family.3-5 The main source of information is often the parents of an affected child,3 by whom 
the information on genetic transmission of CF is sometimes only partially passed on to their 
relatives.4 In addition, relatives tend to under-estimate their carrier risk 5-7 and therefore might 
have no intentions to be tested for carrier status. In the present study, the decision to have the 
test was not always supported by others, i.e. GP or family, because they do not always consider 
it to be necessary. One couple had doubts about testing and one of their reasons was that they 
wanted to spare the feelings of their parents. Lack of parental communication as a barrier to 
carrier testing was also reported by 63% of adult CF sibs in a study carried out by Fanos et al.8 
To avoid arousing feelings of guilt in their parents, Williams and Schutte9 also found that after 
testing, carriers had trouble with decisions regarding disclosure of the results to family 
members. The present findings show that it was, indeed, difficult for some parents to hear that 
they had passed the trait on to their children. 
After testing, some couples perceived problems with reproductive decision-making. The 
results suggest that couples who decided before prenatal testing what they would do if the 
results were positive had less difficulty making reproductive decisions. Factors associated with 
problems in the reproductive decision-making process have been reported by Frets et al,10 
including the anticipation of a high-risk level, a decision against having children, and relatives’ 
disapproval of their decision. In the present study, some couples felt that their relatives 
disapproved of their decisions, and this withheld them from talking about their problems. 
Another important factor described in the literature that influences the decision-making process 
is the presence of affected children. The presence of an affected child, or death of a child with a 
birth defect, made couples more likely to remain undecided about further reproductive 
decisions.10-12 This factor is an important difference in decision-making between the 
prospectively identified couples in the present study and a couple identified after an affected 
child is born. In parents of children with CF, the decision concerning further pregnancies is 
based on their experiences with an affected child, whereas in prospectively identified couples, 
the decision is based on the information given by the genetic counsellor or on their experiences 
with CF in the family. In a Dutch study among 288 parents of a child with CF, most parents 
decided against further pregnancies or used other reproductive options to avoid having another 
affected child. Prenatal diagnosis was requested by 72% of parents, whereas 76% of parents 
planning to have more children intended to request it.13 The results of the study reported here 
show that all pregnancies were monitored by prenatal diagnosis, and all those with an affected 
fetus were terminated. The uptake of prenatal diagnosis of high-risk couples prospectively 
identified during prenatal carrier screening for cystic fibrosis was 93%.14 In general, the 
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couples included in the present study supported the idea of screening, although various 
concerns were expressed. The results indicate a preference for testing before pregnancy 
(preconceptional). Prenatal screening leaves limited reproductive options for a carrier couple, 
and might impose time-constraints when decisions about a prenatal diagnosis have to be 
made.15  
In this study, it was found that some couples who had healthy children were concerned 
about the correctness of the results of prenatal diagnosis during infancy. This lack of 
reassurance after favourable test-results was also found in other studies. Weinans et al16 
demonstrated that 13% of women who had a negative serum screening result for Down 
syndrome continued to experience some degree of anxiety, which was in line with the findings 
of Marteau et al.17 Grosfeld et al18 suggested additional counselling for parents questioning the 
reliability of DNA results for their children tested for the early-onset, cancer disorder multiple 
endocrine neoplasia. 
Although the small size of the study and the measurement limitations limit suggestions, 
the results of this study indicate a few practical issues that need to be addressed to the carrier 
testing procedure. Firstly, although couples generally experienced the counselling positively, 
there was dissatisfaction with the psychological support provided, especially during pregnancy 
when awaiting the results of prenatal diagnosis. Therefore, the provision of psychosocial 
support is recommended for couples who decide to undergo prenatal diagnosis. Secondly, the 
period of waiting for the carrier test-results was perceived as very long. Although this waiting 
period may currently be shorter, efforts should be made to speed up the analyses and disclosure 
of test-results. Thirdly, the results suggest that those who received their results by telephone 
were less satisfied with this method of communication. In order to avoid an unhappy situation 
when receiving the results, agreements should be made before testing about the method of 
communication, so that people can share their preference with regard to the way in which they 
want to receive their results. Fourthly, couples should be prepared for the possible indifferent 
reactions of relatives who are informed about the test-results. The findings may be useful in the 
development of additional qualitative and quantitative studies to examine more closely the 
experiences of prospectively identified carrier couples. 
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Abstract 
The feasibility and acceptability of different modes of offering preconceptional carrier screening 
for cystic fibrosis (CF) was investigated, in the absence of established preconceptional care 
services. Individuals, aged 20-35 years, were invited by mail, either by the Municipal Health 
Services (MHS) or by their general practitioner (GP) to participate in a screening programme with 
their partner. Pre-test education was provided either during a group educational session or during a 
GP consultation. The reasons given by participants and non-participants for (non-) participation, 
sociodemographic characteristics and their attitudes were assessed by means of questionnaires. Of 
38,114 individuals who received a first invitation, approximately 20% had a partner with whom 
they were planning to have children. Of these, attendance at an educational session, either invited 
by the MHS or by their GP, was 9.2% and 11.9%, respectively. The response rate was higher 
when information was provided during a GP consultation (24.7%). A total of 559 couples (96%) 
consented to have the test after education. Repetition of the invitation increased the response. The 
main reason given by couples for non-participation was “lack of time to attend” or “forgot about 
it” (48%). Another reason given was that they did not want to know their test-results (28%). Sixty-
nine percent of non-participants and 89% of participants believed that screening should be offered 
routinely to couples planning to have children. The GPs consulted (n=18) reported no negative 
experiences, but due to the extra workload 11 of them would not consider it to be part of their 
task. Among couples planning to have children, there is generally a positive attitude towards 
routinely offering population-based CF carrier screening. Preconceptional CF carrier screening 
appeared feasible, both in terms of practical achievements and target group accessibility. 
Participation varied according to the pre-test education setting, with the primary care setting 
producing the highest rate of attendance.  
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Introduction 
Cystic fibrosis (CF) carrier couples have a 1-in-4 risk with each pregnancy of having a child 
with CF. The purpose of CF carrier screening programmes in the general population is to 
inform such couples, if they wish, about their risk and the reproductive options available. In 
most countries, CF carrier screening is not included in standard care and the debate centres on 
the question of whether it is, indeed, desirable. However, in the USA, a Consensus 
Development Conference convened by the National Institutes of Health recommended that 
genetic screening for CF mutations should be offered to couples currently planning a 
pregnancy and to couples seeking prenatal care.1 If population screening takes place, additional 
questions arise, e.g. where it should be offered (in primary care, in the antenatal clinics or in 
some other setting), who should offer it (GPs, practice nurses, co-workers in genetics, 
midwives, or other health professionals), and about the timing (before or during pregnancy). 
Several studies have compared different methods of approach to population-based 
screening.2-5 However, these studies all focused on the level of uptake as the main study 
outcome. Since participation in screening must be voluntary and based on an informed 
decision,6 a number of conditions should be met before a screening programme is initiated. 
Firstly, population-screening programmes should comply with current legislation. For 
example, in the Netherlands screening should meet the criteria for genetic screening formulated 
by the Health Council of the Netherlands.7 Secondly, if screening is offered to the general 
population, this should be done in such a way that all individuals are ensured of an equal 
opportunity to participate. It should not be dependent on a person’s occasional visit to a general 
practice. Thirdly, to ensure that people accept the test because they are motivated, strong 
recommendation or persuasion by direct personal contact and the possibility of immediate 
testing must be avoided.8 9 Fourthly, individuals should make some effort to participate, to 
ensure their motivation, but serious practical barriers should be avoided. Finally, those 
approached should be provided with comprehensible, objective and balanced information, and 
enough time to make a decision on whether or not to participate.  
In view of (a) current legislation, (b) the high percentage (85%) of planned 
pregnancies,10 and (c) the late presentation of pregnant women to a health care worker, a 
preconceptional approach seems to be a suitable method of choice for CF carrier screening in 
the Netherlands. Preconceptional screening also provides a maximum number of reproductive 
options and a minimum of (time) constraint.11 One disadvantage of this approach, however, is 
the absence of an appropriate health care structure, and the resulting considerable effort needed 
to reach the target population. Given these considerations, a preconceptional screening 
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approach was chosen for this study. Individuals aged 20-35 years were offered screening by 
mailed invitation. Pre-test information on CF was provided in writing and verbally by a health 
worker. The screening unit in the study was the couple, since it has been reported that the 
attitudes and perceptions of both partners are important in the decision on whether or not to 
have the test.12 
  As the objective of the study was to assess the acceptability and feasibility of offering 
preconceptional CF carrier couple screening, the following questions were addressed: 1) What 
is the response rate to screening? 2) Are there differences in sociodemographic characteristics 
between participants and non-participants? 3) What is the main reason given for (non-) 
participation in screening? 4) What are the attitudes of participants and non-participants 
towards offering carrier screening programmes in the general population? 5) What are the 
practical aspects of offering screening? Furthermore, the answers to each question were 
compared between four different organisational approaches, that varied in mode of invitation 
and pre-test education of couples.  
 
 Invitations sent by: 
 
Education provided during: 
 
MHS 
 
GP 
  
Educational session   
 
A 
 
 
B 
 
      GP consultation 
 
C 
 
D 
 
Figure 1 — Design of four organisational approaches to preconceptional cystic 
fibrosis carrier screening; MHS=Municipal Health Services; GP=general practitioner. 
 
Methods 
Participants and Procedure 
CF carrier screening was targeted to couples who were considering a pregnancy in the future, in 
the mid-western region of the Netherlands, between May 1997 and December 2000. To reach the 
target group, individuals, aged 20 to 35 years, were invited by mail to participate in the screening 
programme with their partner. Figure 1 shows the study design with four different organisational 
approaches that varied in mode of invitation and pre-test education setting.  
One Municipal Health Service (MHS) sent invitations to individuals in two separate 
geographical areas (one polder area with 26 villages and one small town) in approach A and C, 
respectively. Individuals were selected from the population register by local authorities.  
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In approach B and D, practice registered individuals were sent a written invitation 
signed by their general practitioner (GP). These individuals were recruited from seven general 
practices located in a small town and three general practices (two in a village and one in a city 
district), respectively. The GPs excluded patients with fertility problems or psychosocial 
problems from the mailing list to spare them any possible emotional disturbance caused by the 
invitation. 
In approach A and B, the letter invited couples to attend a 45 minute pre-determined 
educational group session during which pre-test education was provided by one of the authors 
(LH). Sessions were held at a nearby location on two or three evenings in one week. 
In approach C and D, couples were invited to make an appointment with their GP for a 
consultation within one month. Fourteen GPs from ten general practices (approach C) and four 
GPs from three general practices (approach D) held consultations. Each participating practice 
was visited by one of the authors (LH), who explained the project to the GP and the staff and 
delivered the questionnaires, consent forms and brochures. In addition, the GPs were provided 
with a brief instruction manual to keep on their desk and a comprehensive educational folder, 
which they could use before or during consultations. The practice assistant was offered a 
notebook in which the questions asked by patients could be recorded. At the end of the project, 
consulting GPs were asked to complete an evaluation form.  
The letters of invitation were non-directive, and clearly stated that this was a scientific 
study to determine the actual interest in participation. Enclosed with each letter was an 
information leaflet with a contact telephone number. The leaflet described the clinical and 
genetic aspects of CF, the carrier prevalence in the population, the implications of a positive 
carrier screening test, and how testing takes place. It also included information about the 
imperfect sensitivity of the test. Exclusion criteria for participation were: pregnancy and age 
younger than 18 years. Individuals with a positive family history of CF who were interested in 
screening were also excluded. They were referred to a clinical geneticist for counselling and 
family testing.  
During the educational sessions and the GP consultations questions were answered and 
more detailed information was provided, including information on reproductive choices, the 
method of testing, and the residual risk with the possible test-results. In addition, an outline of 
the possible advantages and disadvantages of screening was given. The verbal information was 
backed-up with a 15-page brochure. After the information had been provided, the couples were 
offered the carrier test, which would be performed by mutation analyses on a mouthwash 
sample. All of this was offered free of charge. Both partners in a participating couples were 
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requested to provide a mouthwash sample, after which the couples were given an informed 
consent form to take home. If only one partner was able to attend the pre-test education, a kit 
was provided in which the mouthwash sample of the other partner had to be collected at home. 
If both partners were unable to attend, a short explanation and answers to questions were given 
by telephone and the kit and an additional brochure were sent to their home address. To 
determine the effect of a repeated invitation, in approach A and B, respectively, 3,037 and 
1,927 non-responding individuals were sent a second invitation one year after the first. 
 
 
Invitation letter + leaflet 
(either sent by MHS or GP) 
 
Couples invited to 
educational session 
(Approach A & B)  
 
Non-respondents 
to the invitation 
 
Couples invited to 
GP consultation 
(Approach C & D) 
  
Respondents 
 Sample of     
non-respondents 
 
Respondents 
  
Q1 
(either completed at 
home or before the 
session) 
 Q1 
(completed at 
home) 
 Q1 
(either completed at 
home or in GP’s 
waiting room) 
  
Pre-test education at 
educational session 
mouthwash sampling 
   
Pre-test education at 
GP consultation 
mouthwash sampling 
  
Q2 
(completed at home) 
brochure, consent form 
   
Q2  
(completed at home) 
brochure, consent form 
  
Q3                
(completed at home, 
six months after 
receipt of test-results) 
   Q3                
(completed at home, 
six months after 
receipt of test-results) 
 
Figure 2 — Outline diagram of the method of approach and education in carrier 
couple screening and time of completion of questionnaires. MHS=Municipal Health 
Services; GP=general practitioner; Q=questionnaire. 
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A schematic overview of the test procedure and time of completion of questionnaires is 
presented in Figure 2. Participants completed a questionnaire before they received information 
during the group educational session or GP consultation (Q1), within one week after the 
education (Q2), and at six months after receipt of test-results (Q3). Detailed reporting 
information of Q2 and Q3 is given elsewhere (this thesis, Chapter 7). 
 The Medical Ethics Committee of the VU University Medical Center in Amsterdam has 
approved the study. The study was also positively evaluated against the Dutch Health Council’s 
criteria for genetic screening,13 and the research activities are in conformity with the Dutch 
Population Screening Act.14 
 
Eligible couples and recruitment of non-participants 
Eligibility for screening was defined as having a relationship and planning to have one or more 
children with their partner. A non-response survey by telephone was performed among 545 
randomly selected individuals who did not respond to the invitation of screening (non-
participants), to estimate the percentage of eligible persons in the invited population, between 
1997 and 1999. The telephone survey showed that 20% (110/545) of the individuals invited 
was eligible for participation.  
At the end of 2000, an additional number of 118 eligible non-participating individuals 
were identified by the telephone survey. These individuals were less randomly selected due to 
logistical restrictions, such as holiday seasons, and the restricted opening hours at the MHS, 
where telephone calls had to be made for privacy reasons, and were therefore not included in 
the estimation of eligibility described above. All 228 non-participating individuals and their 
partners were asked to take part in the research by completing the questionnaire at home and 
returning it by mail (Figure 2). Of these, 17 did not wish to take part in the questionnaire study 
and 74% (156/211) returned the questionnaire. Of the 55 couples who did not return the 
questionnaire, 61% had previously reported by telephone that their main reason for non-
participation was lack of time, 16% did not want to know their test-results, and the remainder 
reported other reasons for non-participation, such as having other problems on their mind.  
  
Questionnaires  
The initial questionnaire (Q1) took approximately 10 minutes to complete, and assessed 
sociodemographic characteristics (age, gender, marital status, level of education, number of 
children, term of planning children), attitudes towards screening, and health belief 
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perceptions.12 Couples were also asked to indicate the single most important reason for 
participation or non-participation in the screening programme.  
 
Mutation analyses 
Subjects were asked to rinse their mouth with 10 ml of 0.9% sterile saline. All mouthwash 
samples were sent to the DNA diagnostic laboratory at the VU University Medical Center in 
Amsterdam. DNA isolation from mouthwash samples was performed according to a procedure 
modified from Lench et al.15 Samples were tested only if the couples had returned by mail their 
signed consent form. At the start of the study, mouthwashes from the participating couples 
were alternately allocated to first and second testing. The second sample was tested only if the 
first was positive (single-entry testing). Reversed dot blot mutation analysis was used to screen 
for 16 mutations with a test-sensitivity of approximately 87% per individual (H. Scheffer, 
personal communication). When the study was partially completed (about one-fifth), the 
sensitivity of the test was improved to 95% per individual. This was done by changing the 
mutation detection technique to Denaturing Gradient Gel Electrophoresis (Ingeny International 
BV, Goes, the Netherlands) described by Wu et al,16 and screening exons 2-5,7,9-11,14,19-21. 
In addition, couples were then offered the opportunity: a) to decide who was to be tested first, 
i.e. the man or the woman, and b) to have both partners tested at the same time (double-entry 
testing) if they paid 45.50 EURO (100 Dutch Guilders). Couples were notified of their test-
results by mail within 8 weeks. Unless the couples objected, copies of positive carrier test-
results were sent to their GP. Positive results were always confirmed by testing of new 
mouthwash samples. 
 
Data analyses 
For each approach, the response rate and 95% confidence interval were assessed. In the 
calculation of response rates, the responses of individuals, and not couples, to the invitation 
were considered, since the invitations were sent to individuals and some partners did not receive 
an invitation because their age-group was not included or they were not registered with the GP 
or local authority. The response was calculated from the eligible (target) population (20% of the 
total of individuals invited). Individuals whose mail was returned by the post office as 
undeliverable (n=177) were excluded from the denominator. 
Within the couples, the sociodemographic characteristics of both partners were 
compared, using McNemar non-parametric tests for categorical data and paired t-tests for 
continuous data. Differences between participants and non-participants and between participants 
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within the four approaches were analysed, using chi-square tests and Fisher’s exact tests on 
cross tabulations. All analyses were performed in SPSS for Windows (version 7.5.2.; SPSS Inc). 
A p-value <0.05 was considered to indicate statistical significance.  
 
Table 1 — Number of invited and responding individuals, attending and participating couples, and 
percentages of individual response rate and couple participation rate in four different approaches  
 
                                    Approach 
 A  B  C  D 
 
Individuals invited,a n 
 
Individuals invited 
excluding undeliverable, n 
 
Individuals responding  
to invitation, n 
 
Estimated response rateb 
of individuals, % (95%CI) 
 
Attending couples, n 
 
Participating couples, n 
 
Participation rate, % (95%CI) 
 
 
25,281  6,710  5,173  1,127 
 
25,252  6,602  5,166  1,094 
 
 
466  157  255  54 
 
 
9.2 (8.4-10.0) 11.9 (10.2-13.8) 24.7 (22.1-27.4) 24.7 (19.1-30.9) 
 
 
283  109  156  32 
 
265  107  155  32 
 
94 (90-96)  98 (94-100) 99 (96-100) 100 (89-100) 
 
A=invitations sent by MHS, couples educated at educational session; B=invitations sent by GP, couples educated 
at educational session; C=invitations sent by MHS, couples educated at GP consultation; D=invitations sent by 
GP, couples educated at GP consultation; CI=confidence interval; a In approach B and D, respectively, n=846 and 
n=311 individuals were excluded from the mailing list by the GPs to avoid any possible emotional disturbance 
caused by the invitation; b Response rate is calculated as the number of individuals responding to the invitation 
divided by eligible individuals (20% of the total number of individuals invited, excluding undeliverable mail). 
 
 
Results 
Response to screening in four approaches 
Response rates for the four different approaches are shown in Table 1. The estimated response 
of the eligible (target) population differed between the approaches. The response rate was 
higher when the MHS or a GP invited couples to attend a GP consultation (24.7%) compared 
to couples invited to attend an educational session (9.2% and 11.9%, respectively). Of the 580 
couples who responded, 559 couples gave written consent to have the test. Most of the 21 
couples who did not consent after receiving education gave no reason. Forty-one couples (7%) 
consented to testing without attending an educational session. These couples contacted the 
researcher, saying that they were interested in testing but were unable to attend the educational 
session, and therefore received the information at home. In addition, in 55 couples only one 
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partner was able to attend an educational session (n=39) or a GP consultation (n=16). These 96 
couples, with one or both partners not attending, more often had children than the couples who 
attended the education (40% v. 26%; p=0.006). Four couples in approach C contacted the 
researcher because they were interested in screening, but their GP was not located in the 
research area. They also received the kit at home, but were excluded from the questionnaire 
study. Of the 559 participating and 156 non-participating couples, respectively, four couples 
and six couples did not fully complete the questionnaires and were excluded from the 
questionnaire analyses. 
Repeated invitation after one year, gave an additional response of 3% (19 individuals 
from 13 couples) and 7% (27 individuals from 17 couples), in approach A and B, respectively.  
 
Sociodemographic characteristics of participants and non-participants 
The sociodemographic characteristics of participants and non-participants in each of the four 
methods of approach are shown in Table 2. Overall, the men were significantly older than the 
women. In general in the Netherlands, within a relationship the man is older than the woman.17 
Since, apart from age, no differences were found between men and women within the couples, 
one partner from each couple was selected for assessment of the sociodemographic variables.  
In approach B and C, non-participants were more likely than participants to have one or 
more children. Furthermore, non-participants in approach C were more likely than participants 
to be married. No other significant differences within the approaches were found. Overall, 
couples in approach C and D were more likely than couples in approach A and B to have 
children, and couples in approach C were more likely to be married than couples in the other 
approaches. 
 
Reasons for participation and non-participation 
The most important reason for participation that was given by couples is shown in Table 3. 
Most couples participated “to avoid having a child with CF”. Less than five percent reported 
that their main reason for participation was “to help in scientific research”, or because they felt 
they “could not refuse the test”. There was no significant difference in reasons for participation 
between couples in the four different approaches. 
   
 
Table 2 — Sociodemographic characteristics of participants and non-participants in the four approaches to preconceptional CF carrier screeninga 
 
                   Approach A                  Approach B                  Approach C                  Approach D 
 Participants 
n=262 
Non-participants 
n=46 
Participants 
n=106 
Non-participants 
n=62 
Participants 
n=155 
Non-participants 
n=24 
Participants 
n=32 
Non-participants 
n=18 
Age, mean (range)  
  Men 
  Women 
 
Married (% yes) 
 
Level of education (%)b 
  Low 
  Intermediate 
  High 
 
Children (% yes) 
 
Planning children  
(% within 2 years) 
 
30.8 (21-50)  
28.7 (19-41) 
 
48 
 
 
16 
55 
29 
 
24 
 
60 
 
30.3 (24-40) 
28.6 (21-35) 
 
50 
 
 
20 
63 
17 
 
24 
 
54 
 
30.7 (20-45) 
28.5 (20-44) 
 
43 
 
 
15 
47 
38 
 
24 
 
52 
 
30.4 (23-41) 
27.8 (20-37) 
 
44 
 
 
26 
44 
31 
 
39  
 
57 
 
32.0 (20-47) 
29.2 (20-37) 
 
57 
 
 
22 
57 
21 
 
37 
 
57 
 
30.8 (24-41) 
28.8 (22-33) 
 
83  
 
 
21 
58 
21 
 
58  
 
58 
 
31.8 (26-40) 
29.3 (22-35) 
 
41 
 
 
25 
47 
28 
 
38 
 
60 
 
31.2 (23-35) 
29.7 (20-35) 
 
33 
 
 
11 
33 
56 
 
50 
 
63 
 
A=invitations sent by MHS, couples educated at educational session; B=invitations sent by GP, couples educated at educational session; C=invitations sent by MHS, couples 
educated at GP consultation; D=invitations sent by GP, couples educated at GP consultation; a Age of both partners of a couple is shown. For all other characteristics, data of 
one randomly selected partner was used; b Low: primary school, lower level of secondary school, lower vocational training. Intermediate: higher level of secondary school, 
intermediate vocational training. High: higher vocational training, university;  Significant difference between participants and non-participants p<0.05;  Paired t-tests 
significant at p<0.05 for comparison of men and women within the couples. 
 
Offering preconceptional CF carrier screening 
 
 90 
Table 3 — Main reason given by couples (n=555) for participation in CF carrier screeninga 
 
Reason       %   (n) 
To avoid having a child with CF   65  (359) 
CF is a serious disease     11  (62) 
To prepare for a child with CF      8  (43) 
Other          7  (37) 
Fear of regret afterwards      5  (28) 
To help in scientific research      4  (21) 
Feeling that we could not refuse the test   <1  (5) 
 
a For 85 couples this was an open-ended question. Other couples ticked one option from a list of 13 
reasons for participation in screening. There were no differences in answers between the two 
methods of assessment. 
 
Table 4 shows the main reason couples gave for not responding to the invitation for screening. 
Almost half the couples reported “lack of time” or “forgot about it” as their main reason for 
non-participation, and 28% “did not want to know the test-results”. Couples invited to attend 
the educational session reported “lack of time” more often (53%) than couples invited to GP 
consultation (36%), although these differences were not statistically significant.  
 
Table 4 — Main reason given by couples (n=150) for not responding to the invitation for 
CF carrier screeninga 
 
Reason       %   (n) 
Lack of time/forgot about it    48  (72) 
Don’t want to know the test-results   28  (42) 
Lack of concern/never heard of CF       6  (10) 
Fear of the test-results            5  (7) 
Other       13  (19) 
 
a For 53 couples this was an open-ended question. Other couples ticked one option from a list of 14 
reasons for not participating in screening. There were no differences in answers between the two 
methods of assessment. 
 
In 72% of the 72 couples reporting “lack of time” or “forgot about it”, one or both partners 
perceived high benefits from testing. High benefits were perceived by 28% of the 78 couples 
reporting other reasons for non-participation, and by 95% of all participants. Overall, 69% of 
non-participants and 89% of participants believed that genetic carrier testing for CF should be 
offered to all couples planning to have children.  
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Mutation analyses   
In total, mouthwashes of 589 couples were prepared for the carrier test (559 after the first and 
30 after the second invitation). Of the 488 couples, who were offered the opportunity to choose 
which partner would be tested first, 51% chose the woman and 25% chose the man. The 
remaining couples had no preference with regard to which partner should be tested first, and 
their samples were randomly allocated to first and second testing. Twenty-four couples (5%) 
paid to have both partners tested at the same time. Eighteen carriers were identified (delta F508 
(11), R117H (3), R553X (1), W1282X (1), I148T (1), S1235R (1)). The partners of the carriers 
all tested negative, giving a carrier frequency in this study population of 1 in 35 (631/18). Two 
individuals were given an inconclusive result, that is a mutation of unknown pathogenity was 
found, their partners tested negative. Fourteen (2%) samples failed to give a result due to 
inadequate DNA content in the sample, and one tube with a sample broke in the mail. In these 
cases, new samples were provided or, when possible, samples of partners were tested. 
 
Practical aspects of screening  
Overall, the telephone number that was available for further information was contacted 151 
times. The questions were various, for example, related to the exclusion of pregnant women, 
the selected age-group, or to get an alternative to receive the information. Seven individuals 
with a family history of CF were referred to their GP to get a referral for the clinical genetic 
centre for CF family testing.  
In total, the researcher organised 37 educational sessions with an average of 10 couples 
(range 2-27 couples) attending each session. The average time invested by GPs (n=10, 
approach B and D) in printing files and checking patient lists for eligibility was 110 minutes 
(range 15-210 minutes). The estimated average time GPs (n=18, approach C and D) spent per 
couple in offering the screening test and taking mouthwash samples was 12 minutes (range 5–
30 minutes), and this was reported to be “sufficient time” by the GPs. Most GPs thought that 
the information provided (brief manual and educational folder) was helpful in explaining the 
test to couples. Overall, GPs reported no problems with the consultations. In one practice, the 
couples consulted the general practice assistant. Although almost two-thirds (13/18) of the 
consulting GPs perceived CF carrier screening as (very) important, only seven would consider 
it as their actual task. An important reason for not being willing to perform this task was the 
extra workload.  
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Discussion 
In this study, preconceptional carrier screening for cystic fibrosis was offered to couples by 
four different methods of approach without active recruitment. The response rate to screening 
of individuals and their partners who attended a general educational session was lower (9.2% 
and 11.9%) than the response rate of those who attended a GP consultation (24.7%).  
Whether individuals were invited by letters sent by the MHS or by their own GP, had 
no marked influence on the rate of participation. An advantage of invitation via the MHS is 
that in this way an extra workload of the GP is avoided. In a recent study on cervical cancer 
screening in the Netherlands, in which a high uptake is essential if screening is to be effective, 
an approach in which invitations were sent by the GP resulted in higher attendance rates than 
an approach in which invitations were sent by the local authority or the MHS.18  
In genetic screening for reproductive purposes uptake is not the most important 
determinant of the success of the screening. Participation in this type of screening should be 
completely voluntary, and people should be autonomous in their decision on whether or not to 
take the test. Therefore, it is encouraging to find that the couples did not participate because 
their GP had told them to do so, and that less than 1% of the couples participated because they 
felt that they “could not refuse the test”. The GPs reported no negative experiences with the 
consultations, which usually lasted as long as an average consultation. On the one hand, the GP 
might be the ideal person to provide information on screening, since general practice in the 
Netherlands has a very high coverage of the population, and patients and families are usually 
familiar with their GP. Furthermore, the GPs could provide personal education for carriers and 
their family, when needed. Honner et al19 also suggested that screening through primary care 
might provide an opportunity for educating health professionals about genetics more generally. 
On the other hand, the results suggest that due to the extra workload, most GPs do not consider 
screening to be part of their task. In addition, offering information during educational sessions 
might be more (cost) efficient. Alternatively, consultations might be delegated to the practice 
assistant, or given at an individual consultation with other health professionals than GPs, for 
example at the MHS.  
The response in approach B (11.9%) was very similar to the reported 13.6% uptake 
among individuals planning to have children who were invited to attend an educational session 
in a study carried out by Tambor et al.4 The lower uptake in the present study may be due to 
the fact that only couples were included and not individuals. Although carrier status has no 
known harmful effect on individuals, and is only important in reproductive planning, very few 
studies on cystic fibrosis carrier screening have focused on couples before conception.5 20 In 
Chapter 5 
  
these studies, it was concluded that interest in testing was very low. In a study carried out by 
Payne et al5 in the United Kingdom, only two couples participated after receiving a letter 
offering screening. However, this study included only 135 selected couples and offered one 
specific appointment, which may have been inconvenient for the couples. Explanations given 
by Clayton et al20 for the lack of interest in screening shown by non-pregnant couples were that 
they had to give a finger-stick blood sample and the impersonal approach, in which posters and 
take-away letters were used to advertise the study. The results of the present study however 
suggest that, in the Netherlands, preconceptional carrier screening is acceptable to couples. 
Almost half of the couples reported “lack of time” or “forgot about it” as the main 
reason for non-participation. Couples invited to attend an educational session gave this reason 
more often than couples invited to attend a GP consultation. The reason for this may be that 
couples could make their own appointment for a consultation, whereas the date and time of the 
educational session was pre-determined. Another reason may be that couples prefer personal 
contact with their GP, instead of attending an educational session where other couples are 
present. For a majority of the couples reporting “lack of time” or “forgot about it”, one or both 
partners perceived high benefits from testing, suggesting that they might have participated if 
the invitation was repeated. Indeed, repetition one year after the first invitation resulted in an 
increase in response of 3% and 7%. 
In another report,12 comparing 76 participating couples and 53 non-participating couples 
in approach B, it was shown that couples who participated after an invitation from their GP and 
attended an educational session, as opposed to those who did not, perceived less discomfort 
from screening, perceived higher benefits, perceived less impact of the consequences of 
screening, knew more about CF, and had a higher score on the internal health locus of control 
scale (Chapter 6, this thesis).  
Half of the couples chose to have the woman tested first, whereas 25% chose the man, 
which may reflect the greater concern and responsibility in reproductive decisions felt by 
women. Only 5% were willing to pay to have both partners tested. However, a more detailed 
study on a subgroup of the participating couples showed that 20% would prefer to receive the 
results of both partners, suggesting that they wanted simultaneous testing of samples (this 
thesis, Chapter 8).  
There are several limitations to this study. Couples were offered screening within a 
limited geographical region. Uptake and acceptance may be different in other parts of the 
Netherlands. In addition, each approach was carried out in a different geographical sub-area. 
The individuals who received an invitation were not randomised for the education setting 
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within the GP practices or the MHS region. The reason for this was to prevent one partner in 
the couple being invited for one pre-test education setting while the other was invited for the 
other setting. Another reason was that the study location depended on the willingness of the GP 
to participate, and the results may not be representative of all GPs. Furthermore, eligibility in 
the invited population was estimated, thereby resulting in approximated uptake rates. 
Therefore, the results should be interpreted with caution. However, despite these limitations, 
this exploratory study has increased insight into the feasibility and acceptance of couple 
screening and could be seen as a starting point for further research in this area.  
In summary, the results of the present study show that with some effort, the target group 
is indeed accessible. The findings suggest that interest in carrier screening shown by non-
pregnant couples is highest when they are invited to make an appointment for a GP 
consultation. Screening in general practice seems feasible, although there was some evidence 
suggesting that this method is not always supported by the GPs. Furthermore, results to be 
reported elsewhere suggested that couples had inadequate understanding of test-results after 
pre-test education was provided by the GP (Chapter 7, this thesis). Although this study does 
not answer the question of whether preconceptional CF carrier screening should indeed be 
implemented, the results add important information to the issues raised in the debate on the 
feasibility and desirability of offering screening.  
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Abstract 
Factors associated with participation in a preconceptional CF carrier couple screening 
programme were assessed. In total, 5,414 individuals received a letter of invitation for 
screening signed by their own general practitioner. The letter invited couples who were 
considering a pregnancy in the future to attend a 45 minute educational session. Questionnaires 
were completed by participating couples (n=76) and a sample of couples who did not attend the 
educational session (n=53). The results suggest that couples who participated in the screening 
programme, as opposed to those who did not, perceived lower discomfort from screening, 
perceived higher benefits, perceived lower impact of the consequences of screening, knew 
more about CF and scored high on an internal health locus of control scale, that is, they 
perceived their own behaviour to be responsible for their health. Overall, the results were more 
pronounced when partners had similar perceptions. The main reason given by 53 couples for 
not participating in screening was ‘lack of time to attend the educational session’ (53%). These 
couples perceived high benefits from screening. Offering more sessions, providing more clear 
information about the meaning of carrier status, and increasing public awareness could 
diminish barriers to participation. 
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Introduction 
Couples in which both partners are carriers for a particular autosomal recessive disease, such as 
cystic fibrosis, Tay-Sachs disease, or thalassemia, have a 1-in-4 risk for each child to have this 
disorder. Population carrier screening programmes aimed at the identification of carrier couples 
make it possible to inform these couples about their risk and about the reproductive options that 
are available. Before beginning any genetic screening programme, it is important to assess 
community interest in screening.1 
It is well known that the way in which carrier screening is offered and the timing, for 
example, during or outside pregnancy, determine participation in screening and the reasons for 
participation. Screening offered face-to-face with the possibility of immediate testing gives 
high uptake rates, whereas offers made by mailed invitation or poster announcements attract 
little interest.2-6 Most of the data on motives for participation have been obtained from 
programmes offering carrier screening during pregnancy.7-15 In these studies, a high interest in 
screening was reported, although it has been argued that testing during pregnancy is often 
accepted just because it is offered.16 The decision to participate was mostly made by women, 
who were often initially tested without discussing it with their partner. Anxiety has been 
reported among those who are tested positive, while waiting for their partner’s results.10 17 18 It 
can also cause distress when the partner is not available or does not want to be tested.19 
Furthermore, prenatal screening leaves limited reproductive options for carrier couples and 
might impose time constraints when decisions about a prenatal diagnosis have to be made.20 
Offering screening outside pregnancy shows low participation rates when no pregnancy is 
planned, but interest is higher when there are plans for having children (preconceptional).4 7 21 
This study focused on the preconception as the time for screening and considered 
couples as the screening unit. Determining why some couples participate in a preconceptional 
carrier screening programme while others decline provides insight into the desirability of 
screening. It may also give some indications of how to improve accessibility to screening for 
those who are interested. To investigate this, couples can be directly asked for reasons why they 
decided (not) to participate. In addition, determining differences in individual variables and 
attitudes between participants and non-participants can be used to explain participation. Early 
theories on health related behaviour suggest that intention to take a preventive health action is 
likely when people (1) view themselves as susceptible to the condition, (2) consider the disease 
to be serious, (3) perceive high benefits of the health action, and (4) perceive few disadvantages 
in undertaking it.22 These four components are the earliest constructs of the Health Belief 
Model (HBM), which has been considerably expanded, as was reviewed by Janz and Becker.23 
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The present study focused on a select group of variables derived from the HBM. This model 
was chosen because of its applicability to predict behaviour towards voluntary action, such as 
carrier screening. 
In this study, the determinants of participation in preconceptional cystic fibrosis (CF) 
carrier couple screening was investigated, focusing on the characteristics and attitudes of both 
partners. The study was carried out within the framework of a large project on the feasibility 
and desirability of CF carrier screening in the Netherlands. It was designed to address the 
following research questions. What is the main reason why couples choose to participate or 
choose not to participate in carrier couple screening? Are there HBM related factors associated 
with participation among eligible couples invited for screening? 
 
Subjects and Methods 
Procedures 
Participating and non-participating couples were recruited from a feasibility study of 
preconceptional CF carrier couple screening in the Netherlands. Screening was offered to 
couples who were considering a pregnancy in the future, by five general practices, between 
May 1997 and June 1998. In total, 5,414 people, aged 20 to 35 years, received a letter of 
invitation signed by their general practitioner (GP). GPs were asked to exclude patients with 
fertility problems or psychosocial problems from the mailing list to avoid any possible 
emotional disturbance of these people by the invitation. The letter invited couples, interested in 
screening, to attend a 45 minute educational session at a nearby location on two evenings in 
one week. The letters were non-directive, did not encourage couples to participate, and 
mentioned that this was a scientific study on interest in participation. Both partners were asked 
to be present. Enclosed with the letter was an information leaflet. The leaflet described the 
clinical and genetic aspects of CF, carrier prevalence in the population, the implications for the 
couple of a positive carrier screening test, and how testing is conducted, including information 
about the imperfect sensitivity of the test (the test sensitivity in this study was approximately 
87%). A member of the research group (LH) organised the educational sessions. At the session, 
attendees were given more detailed information, and an outline of possible advantages and 
disadvantages of screening was presented. At the end of the session, couples were offered the 
carrier test, which would be performed by mutation analyses on a mouthwash sample. All of 
this was offered free of charge. Exclusion criteria for the participation of couples were: 
pregnancy, a positive family history of CF, and age younger than 18 years. Both partners of 
participating couples provided a mouthwash sample. If only one partner was able to attend the 
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session, a kit was provided in which the mouthwash sample of the other partner could be 
collected at home. After the educational session, couples were given an informed consent form 
to take home and asked to return it by mail within one week. The Medical Ethical Committee 
of the academic hospital Vrije Universiteit in Amsterdam approved the study protocol. 
 
Uptake 
To determine the uptake of screening, a non-response survey by telephone was performed to 
estimate the percentage of eligible persons in the invited population. Eligibility was defined as 
having a steady relationship and planning to have one or more children with the partner. A 
random age-stratified sample of those who did not respond to the initial invitation for 
screening, that is, did not attend the educational session, was contacted by telephone on 
different evenings during the week. Other random individuals replaced those who did not 
answer the telephone after three calls until samples of approximately 10% (n=387) in every 
practice were reached. Respondents were asked whether they had received the letter of 
invitation from their GP, whether they were interested in screening, and whether their situation 
conformed to that of the target population. The non-response telephone survey showed that 
19.6% (76/387) of these invited subjects was eligible for participation. In the calculation of 
uptake rates, the responses of subjects to the invitation were considered, and not the responses 
of couples, since invitations were sent to individual people and some partners did not receive an 
invitation because their age-group was not included or because they had a different GP. 
Subjects whose mail was returned by the post office as undeliverable (n=99) were excluded 
from the study. In total, 108 individuals (related to 79 couples) responded to the invitation for 
screening. The response therefore was 2% of the total population (108/5315) and 10.4% of the 
eligible (target) population (108/1042). Seventy-eight couples consented to participate in the 
test (78/79, 98.7% participation) after the educational session.  
 
Comparison of participants and non-participants 
To determine factors influencing the decision to accept the test, differences between consenting 
couples (participants) and a sample (see below) of eligible couples who did not attend the 
screening session, identified through the non-response telephone survey (non-participants), 
were investigated. Data were gathered by means of questionnaires that were identical for both 
partners and both groups. Questionnaires were administered to all attendants at the beginning of 
the educational session. Each partner in a couple was asked to complete the questionnaire 
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individually without consulting the other partner. Of the 78 participating couples, 76 completed 
the questionnaire.  
Non-participants who confirmed during the non-response telephone survey a desire to 
have children with their partner, that is, they were eligible for participation (n=76), were asked 
whether they and their partner would be willing to complete the questionnaire and return it by 
mail. Of these 76 non-participants, six did not wish to take part in the study. In total, 76% 
(53/70) of the non-attending eligible couples returned the questionnaire. Those who did not 
return the questionnaire (n=17) had previously reported by telephone that their main reason for 
non-participation was lack of time. Eventually, 76 participating and 53 eligible non-
participating couples could be compared. 
 
Questionnaire design 
The questionnaire was developed and tested for homogeneity specifically for this study. 
Subjects were asked, in an open-ended question, to indicate the single most important reason 
for participating or not participating in the screening. In addition, they were asked to report 
which partner (both partners, man or woman) had influenced the decision most, and their 
agreement over the final decision (both agree, partner disagrees, or I disagree). Furthermore, 
the questionnaire assessed certain components of the Health Belief Model (HBM) including the 
following: 
 
(1) Sociodemographics Subjects provided information on age, gender, marital status, highest 
level of education, number of children, and religiousness. Couples were also asked to 
indicate whether a pregnancy was planned in the short term (within the next two years) or 
in the long term (after the next two years). 
 
(2) Familiarity with the disease Familiarity with the disease was derived from the response to 
the question: had you heard about the disease cystic fibrosis before receiving the invitation 
for screening?  
 
(3) Knowledge of the disease This consisted of seven multiple choice questions, assessing the 
level of understanding of the medical and genetic aspect of CF and carrier testing. A 
response of “don’t know” was scored as an incorrect answer. The number of questions 
answered correctly was calculated as a sum score. The answers to the separate questions 
were also considered. 
Chapter 6 
 103 
(4) Health locus of control The validated subscale of the Multidimensional Health Locus of 
Control scale with the locus dimension ‘internal control’ was used to indicate the extent to 
which subjects perceived their behaviour as responsible for their own health (IHLC).24 
According to this model, a person is more likely to engage in healthy behaviour if he or she 
has a strong internal locus of control. The subscale consists of six items, and the answering 
format was a six point Likert-type scale (completely agree (1) to completely disagree (6)). 
A total sum score was computed for each subject, with high scores indicating a higher 
likelihood of engaging in healthy behaviour. Cronbach’s  for IHLC on the data was 0.76.  
 
(5) Perceived discomfort The respondents were asked to indicate the extent to which they 
agreed that screening requires too much of their time and effort (completely disagree (1) to 
completely agree (5)).  
 
(6) Constructs of HBM The questionnaire included 14 items specifically addressing carrier 
screening, to measure perceptions concerning carrier testing (see Appendix). The newly 
developed constructs were derived from the four basic HBM dimensions:22 (1) perceived 
risk of being a carrier (couple) and having a child with CF (‘Perceived susceptibility’, three 
items), (2) perceived severity of the disease and the burden of treatment of a child with CF 
(‘Perceived seriousness’, three items), (3) perceived benefits of testing (‘Perceived 
benefits’, five items), and (4) perceived barriers related to screening, such as worries about 
testing, the perceived impact of carrier status, and the perception that other people will look 
differently at them when they are identified as carrier (‘Perceived impact barriers’, three 
items). For ‘Perceived susceptibility’, respondents were asked to indicate the estimated 
likelihood of their risk on a six point scale (very unlikely (1) to very likely (6)). For all 
other items, the respondents were asked to indicate the extent to which they agreed with 
each statement on a five point Likert scale (completely disagree (1) to completely agree 
(5)). Principal axis factor analysis with varimax rotation was performed to verify that the 
items loaded on the four factors of the HBM. Subsequently, a reliability analysis was 
performed on each scale to determine whether all items contributed to the internal 
consistency of the scale. Summing up items results in a single measure for three subscales 
with good reliability: ‘Perceived susceptibility’ (Cronbach’s =0.83), ‘Perceived benefits’ 
(Cronbach’s =0.90), and ‘Perceived impact barriers’ (Cronbach’s =0.64). For ‘Perceived 
seriousness’, the items (n=3) were considered separately, due to the low internal 
consistency of the total scale.  
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Data analyses 
To answer the first research question, the answers of couples to the open ended question about 
the main reason for participating or not participating in screening were coded into general 
categories. Before trying to answer the second research question, it was necessary to determine 
whether the data of both partners should be included as a pair, because both the man and the 
woman of each couple completed a questionnaire. To investigate this, the responses to 
questionnaires of both partners were compared, using McNemar non-parametric tests for 
categorical data and paired t tests for continuous data. Since the sociodemographic status was 
highly correlated between the partners within a couple, data of only one randomly selected 
partner was included in the bivariate analyses comparing participants and non-participants. For 
all the other variables (2) to (6), at first the median split of the sum scores was taken, which 
resulted in subjects with low scores and subjects with high scores (knowledge low (0-3), high 
(4-7); IHLC low (6-23), high (24-36); susceptibility low (3-9), high (10-18); benefits low (5-
19), high (20-25); impact barriers low (3-6), high (7-14), and separate items (discomfort and 
seriousness) low (1-3), high (4-5)). Paired data analyses showed that in the responses to these 
variables, there were moderate to low associations between partners in a couple, indicating that 
both partners provide different information. Therefore, it was not possible to randomly select 
one partner of the couple for the analyses. In addition, since the attendance of a couple at the 
educational session and participation in screening requires a joint decision, it was assumed that 
the association between a given variable and participation in screening would be stronger when 
partners have similar attitudes. To quantify the association between the scores of both partners 
of a couple, a concordance score was formed on a 3-point scale: 2=‘High-High’ (both partners 
in a couple scoring high on the variable), 1=‘High-Low’ (one partner scoring high (male or 
female) and one partner scoring low (male or female), and 0=‘Low-Low’ (both partners in a 
couple scoring low on the variable). Subsequently, bivariate analyses were performed to 
examine the association between participation in screening and the concordance variables (2) to 
(6). Chi-square analysis and Fisher’s exact tests were used to compare responses between 
participating and non-participating couples. Finally, all variables (1) to (6) that showed 
statistical significance in bivariate analyses were entered in one multiple logistic regression 
model simultaneously. All analyses were performed using SPSS for windows.25 A p-value 
<0.05 was considered to indicate statistical significance.  
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Results 
Main reason given for participation and non-participation 
Among the 76 couples who decided to attend the educational session and consented to CF 
carrier testing, the decision was taken jointly in 85%, while 15% reported that the woman had 
more influence on the decision to participate. Nevertheless, none of the couples reported 
disagreement on the final decision. The main reason given by couples for taking the test was 
that they wanted to know whether they were a carrier couple with a high risk of having a child 
with CF (97%). The other couples (3%) gave no specific reasons for taking the testing. The 
reasons non-participants gave (in their own words) for not responding to the invitation for 
screening varied, but the most commonly stated reason for not attending the educational session 
was “lack of time” or “forgot to attend the educational session” (53%, n=28). Other reasons 
given were that “the test-results would not influence our attitudes toward family planning” 
(21%, n=11). Furthermore, 15% of the couples were not interested in testing because they 
“were not concerned” (n=6), or they had “never heard of CF” (n=2). Five percent reported 
“testing would make us too anxious”. The answers of most partners in a couple could be placed 
in the same category. However, for three couples (6%), the partners showed disagreement; the 
women reported that they were interested in screening but they declined the test because their 
partners were reluctant to participate.  
 
Factors associated with participation 
Sociodemographics of participants and non-participants, both men and women, are shown in 
Table 1. Within the couples included in the study, no statistically significant differences were 
found between men and women with regard to educational level, time period in which children 
were planned, and religiousness. The men were significantly older than the women in both 
participating and non-participating couples. In general, within a relationship, men are older 
than women in the Netherlands.26 In bivariate analyses, no associations could be shown 
between participation and the variables age, marital status, level of education, number of 
children, the time period for planning children, or religiousness. While the sociodemographics 
for both men and women within the couples were highly comparable, paired data analyses 
showed that in the responses to the other variables, such as familiarity with CF, knowledge of 
CF, and perceptions with regard to carrier screening, there were differences between partners. 
Therefore, data of both partners were included in the subsequent analyses. 
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Table 1 — Sociodemographic characteristics of participants and non-participants in a preconceptional 
CF carrier screening programmea 
 
 Participants (76 couples) 
 
Women              Men 
n=76                  n=74 
Non-participants (53 couples) 
 
Women              Men 
n=53                  n=52 
Age (mean (range)) 
Marital Status (% married) 
Level of educationb (%) 
  Low 
  Medium 
  High 
Children (% having children)  
Planning children (% within 2 years) 
Religionc (%) 
  No religion 
  Religion, irregular practice 
  Religion, regular practice 
28.5 (20-44) 
45 
 
13 
42 
45 
26 
55 
 
47 
49 
  4 
30.9 (20-45)  
45 
 
16 
42 
42 
27 
49 
 
52 
43 
  5 
27.6 (20-37) 
45 
 
19 
51 
30 
42 
62 
 
53 
34 
13 
30.4 (23-41)  
46 
 
23 
40 
37 
42 
58 
 
59 
31 
10 
 
a Age was evaluated by t-test; all other characteristics were evaluated by chi-square; b Low: primary school, lower 
level of secondary school, lower vocational training. Medium: higher level of secondary school, intermediate 
vocational training. High: higher vocational training, university; c Irregular practice: church attendance < 1 month. 
Regular practice: church attendance > 1 month;  Significant at p<0.05 for comparison of men and women within 
the couples. 
 
Table 2 shows the bivariate associations between components of the Health Belief Model and 
participation in screening for the three different concordance groups (‘High-High’, ‘High-
Low’, ‘Low-Low’). Participating couples scored higher than non-participating couples on the 
knowledge questionnaire, and higher on the internal health locus of control (IHLC) scale and 
perceived higher benefits of testing. In addition, participating couples were more likely than 
non-participating couples to perceive low discomfort of screening and low impact barriers of 
screening. No associations were found between participation in screening and familiarity with 
CF, perceived susceptibility or the items on perceived seriousness. Furthermore, no differences 
in responses were found between the five general practices that participated in offering the 
screening. 
The relevant components found in the bivariate analyses were entered into one multiple 
logistic model simultaneously. Coefficients, odds ratios (OR), 95% confidence intervals 
(95%CI), and p-values for this model are presented in Table 3. Perceived discomfort and 
perceived benefits appeared to be the strongest predictors for participation in screening. 
Couples in which both partners perceived low discomfort of screening were more likely to 
participate than couples in which at least one partner perceived high discomfort of screening.  
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Table 2 — Bivariate associations of components of the Health Belief Model and concordance variablesa 
of participating and non-participating couples 
 
 Participants  
n=76 couples (%) 
Non-participants  
n=53 couples (%) 
 
Familiarity with the disease 
Yes-Yes 
Yes-No 
No-No 
 
Knowledge of the disease 
High-High 
High-Low 
Low-Low 
 
IHLCb 
High-High 
High-Low 
Low-Low 
 
Perceived discomfort 
High-High 
High-Low 
Low-Low 
 
Perceived susceptibility 
High-High 
High-Low 
Low-Low 
 
Perceived benefits 
High-High 
High-Low 
Low-Low 
 
Perceived impact barriers 
High-High 
High-Low 
Low-Low 
 
Burden of disease 
High-High 
High-Low 
Low-Low 
 
Burden of child with disease 
High-High 
High-Low 
Low-Low 
 
Burden of treatment 
High-High 
High-Low 
Low-Low 
 
34 
36 
30 
 
 
62 
26 
12 
 
 
33 
40 
27 
 
 
  0 
  3 
97 
 
 
  1 
13 
86 
 
 
77 
18 
  5 
 
 
  5 
32 
63 
 
 
67 
17 
16 
 
 
75 
18 
  7 
 
 
22 
38 
40 
 
28 
30 
42 
 
 
34 
25 
41 
 
 
23 
24 
53 
 
 
11 
23 
66 
 
 
  4 
  8 
88 
 
 
34 
26 
40 
 
 
38 
38 
24 
 
 
55 
24 
21 
 
 
64 
25 
11 
 
 
19 
26 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For five couples, data for only one partner were available. In the analyses, data of the available partner 
were used for the missing data of the other partner. Analyses without these five couples showed the same 
results; a High-High/Yes-Yes (both partners of a couple scoring High/Yes on the variable). High-
Low/Yes-No (one partner scoring High/Yes (male or female) and one partner scoring Low/No (male or 
female)). Low-Low/No-No (both partners of a couple scoring Low/No on the variable); b Internal health 
locus of control scale; Overall significant Chi-square tests for comparison of participating and non-
participating couples  p<0.01;  p<0.001. 
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Compared to couples perceiving low benefits from screening, couples in which one or both 
partners perceived high benefits were more likely to participate. Couples in which both 
partners perceived low impact barriers were more likely to have the test as couples in which 
both partners perceived high barriers. Couples with high knowledge scores were more likely 
than couples with low knowledge scores to participate in screening. Finally, couples with one 
partner scoring high on the internal health locus of control scale were more likely to participate 
than couples with low scores. 
 
Table 3 — Multiple logistic regression model: odds of participation 
of couples in CF carrier screening 
 
Predictor Odds ratio (95%CI) 
Knowledge of disease 
High-High 
High-Low 
Low-Low 
 
IHLCa 
High-High 
High-Low 
Low-Low 
 
Perceived discomfortb 
High-High/High-Low 
Low-Low 
 
Perceived benefits 
High-High 
High-Low 
Low-Low 
 
Perceived impact barriers 
High-High 
High-Low 
Low-Low 
 
6.1  (1.5-24.9)  
3.2  (0.8-13.5) 
Ref 
 
 
2.3  (0.7-8.1) 
5.2  (1.4-19.4)  
Ref 
 
 
Ref 
19.2 (2.9-125.5)  
 
 
16.2 (3.8-69.1)  
7.9  (1.6-39.4)  
Ref 
 
 
Ref 
3.7  (0.8-17.5) 
7.0  (1.5-32.2)  
 
Ref=reference category; a Internal health locus of control scale; b In the 
analyses, the subgroups High-High and High-Low were added together, to 
account for empty cells in the subgroup High-High;  p<0.05;  p<0.01.  
 
Attitudes of couples with different reasons for non-participation 
Over half of the couples who did not attend the educational session (53%) reported that the 
main reason for non-participation was that they had no time or had forgotten to attend the 
educational sessions. These couples may differ in their attitude towards testing from the other 
non-participating couples. To analyse this, couples who did not attend were divided into two 
sub-groups: (1) those who reported that they had no time or had forgotten to attend, but were 
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possibly interested in screening (“lack of time”, n=28), and (2) those who did not attend for 
other reasons (“other reasons”, n=25). Bivariate analyses of the variables (1) to (6) showed that 
only one variable was associated with reporting “lack of time”. In non-participating couples 
reporting “lack of time”, it was more likely that both partners perceived high benefits of 
screening than in non-participating couples reporting “other reasons” (50% v. 16%) (OR=8.7 
(2.0-37.7)). In addition, two-thirds of these couples perceiving high benefits and reporting ‘lack 
of time’ had high knowledge scores. 
Of all non-participants, 76% supported the view that genetic carrier testing for CF 
should be offered to all couples planning to have children, 15% did not favour this opinion, and 
9% were not sure. Among those who reported ‘lack of time’, only two respondents were 
opposed to offering screening in the general population.  
 
Participant and non-participant knowledge 
With regard to more detailed knowledge of CF, a comparison was made of correct answers of 
participants (before the educational session) and non-participants to five multiple choice 
questions on the knowledge questionnaire. The answers to these questions could all have been 
found in the information leaflet, which was sent with the letter of invitation for screening. 
Participants were significantly more likely than non-participants to be aware of the most 
important symptoms of CF (64% v. 32%), to know that carriers do not need to have a family 
history of CF (83% v. 69%), to recall the risk of being a CF carrier (61% v. 39%), and to 
understand that carriers of CF would not develop CF-related health problems (66% v. 41%). 
There was no association between knowledge scores and level of education. In both groups, 
women scored higher on the knowledge questionnaire than men. In addition, more women than 
men had previously heard about CF. 
 
Discussion 
In this study, factors associated with participation in preconceptional carrier couple screening 
were assessed. The results suggest that couples who participated in the CF carrier screening 
programme, as opposed to those who did not, perceived lower discomfort from screening, 
perceived higher benefits, perceived lower impact of the consequences of screening, knew 
more about CF and perceived their own behaviour to be responsible for their health. Overall, 
the results were more pronounced when partners had similar perceptions. The main reason 
given for not participating in screening was lack of time to attend the educational session. The 
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results showed that couples who lacked the time to attend perceived more benefits from 
screening than couples reporting “other reasons” for non-participation. 
 As expected, higher perceived benefits of the test was associated with more 
participation in screening. Benefits from testing reflect the importance couples attach to 
knowing their chances of having a child with CF, which was also found to be the most 
frequently reported reason for participation in screening. It also reflects the expectations of the 
couples that they will have more reassurance and that the test-results will help them to make 
decisions about having children. Higher awareness of the benefits of screening may increase 
the acceptance and participation of couples in screening. In 34% of the non-participating 
couples, the perception of the discomfort of screening was high for at least one partner. These 
couples will probably only participate if screening takes less of their time and does not require 
an extra visit. The results also suggest that those who perceive low impact barriers, such as the 
impact of carriership on their general health status and the perception that other people will 
look differently at them, are more likely to accept screening. Only 41% of all non-participants 
stated correctly that carriers of CF would not develop health problems due to their carrier 
status. These results suggest that anxiety about screening and the burden of carrier status are 
partly based on misconceptions owing to lack of knowledge.  
Knowledge of CF was also a predictor for participation in screening, although this is 
probably more reflective of the interest couples have in screening and reading the leaflet before 
attending to the educational session, than knowing about CF before the invitation for screening. 
Nevertheless, inadequate understanding could lead to increased anxiety, and therefore result in 
non-participation. Bernhardt et al27 stated that better baseline understanding of human genetics 
in the public might give a basis for understanding genetic screening tests and increase interest 
in learning about screening tests. The percentage of respondents who were familiar with CF is 
comparable with the percentages in the general Dutch population in general, in which 60% 
know about the disease and 15% know somebody with CF.28 Familiarity with the disease was 
not associated with participation. This could be explained by the fact that people may have 
heard about CF, but do not know the clinical implications or the hereditary pattern of the 
disease. Possibly therefore, this variable was not a motivated factor in participation.  
Studies have shown that people are more likely to participate in screening if they 
consider themselves susceptible to being a carrier or to having an affected child.4 12 29 30 This is 
in contrast with the finding of the present study, in which no association was found between 
perceived risk and participation. Most respondents thought it very unlikely that they would be a 
carrier or that they would have a child with CF. The percentage of respondents knowing the 
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carrier risk was 61% in the participants and 39% in the non-participants. Again, this might 
imply that non-participation is partly based on lack of knowledge and the assumption that CF is 
not very common. The question remains as to whether a more accurate understanding of actual 
risk might have led to a different perception of risk, which would influence participation. A 
previous study has shown that perceived risk, rather than actual risk, influences the 
participation of women in prenatal screening tests.31 Presumably, couples participate because 
they want to be reassured that their risk is low, and not because there is a chance of their being 
carriers or having a child with CF. This is supported by the findings of Loader et al,12 that the 
desire for reassurance of a low risk of having a child with CF was mentioned twice as often 
(50.6%) as the intention to avoid having such a child (27.8%). 
Other studies4 29 have also reported the lack of an association between perceived 
seriousness of the disease itself and participation in screening. In the present study, the burden 
of the disease and the burden of a child with CF was perceived as high for most respondents, 
whereas the impact of treatment was perceived as moderate to low. This suggests that 
respondents perceive CF as a very serious disease, but think they can cope with a sick child in 
practice. In the present study, no influence of the level of education on participation was found, 
which is in contrast with the findings of other studies.4 12 13 21 29 Furthermore, already having 
children was not found to be a reason to decline screening, suggesting that the couples 
understood this aspect of inheriting CF. Overall, 45% of the couples was married, as expected 
from this age group in the Dutch population.26 
The effect of factors predicting participation in screening was more pronounced when 
couples shared their views. To our knowledge, only one other study29 described the agreement 
of husband and wife in predicting participation in a carrier screening programme. In this study, 
it was found that the combined beliefs of couples increased precision in the prediction of who 
will participate in screening for Tay-Sachs disease.  
In the present study it was stressed that both partners should attend the educational 
session to receive the same information, on which subsequent decision-making could be based. 
Of all participating couples, 15% reported that the decision to accept screening was merely a 
woman’s decision, whereas 6% declined because the male partner did not wish to participate. 
The results also showed that women had more often heard about CF than men, and knew more 
about the disease. Overall, these results are consistent with the findings of other studies,3-7 21 32 
that is, that interest in testing is greater among women than among men. This may reflect the 
greater concern and responsibility in reproductive decisions felt by women. Future analyses of 
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additional data will be performed to determine whether gender differences in the response to 
the test-results can be found, as has been reported in other studies.33 34 
Lack of time was the most frequently reported reason for non-participation. The 
invitation to attend the educational session on two evenings in one week was sent 14 days in 
advance. This might have been too short for people who already had other appointments on 
these evenings. Moreover, it has been found that when screening is offered a second time, on 
more evenings, or when people can make their own appointment, for example with their own 
GP, participation increases (this thesis, Chapter 5). Although not reported, another reason for 
non-participation might be that couples prefer personal counselling instead of attending a 
general educational session with other couples. In a study carried out by Clayton et al,6 non-
pregnant couples showed lack of interest in carrier screening. Reluctance to participate was 
ascribed to worries about factors such as insurability, being at risk, what they would need to 
learn, abortion, and religious beliefs. However, the authors believe that lack of interest in that 
study might also be explained by the mode of invitation: letters placed in pockets on signs and 
not personally addressed to those who were offered screening. Mode of invitation has been 
found to be the most important factor influencing acceptance.2-4 Invitations that were more 
personal might have increased interest in that specific screening programme. In prenatal carrier 
screening, unwillingness to terminate an affected pregnancy was mainly found to be the most 
frequently reported reason to decline screening,9 12 35 although lack of time has also been 
reported.14  
The uptake of the pre-educational screening session of couples who planned to have 
children was 10.4% in the present study. This uptake is not high, compared with other 
screening programmes offered before pregnancy2 3 5 and during pregnancy.9 10 13 36 However, 
the authors are of the opinion that uptake rate is not the most important determinant, if not for 
economic reasons, of the desirability of screening. Yet, knowledge about motives and barriers 
for participation is important. As Marteau37 also emphasised: one of the key research questions 
for the next ten years should be to find the best way of offering tests to achieve informed 
choice. In the present study, the main reason couples gave for participation in the screening was 
to find out whether they were at high risk of having a child with CF. None of the couples 
reported that they participated in the screening because they were told to do so by their GP or 
that they felt that they could not refuse. These results suggest that because of the time and effort 
needed to participation, couples were stimulated to make a decision based on the conviction 
that screening is important, and not just because it is offered or strongly recommended, as was 
argued for opportunistic screening programmes with high uptake rates.36 38 
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For this study, new scales based on the Health Belief Model (HBM) were developed to evaluate 
the response of couples to CF carrier screening. Several other components of the HBM, that 
were not addressed in the present study for practical reasons, may also be important, such as 
interpersonal interactions and mass media communications,22 and the influence of 
psychological defence mechanisms, such as avoidance behaviour.30 There has also been more 
general criticism of the model, like other rational choice theories, i.e. that it provides an 
idealised view of how decisions should be made and that it gives insufficient attention to 
emotion in decision-making and the role of cultural standards and values.39 However, the HBM 
provided more insight into the motives and barriers reported by couples who were offered 
carrier screening. In addition to HBM related variables, other variables are also considered to 
be important in affecting participation in carrier screening, such as tolerance for test 
uncertainty.4 
This article specifically addressed the participation in preconceptional CF carrier 
screening in the Netherlands. Differences between other screening programmes and other 
countries will exist, but many similarities are evident, and the results of this study can be used 
in the development of other programmes. Preconceptional screening was chosen because it 
provides a maximum number of reproductive options for identified carrier couples and 
involves a minimum of (time) constraint. Furthermore, there are three other reasons why 
preconceptional screening is highly applicable in the Netherlands. Firstly, prenatal screening is 
difficult for practical reasons, because many pregnant women visit a clinic late in their 
pregnancy. Secondly, preconceptional screening meets the requirements formulated by the 
Committee for Genetic Screening of the Dutch Health Council, whereas prenatal screening 
does not.40 Thirdly, there are a large number of planned pregnancies in the Netherlands (85%-
90%), creating an ideal situation for contacting couples before conception. These reasons may 
also be valid for other countries. In addition, preconceptional screening can be considered for a 
number of other reasons, as has recently been suggested for Tay-Sachs disease41 and 
haemoglobin disorders.42 43 For example, in the UK, prenatal screening for haemoglobin 
disorders is recommended as a routine practice,44 although it has been shown that the present 
practice does not always meet the needs for early information and leads to the late recognition 
of risk.45 46 Moreover, at the beginning of a thalassemia screening programme43 in Sardinia in 
the mid 70s, the largest category of participants consisted of pregnant women, whereas the 
number of couples without a pregnancy is currently increasing. In other countries however, 
cultural differences influence the approach to carrier screening.47 For example, screening is 
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offered premaritally to communities of Orthodox Jews, to prevent the marriage of two carriers 
of recessive disorders.48  
In this study, interest in preconceptional CF carrier screening, requiring time and effort 
to participate, is shown, both by the actual participation of couples and by the perceived 
benefits of screening of couples who did not participate. The results of the study could be used 
as a model for other screening programmes. Lack of time to attend the educational session was 
found to be of main influence on participation in carrier screening by non-pregnant couples. 
However, the results suggest that these couples have positive attitudes towards screening and 
will attend when screening is offered more conveniently. The results also indicate that 
participation is influenced by ‘psychological’ barriers, possibly caused by an inadequate 
understanding of the consequences of carrier testing. These barriers could be removed by 
providing more clear information about the meaning of carrier status, and by increasing public 
awareness. In addition to participation in screening, the psychological and cognitive 
consequences of screening are being investigated.  
 
Appendix — Constructs of the Health Belief Model: subscales and items with good reliability  
and associated  (n=3) and separate items of subscales with low reliability (n=1)  
 
Subscales:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Perceived Susceptibility (Cronbach’s  0.90) 
Estimated likelihood of being a CF carrier 
Estimated likelihood of being a CF carrier couple 
Estimated likelihood of having a child with CF 
 
Perceived Benefits (Cronbach’s  0.83) 
Carrier testing gives me more reassurance 
It is important for me to know if I am a carrier  
It is important for me to know my risk of having a child with CF 
The test-results will help me making childbearing decisions 
Carrier testing should be offered to all couples who are planning to have children 
 
Perceived Impact Barriers (Cronbach’s  0.64) 
If I had carrier testing, I would feel worried 
If I were a carrier, I would feel less healthy 
If I were a carrier, people would look differently at me 
Separate items: Perceived Seriousness of diseasea 
CF is one of the worst diseases there is (burden of disease) 
I would find it hard if my child had CF (burden of child with disease) 
I would find it hard to give my child the treatment (burden of treatment) 
 
a Cronbach’s  less than 0.40. 
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Abstract 
The impact, understanding of test-results, and satisfaction among participating couples in a 
preconceptional cystic fibrosis (CF) carrier screening project were assessed by means of 
questionnaires, six months after testing. Questionnaire data were obtained from 17/18 identified 
carriers, 15 partners of carriers with negative test-results, and 794 (73%) participants with a 
negative or no test-result. None of the carriers changed their reproductive plans because of their 
test-results. Eight participants were worried about their results, including four carriers. Those who 
attended a GP consultation for pre-test education were less worried than those who attended an 
educational session. Seven carriers felt less healthy. Predictors of a correct understanding of test-
results (correct in 62% of participants) were: positive test-results, a high level of knowledge of CF 
at six months, a high level of education, attending an educational session, and previously heard of 
CF. All participants who reported that they were worried, all carriers, and 95% of the other 
participants said that they would make the same decision to be tested again. Overall, 88% would 
recommend testing to others. Although the primary care setting achieved the highest couple 
attendance, and couples who were educated during a GP consultation were less worried, the 
results of the study suggest that recollection and interpretation of the test-results is more correct in 
couples attending an educational session. The results further suggest that since satisfaction with 
the screening was high, worries and feeling less healthy due to the test-results are probably not a 
great burden.  
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Introduction 
An important criterion that is applied to genetic screening programmes is that such a programme 
should only be considered if the benefits outweigh its potential harm.1 Therefore, pilot studies 
should collect and evaluate data on these aspects, prior to the decision to introduce large-scale 
screening. The benefit of population carrier screening for cystic fibrosis (CF) is to identify carrier 
couples to enable them to make informed reproductive decisions.  
The most commonly described harmful aspects of CF carrier screening are anxiety and 
false reassurance among participants. Anxiety has been reported among CF carriers who were 
identified by screening during a pregnancy2-4 and outside a pregnancy.5-7 However, for most 
carriers, anxiety levels return to normal after a few months,6 especially when there is a negative 
test-result for their partner.2 However, because the test is not 100% sensitive, false reassurance 
may occur when individuals receive a negative test-result and incorrectly believe that there is 
no risk of having a child with CF. Also of concern are the test positive individuals who believe 
that they are only likely to be carriers.8 These misunderstandings occur when people do not 
remember the test-results they have received, or when they do not correctly understand the 
implications of these results. One of the key questions at present is to investigate the best way 
of offering tests in order to maximise understanding of the meaning of the results, as was 
proposed recently in a research agenda compiled by Marteau.9 
The aim of the present study was to assess the impact, understanding and satisfaction 
among participants in a preconceptional cystic fibrosis carrier couple screening programme, in 
terms of the reproductive intentions of the participants, their level of concern, perception of 
health, level of knowledge of CF, recall and understanding of the test-results, and attitude 
towards carrier testing. In addition, outcome measures were evaluated for two different settings 
in which the education, counselling and mouthwash tests had been provided. The results 
provide more insight into the beneficial and harmful aspects associated with carrier screening. 
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Methods 
Participants and procedure  
Individuals, aged 20 to 35 years, were invited by mail, either by their own general practitioner 
(GP) or by the Municipal Health Services (MHS) to take part in a preconceptional CF carrier 
screening programme with their partner, between May 1997 and December 2000. Enclosed 
with each letter was an information leaflet describing CF and various aspects of the carrier test, 
which was offered free of charge. In some geographical areas, couples planning to have 
children were invited to attend a pre-determined session during which education was provided 
by the researcher (LH), in other areas they were invited to make an appointment with their GP 
for a consultation. During the educational sessions and the GP consultations, more detailed 
information was given, and questions were answered. An extensive description of the 
recruitment procedure, response rate and educational methods is given elsewhere (Chapter 5, 
this thesis).  
Attendance of individuals and their partners at an educational session, either invited by 
their GP or the MHS, was approximately 10%. Uptake was higher when couples were invited 
to make an appointment with their GP (25%). A total of 559 couples (96%) gave written 
consent to CF carrier testing. Of these, 41 couples (82 individuals) received no personal 
education. They contacted the researcher, saying that they wanted to participate but were 
unable to attend the educational session, so the information materials were sent to them at 
home. In 55 couples, only one partner was able to attend an educational session (n=39) or a GP 
consultation (n=16). This partner passed the information on to the other partner.  
Testing in the laboratory was step-wise; one partner was tested first, and the second 
partner was tested only if the test-result of the first was positive. The test-result was sent to the 
couples by mail within eight weeks of testing. Again, the letter with the results emphasised that 
with a negative test-result there still might be a small chance of being a carrier, and a residual 
risk of having a child with CF. Eighteen carriers were identified, 7 of whom had attended a GP 
consultation and 11 an educational session. The partners of these carriers tested negative. 
Carriers and their partners were given a residual risk of  1 in 2000 (for two carriers at the 
beginning of the study the test-sensitivity was lower (87%) and the residual risk was 1 in 870). 
They received a contact telephone number, and were invited to make an appointment for 
further counselling. Carriers were informed that their family members could contact the 
researcher for more information, since family members had an increased chance of being 
carriers.  
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Questionnaires 
Impact, understanding and satisfaction among participants were assessed by means of three self- 
administered questionnaires (Q1-Q3). Each questionnaire took approximately 10 minutes to 
complete. Individuals completed Q1 before they received pre-test education and counselling. 
After the information had been provided, but before they received the test-results, they were 
given Q2 to take home and to be returned by mail within one week. Six months after sending the 
test-results, a follow-up questionnaire (Q3) was mailed to all participants. All three 
questionnaires investigated knowledge of CF with five multiple-choice questions, assessing the 
level of understanding of the frequency of carrier status, the impact of carrier status on health, the 
main symptoms of CF, the chance of having a child with CF if both partners are carriers, and the 
consequences of a negative test-result. The number of questions answered correctly was 
calculated as a sum-score. A response of “don’t know” was scored as an incorrect answer.  
Furthermore, Q1 assessed sociodemographic characteristics, whether respondents had 
heard about CF before receiving the invitation for screening, the most important reason for 
having the test, and health belief perceptions concerning CF carrier testing. Details and results of 
this questionnaire can be found elsewhere (Chapters 5 and 6, this thesis).10 Q2 recorded 
reproductive intentions if both partners were found to be carriers (intention to refrain from 
having children, intention to make use of prenatal diagnosis, and intention to terminate affected 
pregnancies), on a five-point Likert scale (completely disagree (1)-completely agree (5)). Q3 
asked the respondents to indicate the extent to which they had felt worried while awaiting the 
test-results. The response to the test-results after six months was assessed by asking the 
participants whether they felt worried at the time they completed Q3. Furthermore, the 
perception of health was assessed by asking participants whether they felt less healthy after 
hearing the test-results. These feelings were also assessed on a five-point Likert scale. 
Recollection of the test-result (“do you know what your test-result was?”), and understanding of 
the residual risk (“if you and your partner are planning to have children in the future, what is, 
with your test-result, the chance of having a child with CF?”) were assessed by means of 
multiple-choice questions. Carriers were asked if they shared knowledge of their test-result with 
others and if so, with whom. Furthermore, couples were asked whether they had kept their letter 
containing their test-results and the brochure. The questionnaire also assessed possible changes 
in reproductive plans due to the results of the test (“did the test-results change your ideas about 
having (more) children?”), and the impact of testing on the relationship with their partner and 
other family members. Satisfaction with screening was assessed by asking participants whether 
they would decide to have the test again, and whether they would recommend testing to other 
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couples (answering format: “yes”, “no”, and “don’t know”). They were also asked, in an open-
ended question, to mention any positive or negative aspects they associated with the whole 
procedure.  
 
Table 1 — Response rates to the questionnaires at each assessment point (Q1, Q2, and Q3) according to 
pre-test education mode 
 
 
Pre-test education mode 
 
Participants 
n 
Q1 
Before education 
%  (n) 
Q2 
After education 
%  (n) 
Q3 
After 6 months 
% (n) 
 
Educational session 
GP consultation 
No personal education 
 
All participants 
 
623 
358 
137 
 
1,118 
 
97  (604) 
99  (357) 
99  (135) 
 
98  (1,096) 
 
94  (583) 
97  (346) 
99  (135) 
 
95  (1,064) 
 
73  (457) 
73  (262) 
78  (107) 
 
74  (826) 
 
Q=questionnaire  
 
Data analyses 
Data from the questionnaires were analysed using chi-square tests or Fisher exact tests when 
needed. P-values below 0.05 were considered to be significant. Five-point Likert scales were 
reduced to three categories to avoid empty or small cells. Understanding of the test-result was 
based on two variables; recollection of the test-result and understanding of the risk, and reported 
as correct or incorrect (including “don’t know”). Using correct understanding of the test-result at 
six months as the dependent variable, associations with the following variables were analysed: 
educational setting, outcome of test-result, feeling worried, feeling less healthy, gender, level of 
education, previously heard of CF, and level of knowledge of CF at six months follow-up. To 
assess predictors of understanding of the test-result, variables that showed statistical significance 
(p<0.1) in the univariate analyses were entered simultaneously in one multiple logistic regression 
model. 
Analyses of knowledge scores were carried out for those who had completed the 
knowledge questions on all three questionnaires. The mean knowledge scores and the change in 
scores between Q1 (before education), Q2 (after education) and Q3 (after six months) in the 
different modes of education were analysed, using general linear modelling with an intra and 
inter-subject design. The statistical programme SPSS for Windows was used for all statistical 
analyses (SPSS, version 7.5.2.; SPSS Inc.). 
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Results  
Response to the questionnaires 
Response rates to the questionnaires, according to pre-test education mode, are shown in Table 1. 
In total, Q1 was returned by 98% participants, Q2 by 95%, and Q3 by 74%. The response rate for 
completion of all questionnaires was 94% for carriers (17/18; 9 men and 8 women), 83% (15/18) 
for their partners with negative test-results, and 73% (794/1,082; related to 417 couples) for 
individuals with negative test-results and their partners who were not tested.  
A total of 665 respondents (59%) completed the knowledge questions at each assessment 
point. The knowledge questions in Q2 were added during the course of the study. Therefore, 93 
individuals who attended an educational session, and 45 individuals who received no personal 
education, did not complete this questionnaire. Knowledge questions were completed by 341 
(55%) participants attending an educational session, 254 (71%) participants attending a GP 
consultation, and by 70 (51%) participants who received no personal education.  
There were no differences between those who filled in the questionnaires and those who 
did not in terms of sociodemographic characteristics (age, gender, level of education), and 
previously heard of CF. 
 
Reproductive intentions 
The responses to the question (in Q2), about what they would do if both partners were found to 
be carriers, are shown in Table 2. Overall, 36% thought that they would refrain from having 
(more) children, 87% would make use of prenatal diagnosis if pregnant, and 68% of those who 
would make use of prenatal diagnosis would consider termination of the pregnancy if the child 
was found to have CF. 
 
Table 2 — Reproductive intentions if both partners were found to be carriers reported by 1,064 
participants after pre-test education (Q2) 
 
 Yes 
n  (%) 
No 
n  (%) 
Undecided 
n  (%) 
Would refrain from having (more) children 
Would make use of prenatal diagnosis when pregnant 
Would consider termination of pregnancy if fetus had CF 
36  (379) 
87  (925) 
60a (644) 
36  (386) 
4  (48) 
15  (156) 
28  (299) 
9  (91) 
25  (264) 
 
aEquivalent to 68% of participants who would make use of prenatal diagnosis. 
 
At six months (Q3), a total of 42 participants (5%) reported a change in reproductive plans as a 
consequence of the test-results. Of these, 39 were more certain about having children, and three 
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wanted more children than planned before the carrier test. Carriers and their partners reported 
no impact of the test-results on their reproductive plans. Overall, six months after testing, 17% 
(72/434) of the couples reported a pregnancy. 
 
Feelings about the test-results 
In Q3, 154 out of 826 (19%) participants reported that they had been feeling worried while 
waiting for their test-results. More women than men reported that they had been worried (24% 
v. 13%: p<0.001). 
Table 3 shows the feelings about the test-results at six months follow-up. Eight 
respondents reported feeling worried (five women and three men), four of whom were carriers. 
Participants who had attended an educational session and those who did not receive personal 
education were more likely than those who had attended a GP consultation to be worried or to 
be undecided about these feelings (p=0.04).   
Seven out of 17 carriers reported that they felt less healthy due to their test-results. Two 
of these were also worried about the test-results. At that time, none of the participants had 
made an appointment for further counselling. One couple had received post-test counselling by 
telephone. The female partner was an identified carrier, and reported that she was anxious.  
 
Table 3 — Feelings about the carrier test-results at six months follow-up     
 
  
n 
Yes 
n  (%) 
No 
n  (%) 
Undecided 
n  (%) 
Feeling worried about the test-results   
  Carriers 
  Negative tested partners of carriers 
  Others negative tested or not tested 
 
Feeling less healthy due to the test-results 
  Carriers 
  Negative tested partners of carriers 
  Others negative tested or not tested 
 
17 
15 
794 
 
 
17 
15 
794 
 
4 
1 
3  (<1) 
 
 
7 
0 
0 
 
9 
13 
762  (96) 
 
 
9 
15 
776  (98) 
 
4 
1 
29  (4) 
 
 
1 
0 
18  (2) 
 
The majority of participants (98%) perceived no impact of carrier testing on the relationship 
with their partner. Of the 15 participants (2%) who perceived a positive influence on their 
relationship, six reported an improvement in communication with their partner, five reported an 
increased certainty about having children, and the remaining four gave no reason. One man 
reported a negative impact, but gave no specific reason. None of the participants reported a 
change in their relationships with other family members due to the test-result. 
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Figure 1 — Knowledge scores of participants before (Q1) and after (Q2) pre-test education, 
and at six months follow-up (Q3) according to mode of pre-test education.  = educational 
session (n=341);  = GP consultation (n=254);  = no personal education (n=70). 
 
 
Knowledge 
At all three assessment points (Q1, Q2 and Q3), the knowledge scores were significantly 
higher for participants who attended an educational session than for participants who received 
education during a GP consultation (Figure 1). The increase in knowledge scores between Q1 
and Q2 was significant for both settings. Although the decrease in knowledge scores between 
Q2 and Q3 was also significant, the level of knowledge after six months (Q3) was still 
significantly higher than before education (Q1). General linear modelling with correction for 
gender, previously heard of CF, referral to the leaflet or brochure while answering the 
knowledge questions, and level of education showed that the change in knowledge was 
dependent on the method of education. The increase in knowledge after education (Q2) was 
significantly higher, and the decrease at six months follow up (Q3) was significantly lower, 
after attendance at an educational session than after attendance at a GPs consultation 
(p<0.001). For those who did not receive personal education, knowledge increased at Q2, and 
fell back to the initial level of knowledge after six months. At six months, the level of 
1,5
2
2,5
3
3,5
4
4,5
5
Before education After education Six months follow-up
Knowledge 
scores 
Q1 Q2 Q3 
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knowledge of those who had attended a GP consultation was similar to that of those who 
received no personal education, while the level of knowledge of those who had attended an 
educational session was significantly higher. 
 
Table 4 — Recollection of test-results and understanding of residual risk at six months follow-up 
 
  
n 
Correct 
n  (%) 
Incorrect 
n  (%) 
Don’t know 
n  (%) 
Recollection of test-results 
  Carriers 
  Negative tested partners of carriers 
  Others negative tested or not tested 
 
Understanding of risk 
  Carriers 
  Negative tested partners of carriers 
  Others negative tested or not tested 
 
17 
15 
794 
 
 
17 
15 
794 
 
17 
15 
739  (93) 
 
 
14 
13 
509  (64) 
 
0 
0 
52  (6) 
 
 
3 
2 
272  (34) 
 
0 
0 
3  (<1) 
 
 
0 
0 
13  (2) 
 
Recall and understanding of residual risk 
Table 4 shows the recollection of test-results and understanding of the residual risk after six 
months. All carriers and partners knew their test-results, but three carriers and two of their 
partners believed there was no residual risk of having a child with CF. Fifty-five (7%) 
participants with a negative test-result, or not tested, could not correctly recall their test-result, 
according to Q3. They either did not know the result (n=3), thought that the other partner had 
been tested (n=11), incorrectly believed that both partners had a negative test-result (n=39), or 
gave some other incorrect answer (n=2). Furthermore, 64% of those with a negative test-result, 
or not tested, correctly remembered that their risk of having a child with CF was reduced, but 
not zero, while 34% incorrectly believed that they could not have a child with CF.  
Overall, 512 (62%) participants (related to 81% [351/434] of the couples) had a correct 
understanding of the test-results, i.e. they recalled their results correctly and knew that there 
was a residual risk. The most important determinants of a correct understanding of test-results 
were identified by multiple logistic regression. The five relevant components found in the 
univariate analyses for correct understanding their test-result were entered simultaneously into 
one multiple logistic regression model. Coefficients, odds ratios, and 95% confidence intervals 
(95%CI) for this model are presented in Table 5.  
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Table 5 — Predictors of correct understanding of test-results at six months follow-up 
 
Predictors n  % Correct Odds ratio  95% CI 
Outcome test-resulta 
  +/– couple 
  –/? couple 
 
Knowledge of CF at six months  
  High score (3-5) 
  Low score (0-2) 
 
Level of educationb 
  Low 
  Intermediate 
  High 
 
Pre-test education mode 
  Educational session 
  GP consultation 
  No personal education 
 
Previously heard of CF  
  Yes  
  No  
 
32 
794 
 
 
573 
253 
 
 
132 
363 
331 
 
 
457 
262 
107 
 
 
466 
360 
 
84 
61 
 
 
69 
46 
 
 
49 
59 
71 
 
 
72 
47 
58 
 
 
68 
54 
 
3.2 
 
 
 
2.0 
 
 
 
1.0 
1.4 
1.9 
 
 
1.7 
0.6 
1.0 
 
 
1.5 
 
  1.2-8.8  
 
 
 
  1.5-2.8  
 
 
 
 
0.9-2.1 
   1.2-3.0  
 
 
   1.1-2.6  
0.4-1.0 
 
 
 
  1.1-2.1  
 
 
a +/– couple: one partner in the couple is identified as a carrier, the other tested negative, –/? couple: one partner in 
the couple is tested negative, the other is not tested; b Low: primary school, lower level of secondary school, lower 
vocational training. Intermediate: higher level of secondary school, intermediate vocational training. High: higher 
vocational training, university; CI=confidence interval;  p<0.05. 
 
A positive test-result in a couple appeared to be the strongest determinant for correct 
understanding of the test-results. Furthermore, participants with a high level of education and a 
high knowledge score at six months follow-up were more likely to understand their test-results 
than those with a low level of education and low knowledge scores after six months. Compared 
to participants who had never heard of CF before receiving the invitation for screening, 
participants who had previously heard of CF were more likely to understand their results. 
Finally, participants who had attended an educational session were more likely than those who 
had attended a GP consultation, or those who had received no personal education, to correctly 
understand their test-results.  
Six months after testing, 81% of the couples still had the letter with results, and 64% 
had kept their brochure or information leaflet.   
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Satisfaction 
All carriers, 13 of the 15 partners with negative test-results, and 95% of the other participants 
would decide to have the test if they had to decide again (Table 6). Interestingly, all 
participants who reported feeling worried, or who were undecided about these feelings, would 
make the same decision to be tested again. Reasons reported by the seven participants who did 
not want to have the test again were: “the test-results do not give full certainty” (n=3), “only 
one partner is initially tested, and the second partner is tested only if the first is positive” (n=2), 
“the GP lacked knowledge” (n=1), and “the burden of questionnaires” (n=1). Overall, 88% 
would recommend testing to others. The amount of money the couples said they would be 
willing to pay out of their own pocket was, on average, 101 Dutch guilders (45.5 EURO) 
(range 0-2000 Dutch guilders). All but one of the carriers whose parents were still alive had 
told them about their test-results. Ten carriers had shared the information with their brothers 
and sisters, but two had not. Only two carriers had told more distant relatives about their test-
results. Although most carriers shared the information with parents and siblings, there was only 
one request for relative testing.  
 
Table 6 — Attitudes towards carrier testing at six months follow-up 
 
  
n 
Yes 
n  (%) 
No 
n  (%) 
Undecided 
n  (%) 
If you had to decide again, would you be tested?  
  Carriers 
  Negative tested partners of carriers 
  Others negative tested or not tested 
 
Would you recommend testing to other couples? 
  Carriers 
  Negative tested partners of carriers 
  Others negative tested or not tested 
 
17 
15 
794 
 
 
17 
15 
794 
 
17 
13 
756  (95) 
 
 
15 
13 
703  (88) 
 
0 
1 
6  (1) 
 
 
0 
1 
15  (2) 
 
0 
1 
32  (4) 
 
 
2 
1 
76  (10) 
 
Although a majority of 85% of the participants reported one or more positive aspects related to 
the study, there were also 400 negative aspects reported by 334 participants (40%). Most of the 
complaints (31%) were related to the burden of the questionnaires (n=127). Overall, 107 
participants expressed dissatisfaction about the fact that only one partner was initially tested. 
They reported that they would have preferred to have the results of both partners. Other aspects 
included the content of the information (n=52), the way in which the information was provided 
(n=28), the long waiting time between the test itself and receipt of the test-results (n=28), the 
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absence of mass media attention to CF (n=19), complaints related to the mouthwash sample 
(n=10), and other negative aspects (n=29).  
 
Discussion 
In the present study, the impact, understanding, and satisfaction among participants in a cystic 
fibrosis (CF) carrier screening programme was investigated to gain more insight into the 
beneficial and harmful aspects associated with carrier screening. Participants’ knowledge of CF 
increased after pre-test education, thus aiding informed decision-making. Furthermore, 
participants intended to make use of the reproductive options available. Six months after 
testing, eight participants were worried, and seven reported that they were feeling less healthy. 
Overall, 95% would decide to have the test again, and 88% would recommend testing to 
others. 
 
Harmful aspects of screening 
While most carriers and their partners reported no worries six months after they had received 
their test-results, four carriers and one partner did worry about their results. It has been 
reported that 16% of 280 identified carriers remained worried after three years of follow-up.8 
This lasting effect has also been documented in screening programmes for other recessive 
inherited diseases, such as Tay-Sachs.11 The results of the present study show that some 
participants who were partners in a couple in which neither of the partners was identified as a 
carrier felt worried about the test-results, or were undecided about these feelings. This might be 
explained by the fact that only one partner was tested. 
Seven out of 17 carriers felt less healthy due to their test-results, despite being 
informed, both verbally and by letter, that their carrier status would have no effect on their 
health status. This is also in agreement with the findings of previous studies. After three years 
of follow-up, CF carriers were reported to have a poorer perception of their current health than 
non-carriers.8 In addition, an earlier study, in which subjects had undergone carrier screening 
for Tay-Sachs disease, reported that carriers viewed their future health with less optimism than 
non-carriers.12 Several explanations, such as poor understanding of the test-results, have been 
suggested for this observation. In the present study, however, all carriers correctly understood 
that CF carriers would not develop CF-related health problems (data not shown), implying that 
if knowledge of CF was good, then other mechanisms must play a role, such as reduced 
optimism of carriers when considering their chances of becoming ill,12 or a diminished self-
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image.13 Nevertheless, Denayer et al14 demonstrated that carrier status, identified in persons 
within CF families, had no lasting effect on their self-concept. 
The inability to recollect the residual risk related to the test-results, reported in this 
study, has been found in most previous studies, although it has been suggested that it is more 
likely to reflect the way in which people deal with risk information rather than a poor 
understanding.8 However, the present results show that various factors that can more or less be 
influenced, such as level of education, previously heard of CF, level of knowledge of CF, and 
educational setting are all associated with understanding of the test-results. These findings 
therefore suggest that such external factors, leading to a misunderstanding of the test-results, 
are one part of the story, and incorrect recollection of the residual risk as a way of coping with 
the information, is another part of the story. 
The results of this study suggest that an intermediate couple test-result (+/– couple) is 
unlikely to cause problems in the relationship, and there was no request for face-to-face 
counselling. Furthermore, most carriers shared the information with others, as has been found 
in previous studies,4 5 suggesting that they do not feel stigmatised in their relationships with 
others. 
 
Beneficial aspects of screening 
The results show that if both partners had positive test-results, the couples would make use of 
the reproductive options available. None of the +/– couples changed their reproductive plans 
because of their test-results. However, Payne et al7 showed evidence for a damaged 
reproductive self-esteem. Three months after testing, for both carriers and non-carriers, 
knowledge of carrier status in one member of the couple seemed to limit plans to have more  
children.7 
Knowledge of CF increased after testing, thus supporting informed decision-making. 
However, soon after testing, this knowledge decreased again, which has also been found in 
other studies, suggesting that the knowledge was only superficial.15 
Overall, satisfaction was high, 88% would recommend testing to others, and 95% 
would decide to have the test if they had to decide again. Some of the negative aspects that 
were mentioned, such as the burden of questionnaires and the absence of media attention, can 
be eliminated when large-scale screening is offered. One important aspect has to be discussed 
before the implementation of a large-scale screening programme. That is the fact that 13% of 
participants reported that they preferred to have the results of both partners, suggesting they 
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wanted both partners to be tested simultaneously, as was shown in a more detailed study on a 
subgroup of the participating couples.16 
 
Pre-test educational setting 
The higher percentage of participants who misunderstood the meaning of the test-results after 
receiving education during a GP consultation most likely reflect poorer knowledge of CF in 
this group, and especially about the negative consequences of the test. There is no clear 
explanation for these differences. On the one hand both groups may differ in their attitudes 
towards testing. We may even speculate that those attending a GP consultation tended to rely 
more on their physician, and may have taken less notice of the provided information. On the 
other hand it may be a difference in the way of education e.g. time to explain, content of 
information, motivation of the provider, that influenced the knowledge and thereby the 
understanding of couples.  
At the same time, participants who attended a GP consultation were less likely to be 
worried than participants who attended an educational session. No association between the 
understanding of test-results and the degree of worry was found, suggesting that it is the GP 
who reassures people, and not the lack of knowledge about the residual risk. This is supported 
by the finding that those who received no personal education had lower levels of 
understanding, but higher levels of worry than those who attended a GP consultation. 
 
Conclusions and further research 
The main objective of this study was to gain more insight into the beneficial and harmful 
aspects of participation in preconceptional CF carrier couple screening. Although eight 
participants were worried, and seven carriers reported feeling less healthy, the results suggest 
that these drawbacks are tolerable, since the same subjects would unanimously decide to have 
the test again. Long-term follow-up studies are needed to assess the actual impact of 
information about carrier status, whether or not correctly understood, on decision-making and 
reproductive uncertainty. Furthermore, it is recommended to further investigate the exact 
nature of the worries. Overall, the preliminary findings in the present study show that there is 
no evidence that the psychological effects of a carrier screening result are so serious as to make 
it unacceptable to offer such a test. 
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Abstract 
Couple-based carrier screening, in which both partners provide samples and a positive result is 
given only if both partners are found to be carriers, has generated much debate. The objective 
of this study was to find out how much couples wish to know about their screening test-results. 
In total, 108 couples participating in cystic fibrosis (CF) carrier screening were offered the 
opportunity to choose whether they wished to be fully informed about the test-results or 
whether they only wanted to know whether or not they had a 1-in-4 risk. The advantage of the 
latter choice is the avoidance of possible anxiety about a residual risk in those couples in which 
one partner is found to be a carrier and the other is not. Questionnaires were used to assess the 
reasons for the choice. Most couples (94%) wished to be fully informed, and the main reason 
was that they did not want any information to be withheld from them (50%). Other reasons 
given were: to inform relatives (25%), for their own sake (13%), and for use in case of a new 
partner (5%). The results show that the great majority of couples want to be fully informed 
about their test-results, including the results if only one partner was tested positive, and the 
other partner negative. These findings may be useful in the development of future carrier 
screening programmes. 
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Introduction  
Carrier screening programmes, aimed at the identification of carrier couples in the general 
population, provide these couples the opportunity to be informed about their risk and about the 
reproductive options that are available. It has been argued that the imperfect sensitivity of the 
carrier test, for example in the case of cystic fibrosis (CF), might cause anxiety in couples if a 
mutation is detected in one of the partners, while the other tests negative, but may still carry a 
rare mutation (in future referred to as +/– couples).1 Such couples have a residual risk, and may 
be distressed by the lack of clear options, such as prenatal diagnosis.  
 Wald2 therefore proposed a couple-based screening method, where both partners provide 
samples simultaneously. Only those couples in which both partners are found to be carriers are 
informed about their carrier status, while all others are told that they have no marked increased 
risk, circumventing the possible anxiety in a +/– couple. To a certain extent, Wald’s proposal 
can be considered favourable. Simultaneous sampling prevents the anxiety and need for 
counselling that might arise among those who are tested positive while awaiting the partner’s 
results, which can occur in stepwise screening.3-5 In addition, sampling one partner later 
requires an extra effort. A major disadvantage of couple screening without full disclosure of 
the test-results is that information is withheld from identified carriers who might need it at a 
later date with a new partner or whose relatives might wish to be tested. Moreover, Wald’s 
procedure can be considered as directive counselling, because the patient is not given the full 
information on which choices can be based.5 The advantages and disadvantages of disclosure 
and non-disclosure of +/– results have generated much debate. Studies have reported anxiety 
and false reassurance among participants in both approaches. Some results support the non-
disclosure strategy proposed by Wald,6-9 although it remains controversial.5 10 11 To investigate 
what the couples themselves prefer with regard to the disclosure of test-results, couples 
participating in a preconceptional screening programme were offered the opportunity to choose 
whether they wished to be fully informed about the test-results (including disclosure of +/–) or 
only informed about whether or not they had a 1-in-4 risk as a couple.  
 
Procedure and methods 
The sample consisted of 108 couples planning a pregnancy and participating in preconceptional 
CF carrier screening. In short, the couples responded to a letter of invitation from their general 
practitioner (n=5) offering screening to all individuals (aged 20-35 years) and their partners 
between May 1997 and November 1999. The letter invited couples to attend a 45 minute 
educational session organised by one of the authors (LH) on two evenings in one week. The 
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response rate was approximately 10% of the eligible target population (couples planning to 
have children) (data not shown). Detailed information on the screening procedure and 
calculation of the response has been described in a previous paper.12 During the educational 
session, the couples were provided with detailed information about the clinical and genetic 
aspects of CF, and the implications and options for couples with positive and +/– test-results. 
Furthermore, the couples were informed about the method of testing, including the imperfect 
sensitivity of the test (the test sensitivity in this study was approximately 87%). The verbal 
information was backed up with a 15-page booklet. At the end of the educational session, both 
partners of the participating couples provided mouthwashes simultaneously, and they were 
given a consent form to sign at home. Mutation analysis was performed only for couples who 
had returned their signed consent form by mail. The method of testing was stepwise, that is, the 
sample of one partner was tested first, and the other sample was only tested if the first one 
tested positive. An additional section of information in the booklet explained three ways in 
which the test-results could be received, and the couples could indicate their choice on the 
consent form: (A) “we will be informed whether or not we are both carriers”, (B) “we will be 
informed whether or not we both are carriers, or whether or not the first partner tested is a 
carrier”, (C) “we have no preference for either A or B, the choice will be made at random”. 
The booklet and a kit with which the mouthwash sample was to be collected were sent to the 
home address of couples who were not able to attend the session, but were interested in the 
screening. All couples completed sociodemographic assessment questionnaires, in which they 
were also asked to describe in their own words the motivation for their choice with regard to 
the way in which they wished to receive their test-results. 
 
Results and discussion 
Of the 108 couples, 41% was married. The mean age of the men was 30.8 (range 20-45 years) 
and the mean age of the women was 28.6 (range 20-44 years). The level of education was high 
for 37% of the couples (higher vocational training, university), intermediate for 49% (higher 
level of secondary school, intermediate vocational training) and low for 14% (primary school, 
lower level of secondary school, lower vocational training). There was no difference in 
sociodemographic characteristics between the eligible couples who participated in screening 
and those who did not, as was shown in a previous study comparing 76 of these participating 
couples and 53 non-participating couples (Chapter 6).12 This in contrast with the findings of 
others, showing, for example, that those with high levels of education were more likely have 
the test.13 14 
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Table 1 — Choices of couples with regard to the communication of cystic fibrosis carrier test-results 
 
Choice Total (%) 
A. Informed whether or not both are carriers  
B. Informed whether or not both are carriers, or whether or not the first partner tested is a carrier 
C. No preference for A or B 
    4  (4) 
102  (94) 
    2  (2) 
 
In total, 87 couples (81%) attended the educational session and 21 couples (19%) received the 
information at home. Table 1 shows that most couples (94%) chose to be fully informed about 
the test-results, including a +/– result (B). Four couples reported that they only wanted to know 
whether both partners were carriers (A), and two couples had no preference for the way in 
which they would be informed (C).  
 Half of the couples (n=51) who chose to be fully informed (B) explained their choice by 
stating that they did not want any information to be withheld from them. Other reasons 
reported were that they wanted to be able to inform other family members (25%), or that they 
wanted to know for their own sake (13%). Five couples argued that the information could be 
used in a new relationship and seven couples gave no reason for their choice. Reasons why 
couples did not wish to know +/– results (A) were that they perceived the residual risk (1/870) 
of having a child with CF as low, and that it would not influence their decision to have children 
(two couples). One couple stated that knowing +/– results would cause anxiety, because no 
options are provided to reduce the uncertainty. One couple gave no reason for their choice. Of 
the four couples choosing (A), one couple did not attend the educational session.  
 The results of this Dutch study are in line with the findings of Miedzybrodzka et al15 in 
the United Kingdom. Out of a total of 450 pregnant woman who were asked which screening 
method they preferred, if screening was available, 62% preferred stepwise screening with full 
disclosure of the test-results, 26% preferred couple screening with non-disclosure, and 12% 
had no preference.15 However, differences with other screening programmes and other 
countries will exist, so the question remains whether the attitudes of participants in screening to 
the disclosure of test-results in other European populations will be similar. 
 In the present study, 42 individuals (20%) spontaneously stated that they would prefer 
to have results of both partners, suggesting that they wanted simultaneous testing of samples in 
addition to full disclosure of the test-results. Since most couples (94%) wanted to be fully 
informed about the test-results, it was not possible to compare demographic, educational or 
outcome variables, such as satisfaction or understanding of the test-results, between couples 
receiving the results according to method A, B or C.  
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The results of a randomised controlled trial evaluated by Marteau et al8 showed that three years 
after prenatal testing, women who had undergone couple sampling, one partner tested in the 
first instance, and non-disclosure of the test-results (the same as our method A) were 4.5 times 
more likely than those who were sampled and tested stepwise to accurately recall that the test-
results meant that it was unlikely that they were both carriers.8 It was suggested that the time 
and effort spent by staff on explaining the meaning of couple-results might have caused the 
differences found between the two groups. In addition, approaching couples may have resulted 
in more communication between the partners in couple screening than in stepwise screening, in 
which, in most cases, only the women had been approached.8  
  Based on the findings of the present study and the results of others, simultaneously 
sampling of partners and full disclosure of the test-results is recommended for CF carrier 
screening. Recently, the American College of Medical Genetics Subcommittee on Cystic 
Fibrosis Screening recommended either couple-based screening with full disclosure of test-
results or step-wise screening, leaving this decision up to the judgement of the practitioner.16 
The results of this study show that some couples prefer simultaneous testing of partners, 
although this implies that the costs of testing will be doubled, and twice as many +/– couples 
will be identified, with no further options. Whatever method of screening is used, attention 
should be given to the pre-test and post-test counselling of couples, to ensure an informed 
choice and maximum understanding of the test-results and to minimise anxiety.  
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This Chapter discusses various aspects of the feasibility and desirability of a preconceptional 
cystic fibrosis (CF) carrier couple screening programme in the Netherlands. The contribution 
of the screening study, presented in this thesis, to the body of knowledge concerning the 
advantages and disadvantages of CF carrier screening will be discussed. The Chapter 
concludes with the future perspective for genetic carrier screening programmes, including 
recommendations for further research and concluding remarks.  
 
Feasibility of screening in the Netherlands 
Although a preconceptional approach is considered worldwide to be the most appropriate 
strategy for CF carrier screening,1 only a few pilot studies have yet been carried out. One 
important reason for this is that the target group, i.e. couples who are planning to have a child, 
is difficult to reach. Given the limited resources that are available for preconceptional health 
care, and the fact that in most countries an antenatal infrastructure already exists, most CF 
carrier screening programmes aim at screening during pregnancy. Furthermore, pregnant 
women are considered to be the target group that is most receptive to the idea of carrier 
screening.2-5 
Contrary to what has been suggested,6 7 our screening study demonstrated that pre-
conceptional CF carrier couple screening was feasible in a mid-western region of the 
Netherlands, in terms of both logistics and organisation (A), and target group accessibility (B). 
 
A. Logistics and organisation  A brief description of logistics and organisation, with 
rough estimates of the workload experienced from the screening study, is outlined below: 
 
Invitations  Individuals, aged 20 to 35 years, were selected and invited for screening with their 
partner by their own general practitioner (GP) or by the Municipal Health Services (MHS). The 
average time invested by GPs in printing files and checking patient lists for eligibility was 110 
minutes (range 15-210 minutes). The selection of individuals from the population register by 
the local authorities, to sent invitations by MHS, was less time consuming and much easier. 
Consequently, if in the future screening is offered by means of a personal letter of invitation, 
invitations sent via the MHS is advisable.  
 
Education and counselling  Pre-test education was provided during an educational group 
session or during a GP consultation. The 45 minute educational sessions (n=37 in total) were 
organised by the researcher. During the sessions, information was provided by means of an 
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oral presentation and questions were answered. The GPs received a written protocol and half 
an hour of training on how to educate the couples. They were instructed on how to take a 
mouthwash sample and the follow-up procedure was explained. After the study, most GPs 
reported that they were satisfied with the consultations, and the information provided (a brief 
instruction manual and an educational folder) was perceived as helpful in explaining the test to 
the couples. The estimated average time that GPs spent per couple in offering the screening test 
and taking mouthwash samples was 12 minutes (range 5–30 minutes), which was reported by 
the GPs to be ‘sufficient time’. Both settings -educational session and GP consultation- 
appeared feasible in providing pre-test education to the couples. 
 
The carrier test  Mouthwash samples were easy to collect, and this method of sampling was 
acceptable to the participants. Two percent of the samples failed to give a result, due to 
inadequate DNA content in the sample. Initially, reversed dot-blot mutation analysis was used 
to screen for 16 mutations, with a test-sensitivity of approximately 87% per individual. When 
the study was partially completed, the mutation detection technique was changed to Denaturing 
Gradient Gel Electrophoresis (DGGE),8 resulting in an increased test-sensitivity to 95%. 
Although the sensitivity of this method is higher, it also has disadvantages, because mutations 
of unknown pathogenity might be detected. Since this could create unnecessary uncertainty, 
clear protocols should be developed to determine which mutations are considered to be 
pathogenic, to prevent couples from receiving such results.  
 
Registration and test-results The registration of participants, data-management and preparation 
of test-results took place at the research centre. Test-results could be provided within eight 
weeks of testing, and were sent to the couples from the research centre by mail. There were no 
requests for personal counselling from participating couples after (positive) test-results had 
been provided. Copies of positive test-results were also sent to the GPs. 
 
B. Target group accessibility  Approximately 20% of individuals who were invited to 
participate in the screening study had a partner with whom they were planning to have 
children. Of these, approximately 10% attended an educational session. Uptake was higher in a 
region where couples were invited to make an appointment with their GP (25%). Whether 
individuals were invited by letter sent by their own GP or by the MHS had no marked 
influence on the rate of participation (Chapter 5). Several predictors of participation in the 
screening programme were identified. For those invited by their GP to attend an educational 
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session these were: low perceived discomfort (time and effort needed for screening), high 
perceived benefits of screening, low perceived impact of the consequences of screening, high 
level of knowledge about CF, and the perception that they themselves are responsible for their 
own health (high internal health locus of control). Overall, the associations were more 
pronounced when partners had similar perceptions (Chapter 6). Similar findings were observed 
for the other approaches in the screening study, i.e. varying the method of invitation (by MHS) 
and educational setting (during a GP consultation), except that internal health locus of control 
was no longer significant. The main reason given by couples for non-participation was “lack of 
time to attend” or “forgot about it” (48%). Another important reason was that they “did not 
want to know their test-results” (28%) (Chapter 5). 
 
Desirability of screening  
The main question concerning the desirability of a preconceptional CF carrier screening 
programme is whether the potential beneficial aspects (1) outweigh the harmful aspects (2) of 
screening. 
 
1. Beneficial aspects of screening 
 
Benefits of participation  The goal of genetic testing is to provide individuals with information 
that will permit them to make informed decisions.9 The potential benefit of a positive CF 
carrier test-result for couples who are planning to have children is that it will allow them to 
make reproductive decisions on the basis of that information. In our screening study, no carrier 
couples were identified. This was not unexpected, given the relatively small numbers, and in 
any case the identification of carrier couples was not the purpose of the present study.  
Although it is difficult to predict the actual reproductive behaviour of couples who are 
identified as carriers in a screening programme, the couples who participated in our screening 
study stated that if both partners were found to be carriers, they would make use of the 
available reproductive options, that is, refrain from having children and use of prenatal 
diagnosis (Chapter 7). Furthermore, in the Netherlands, carrier couples who are identified 
retrospectively (with an affected child) and prospectively (before the birth of an affected child) 
in CF families make use of the reproductive options that are available (Chapters 3 and 4). 
Worldwide, there is limited information about the long-term reproductive decisions made by 
carrier couples who are preconceptionally identified.10 Results from prenatal screening 
programmes show that 93% of couples with positive test-results chose to have counselling and 
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made use of prenatal diagnosis, and 88% of the couples with a fetus homozygous for CF chose 
termination of the pregnancy (63% in the United States and 100% in Europe).11  
Another potential benefit of screening is the reassurance of a negative carrier test-result 
for couples who are anxious because of previous experiences with the disease or discussions in 
the media. However, it has been argued that if this anxiety is a result of the publicity of the 
screening programme itself, anxiety relief should not be regarded as a benefit.12 
The National Institutes of Health9 report that the effectiveness of genetic testing can be 
judged in terms of its ability to convey information that subjects find useful. The experiences 
with our preconceptional carrier screening programme demonstrate that the great majority of 
those who undergo testing would make the same decision to be tested again, and would also 
recommend testing to others (Chapter 7). Previous studies have shown that, in general, 
participants were highly satisfied, although some studies reported that carriers were less 
satisfied than those who tested negative.13-16 Carrier couples who were prospectively identified 
in CF families before the birth of a child with CF, as described in Chapter 4, were glad to know 
about their risk and did not regret having the test. 
 
Benefits for relatives Apart from the advantages for carrier couples with regard to reproductive 
choices, another potential benefit of a positive test-result is that it reveals information about the 
carrier risk in family members. Although they had the opportunity to be tested, the percentage 
of requests for carrier testing from high-risk family members are reported to be very low,17 18 as 
was also found for the relatives of carriers identified in our screening study (Chapter 7). One 
possible explanation that is suggested is a lack of information about the risk and the availability 
of carrier testing for relatives, due to the limited dissemination of information throughout the 
family.19 20 Furthermore, it has been shown that relatives of CF patients tend to underestimate 
their carrier risk,21-23 and therefore might have no intention to be tested for carrier status. This 
may be even more the case for carriers in families with no history of CF. 
 
Benefits of education  One of the unexpected benefits of a screening programme for CF will 
be the raised awareness about CF and its genetics in the whole community, thereby reducing 
the risk of possible stigmatisation and discrimination of those who participate in screening.24 In 
the present study, a significant increase in the level of knowledge about CF was found in those 
who attended the educational programme before screening (Chapter 7), which can also be seen 
as a benefit from screening. Although the knowledge decreased again several months after 
screening, as was also reported in other studies,16 25 the levels of knowledge were still higher 
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than before screening. Honnor et al26 suggested that, especially when screening through 
primary care, an opportunity is provided for educating health professionals about genetics more 
generally. Offering screening may also increase awareness, not only in families, but also 
among health care providers, about the availability of carrier testing for families with a history 
of CF. According to Super,27 access to testing for CF families is still being blocked by GPs, 
mainly through ignorance, and many families are unaware that tests for relatives exist. 
Therefore, CF patients are still born to parents who could have been identified beforehand 
because of a positive family history of CF. Increasing attention to CF carrier screening may 
also support the early diagnosis of children with the disease. 
 
2. Harmful aspects of screening 
 
Harm from the screening test  Harmful aspects may be related to the test procedure, including 
inconvenience from the test itself. However, in the form of a mouthwash sample or buccal 
swab, the carrier test is unlikely to cause any medical complications, although waiting for the 
test-results may cause anxiety in some participants, as was found in our screening study 
(Chapter 7). 
 
Harm from positive test-results   One of the potential harmful effects of a positive test-result is 
psychological harm, including a diminished self-image and anxiety.28 Indeed, Chapter 7 
describes feelings of worry and of being less healthy among carriers in our screening study, but 
since satisfaction with the screening was high in these subjects, this is probably not a great 
burden. Furthermore, there were no requests for personal counselling by +/– couples when it 
was offered with the test-results. None of the couples changed their reproductive plans, 
suggesting that unwillingness to have children is unlikely to occur in these couples. There was 
also little evidence for a negative impact of carrier testing on the relationship between the 
partners, and it may well, in fact, by some be perceived as having a positive influence on the 
relationship (Chapter 7).  
In the present study, couples preferred full disclosure of the test-results, also when one 
partner was found to be a carrier and the other was not, suggesting that couples think they can 
handle the results even if no options such as prenatal diagnosis are available (Chapter 8).  
Another possible adverse effect of a positive test-result is the potential for social harm, 
including stigmatisation and discrimination based on the test-results after disclosure to third 
parties such as insurers or employers. In our screening study, most carriers shared the 
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information with others, as has been reported in previous studies,13 15 suggesting that they do 
not feel stigmatised in their relationships with others (Chapter 7). Aspects of discrimination by 
insurers or employers were not investigated in the present screening study, or in any other pilot 
studies for CF carrier screening (Chapter 2).  
 
Harm from negative test-results  A negative carrier test-result, received by the great majority 
of those screened, is naturally the most favourable outcome. Receipt of negative test-results 
may result in relief and a sense of security among participants. However, previous studies have 
demonstrated that a sizeable percentage of those who received a screen-negative result believed 
that they were definitely not carriers,4-6 13 15 26 and that there was no risk of having a child with 
CF, as was also shown in our screening study (Chapter 7). This may be due to forgetting or 
misunderstanding the risk information. It is also possible that residual risks of 1 in 2000 (+/– 
couples) or 1 in 50000 (–/? couples) are perceived as being too small to be worth 
remembering.28 A negative carrier test-result could thus induce a false sense of security, and 
because there is a residual risk due to the incomplete sensitivity of the test, these couples may 
be confronted with the unexpected birth of a child with CF.  
Negative emotions, such as survivor guilt and depression, have been reported in 
connection with a negative carrier test-result, for instance for Huntington’s disease,29 but these 
are unlikely to occur in carriers of recessive diseases with no family history of CF.  
 
Harm for relatives  Because genetic information has implications for relatives of the individual 
being tested, the potential of the test to confront family members with their risk and to 
influence family relationships, must be taken into consideration. In our study there was no 
evidence of any changes in inter-family relationships due to the test-results (Chapter 7). 
However, results from our interviews with carrier couples who were prospectively identified 
showed that some couples experienced difficulties in communicating the test-results to other 
family members, especially when there was no family history of CF, sometimes resulting in 
feelings of lack of support from relatives (Chapter 4).  
 
Other disadvantages of carrier screening  Offering large-scale carrier screening may lead to 
undue pressure on individual choice and social stigmatisation of individuals who might decline 
an offer of screening. In the present screening study, very few couples participated only 
because they felt they could not refuse. However the numbers may be higher when screening is 
actually introduced in the community. Nevertheless, uptake rates in the Netherlands for Down 
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syndrome screening, currently offered to all pregnant women age 36 years or older, are only 
approximately 50%,30 suggesting that many people will decline screening if it is offered to 
them. Another disadvantage of screening is that it may induce decision-regret in those who 
decided not to participate, but who are subsequently confronted with the birth of a child with 
CF. Finally, carrier screening in the general population may lead to a devaluation of the lives of 
those who have CF. 
 
Should we introduce cystic fibrosis carrier couple screening? 
The evaluation of preconceptional CF carrier screening was undertaken against the background 
of the general evaluation framework that was formulated in an advisory report issued by the 
Health Council of the Netherlands,31 with reference to internationally applied criteria. Based on 
the general criteria, carrier screening for CF can be morally justifiable, in that it is an important 
health problem in terms of severity and prevalence of the disease, there is a test available, and 
the screened person can take a decision based on the test-results (Chapter 2).  
In a large proportion of the target group, i.e. couples who are planning to have children, 
there was a positive attitude towards routinely offering preconceptional CF carrier screening 
(Chapter 5), suggesting that the offer of screening is acceptable to the target group. Previous 
studies have shown that the great majority of CF parents also support carrier screening in the 
general population.32 33 Only a minority of 10-22% of parents and patients felt that screening 
should be restricted to families with a family history of CF.33 In our study, carried out among 
parents of children with CF and adult patients, the majority supported carrier couple 
identification within CF families. Comprehensively, the results suggest that they will accept 
the reproductive choices of carrier couples identified in population screening programmes 
(Chapter 3).  
But is a preconceptional carrier couple screening programme, as was presented in this 
thesis, both desirable and feasible? When answering this question, several limitations of our 
screening study should be taken into account: (1) Couples were offered screening within a 
limited geographical region; uptake, acceptance and attitudes may be different in other parts of 
the Netherlands. (2) Eligibility in the invited population was estimated, thereby resulting in 
approximated uptake rates. (3) Our screening study has been carried out by a motivated group 
of GPs; therefore the results are not representative for all GPs. (4) No carrier couples were 
identified. (5) There is no long-term information on the psychosocial aspects of screening, and 
the exact nature of the worries was not investigated. (6) This study presents only four ways in 
which preconceptional carrier couple screening, and the beneficial and harmful aspects may 
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vary with other screening strategies. (7) The scientific character of the research may have 
influenced the outcome of the study.  
When weighing the beneficial and harmful aspects of screening, the preliminary 
findings in the present screening study demonstrate that there is no evidence that the 
psychological effects of a positive carrier test-result are so burdensome as to make it 
unacceptable to offer such a test. In addition, the invitational and educational approaches used 
in the study seemed to be feasible, not only for participants but also for those who offered the 
screening. Based on our results, the answer to the question whether we should introduce carrier 
couple screening is a positive one. At this moment, a more extensive pilot study seems 
warranted in order to answer the question whether implementation on a larger scale is possible 
as well. 
 
Future of cystic fibrosis carrier screening 
The organisation of a national screening programme includes an infrastructure for screening, 
information and counselling, and service monitoring, the establishment of laboratory services 
(including a system for collecting samples), a system for reporting the results, and information 
storage.34 Before any carrier screening programme can be implemented, these points must be 
addressed.  
Although the test to identify carriers may never be perfect, test sensitivities resulting in 
a residual risk in couples with only one partner tested positive (and the other negative) that is 
less than the population risk (1 in 3600) are now available in the Netherlands (H. Scheffer and 
J.J.P. Gille, personal communication).  
It is particularly important that the target group receives adequate and balanced 
information. The results of our screening study suggest that anxiety about screening and the 
perceived burden of carrier status are partly based on misconceptions, due to a lack of genetic 
knowledge (Chapter 6). Likely interventions to reduce some of the possible adverse effect of 
screening such as stigmatisation, misbelieve and prejudice, include educational programmes 
aimed not only at the target population, but also the population in general and those offering 
the tests. However, there is no infrastructure for preconceptional counselling in the 
Netherlands. GPs in this country seem to consider preconceptional health counselling as part of 
their job, but indicate that they have a lack of sufficient knowledge to provide adequate 
advice.35 In previous studies it has been shown that in general, GPs seem to approve the 
concept of CF carrier screening,36-38 but demands on GPs are high and most lack training in this 
area.39 Alternatively, screening consultations could be delegated to the practice assistant, or 
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included during an individual consultation with other health professionals than GPs, for 
example at the MHS, or provided at a newly developed centre. 
Although preconceptional carrier screening is the most favourable approach, prenatal 
screening may provide a safety net for pregnant couples who did not participate in 
preconceptional screening and for unplanned pregnancies.  
The effects of neonatal screening for patients with CF are still under debate.40-43 
Although increasing evidence has been provided on the benefits of early diagnosis of CF, 
especially in terms of nutritional status,44 more data from randomised trials of screening with 
lung disease and survival and quality of life included as endpoints was recommended, before 
routine neonatal screening is to be considered.45 Another benefit of neonatal screening is that 
early diagnosis allows parents to have the option of prenatal diagnosis before subsequent sibs 
are born, and carrier testing for relatives.46 In the future, a combination of offering neonatal 
screening for CF patients and preconceptional carrier screening is an option. 
 
Framework for other countries and other diseases 
This thesis addresses the feasibility and desirability of a preconceptional CF carrier screening 
programme in the Netherlands. Differences with other countries and other diseases will exist, 
but many similarities are evident, and the results of our study can be used in the development of 
programmes elsewhere. For example, preconceptional CF carrier screening has been suggested 
in some States of America, where the termination of a pregnancy is not an option.47 A 
preconceptional screening approach has also been suggested for other autosomal recessive 
disorders such as Tay-Sachs disease,48 and thalassemia.49 50 In the Netherlands, carrier 
screening for Fragile X syndrome51 or haemoglobin disorders52 may be optional in the future, 
although each disease will require specific attention. 
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Recommendations for further research 
The following issues deserve more attention in future research: 
 
Extension of the screening study A more extensive pilot will give the opportunity to answer 
the question whether implementation on a larger scale is also possible. Follow-up studies offer 
the opportunity to assess the actual impact of information about carrier status, either correctly 
or incorrectly understood, upon participants’ decisions and reproductive behaviour. 
Furthermore, it is recommended that to obtain more insight into the feelings of worry and 
unhealthy feelings after testing, the exact nature of the worries should be investigated. 
Moreover, research is needed to determine other possible negative effects of genetic screening 
that have not been measured in this study, such as misuse of the information, and 
discrimination based on the test-results in case of disclosure to third parties such as insurers 
and employers. Finally, the interests and considerations of other ethnic groups should be 
addressed, since these were not taken into account in the present study.  
On the long term, a national screening programme will offer the opportunity to study 
what use those who tested positive in the carrier screening will make of the information in 
connection with reproductive choices, particularly in the context of the increasing life 
expectancy for patients with CF. 
 
Pre-test education and counselling As Marteau53 has already stated, one of the key questions 
is to investigate the best way of offering tests in order to maximise understanding of the 
meaning of the test-results, both in the short and the longer term. 
 
Implementation study A research project to study the potentials and barriers with regard to the 
implementation of a preconceptional carrier screening programme for CF is currently being 
carried out at the Institute for Research in Extramural Medicine (EMGO Institute) of the VU 
University Medical Center, to determine the best implementation strategy (F.A.M. Poppelaars 
et al, funded by the Netherlands Health Research and Development Council (grant 23000012)). 
 
Cost-effectiveness Although previous studies have shown that preconceptional carrier 
screening in the Netherlands is most likely to be cost-effective,54 55 an additional study is 
currently being carried out to analyse more up-to-date information resulting from the screening 
study. 
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Concluding remarks 
The screening study presented in this thesis has provided better insight into the desirability and 
feasibility of offering preconceptional carrier screening for CF in the general population. It has 
demonstrated that the approaches to preconceptional carrier couple screening are acceptable to 
couples who are planning to have children, and impose minimal burden on the participants. 
The results give rise to the development of a more extensive screening study to answer the 
question whether screening on a larger scale is also possible, and to find the best way of 
introducing a national programme for CF carrier screening in the Netherlands.  
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Cystic fibrosis (CF) is one of the most common serious genetic disorders in the Netherlands. It 
is characterised by recurrent respiratory and gastrointestinal problems, caused by the 
accumulation of abnormal sticky mucus. There is no cure for CF, but improved treatment has 
increased the median life expectancy to approximately 34 years. CF is an autosomal recessive 
disorder. In order to be affected, a child must inherit a CF mutation from both of its parents. In 
the Netherlands, the birth prevalence is 1 in 3600. So, 1 in 30 individuals is a healthy CF 
carrier. If both partners in a couple are carriers (1 in 900 couples), each child they have has a 1-
in-4 risk of having CF. Most children with CF are born to couples with no previous family 
history of the disease. 
CF carrier screening is a means to enable people to find out whether they are a carrier, 
and to take a decision based on that information. Carrier screening before pregnancy 
(preconceptional screening) offers identified couples all available reproductive options: parents 
can accept the risk, choose to have no more children, opt for prenatal diagnosis and selective 
termination of pregnancy, use pre-implantation genetic diagnosis or use alternatives, such as 
donor insemination, egg-cell donation or adoption.  
The main objective of the thesis was to evaluate the desirability and feasibility of a 
preconceptional CF carrier screening programme in the Netherlands. Besides the evaluation of 
an offer of screening (Chapter 5, 6, 7 and 8), attention was given to other aspects of population-
based carrier screening, i.e.: 
 The evaluation of CF carrier screening programmes described in the literature (Chapter 2).  
 The attitudes towards reproductive issues and carrier testing among CF patients and parents 
of children with CF (Chapter 3). 
 The experiences and reproductive decisions of carrier couples prospectively identified in CF 
families (Chapter 4).  
 
Desirability and feasibility of preconceptional CF carrier screening 
The desirability and feasibility of preconceptional CF carrier screening was evaluated by an actual 
offer of CF carrier testing in the Dutch population. The screening test was targeted to couples who 
were considering a pregnancy (in the future), in the mid-western region of the Netherlands, 
between May 1997 and December 2000. Four different modes of offering carrier screening were 
addressed, that varied in mode of invitation and pre-test education setting. To reach the target 
group, individuals (age 20 to 35 years) were invited by mail either by the Municipal Health 
Services (MHS) or by their own general practitioner (GP), to participate in the screening 
programme with their partner. Pre-test education was provided either during a 45 minute pre-
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determined group educational session or couples were invited to make an appointment for a GP 
consultation. The four scenarios were carried out in different geographical areas. After the 
education, mouthwash samples of each partner were obtained. DNA mutation analysis was 
performed only after the couples mailed back a consent form. The sample of one partner was 
tested first, and the second partner was tested only if the test-result of the first was positive. 
Participants completed a questionnaire before and after education, and at six months after receipt 
of test-results. 
Of 38,114 individuals who received an invitation, approximately 20% had a partner with 
whom they were planning to have children. Of these, participation in screening varied according to 
the pre-test education setting, with education provided in the primary care setting producing a 
higher rate of attendance (25%) than when provided at an educational session (10%). Whether 
letters were sent by the MHS or by the GP had no marked influence on the rate of participation. A 
total of 559 couples (96%) consented to have the test after education. Repetition of the invitation 
after one year resulted in an extra response of 3%-7%. The GPs consulted (n=18) reported no 
negative experiences, but due to the extra workload 11 of them would not consider it to be part of 
their task. Among couples planning to have children, there was generally a positive attitude 
towards routinely offering population-based CF carrier screening: 69% of non-participants and 
89% of participants believed that CF carrier testing should be offered to all couples planning to 
have children. Preconceptional CF carrier screening appeared feasible, both in terms of practical 
achievements and target group accessibility.  
The main reason given by 150 couples for not responding to the invitation of screening 
was ‘lack of time’ or ‘forgot about it’ (48%). Of these couples, 72% perceived high benefits from 
screening. In the scenario where couples were invited by their GP to attend an educational session, 
76 participating couples and 53 non-participating couples were compared to identify factors 
associated with participation in screening. It was shown that couples who participated, as opposed 
to those who did not, perceived less discomfort from screening, perceived higher benefits of 
screening, perceived less impact of the consequences of screening, knew more about CF, and 
perceived themselves responsible for their own health (high internal health locus of control). 
Overall, the associations were more pronounced when partners had similar perceptions. Offering 
more sessions, providing more clear information about the meaning of carrier status, and 
increasing public awareness could diminish barriers to participation. 
Among 108 couples who were offered the opportunity to choose whether they wished 
to be fully informed about the test-results, including the result if only one partner is tested 
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positive, and the other partner negative, or whether they only wanted to know whether or not 
they had a 1-in-4 risk, 94% wished to be fully informed. 
Eighteen CF carriers were identified, the partners of the carriers all tested negative, 
giving a carrier frequency in the study population of 1 in 35. At six months follow-up, the 
impact of participation among participants in the CF carrier screening programme was 
assessed. Full data were obtained from 17/18 identified carriers, 15/18 partners of carriers with 
negative test-results, and 794 (73%) participants with a negative or no test-result. If both 
partners were found to be carriers, 36% thought that they would refrain from having (more) 
children, 87% would make use of prenatal diagnosis if pregnant, and 68% of those who would 
make use of prenatal diagnosis would consider termination of the pregnancy if the fetus was 
found to have CF (reported before receiving the test-results). 
None of the carriers changed their reproductive plans because of their test-results. 
Although eight participants reported feeling worried, four of whom were carriers, and seven 
carriers reported that they felt less healthy due to their test-results, the results suggest that these 
drawbacks are tolerable, since the same subjects would unanimously decide to have the test 
again. In total, 95% of other participants would decide to have the test again. Overall, 88% of 
participants would recommend testing to others. Predictors of a correct understanding of test-
results (correct in 62% of participants at six months) were: positive test-results, a high level of 
knowledge of CF at six months, a high level of education, attending an educational session, 
and previously heard of CF. 
 
Evaluation of CF carrier screening programmes 
Pilot programmes for CF carrier screening, described and published between 1990 and 2001, 
were evaluated in the light of important genetic screening criteria. In total, 13 studies on carrier 
screening during pregnancy and 7 studies on screening programmes aimed at individuals of 
reproductive age or couples planning to have a pregnancy were selected. Overall, CF carrier 
screening meets the prerequisites that justify screening; 1) the disease is serious, well-
characterised and incurable, 2) there is a suitable carrier test available and, 3) participants can 
take a decision on the basis of the test-results. However, more specific criteria for the 
development of screening programmes were not always taken into consideration. Most authors 
concentrated on uptake in screening as an important outcome, and less on informed decision-
making. The results also show that understanding the consequences of the test-results, anxiety 
and satisfaction of participants have been studied extensively, but less attention has been given 
to the long-term psychological and social effects of screening. 
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CF patient and parental attitudes 
Data were used from a Dutch national questionnaire survey on the impact of CF on the 
medical, psychological and social aspects of life. The attitudes towards reproductive issues and 
carrier testing were assessed among two groups of subjects: 287 adult patients with CF (>16 
years) and 288 parents of a child with CF (<16 years). Parents’ reproductive intentions and 
behaviour were also addressed. To avoid having another child with CF, most parents decided 
against further pregnancies or used other reproductive options, such as prenatal diagnosis. In 
total, 72% of parents used prenatal diagnosis, and 76% of parents planning more children 
intended using this option. Intention to use prenatal diagnosis was associated with the strength 
of religious conviction, and was not associated with perceived severity of CF, health of the 
child with CF, or perceived future therapeutic possibilities. Both parents and adult CF patients 
showed doubts in deciding to abort for CF. A majority of parents and adult patients supported 
carrier couple identification within CF families. Overall, the results suggest that CF parents and 
adult patients with CF will accept the reproductive choices of carrier couples identified in 
population-based screening programmes.  
 
Personal experiences of CF carrier couples 
Experiences of CF carrier couples with genetic testing and the impact of the resulting genetic risk 
on reproductive behaviour were described. Data were obtained from interviews with carrier 
couples identified in CF families before the birth of a child with CF. Of 12 couples identified until 
1997, seven couples participated in semi-structured interviews and two couples filled in a 
questionnaire, two to eight years after receipt of the test-results. The main reason for wanting to be 
tested was to gain certainty. For two couples, the GP wondered whether the test was necessary. 
After receiving the test-results, most couples reported that they were shocked. Those couples who 
were pregnant at the time of testing (n=4) expressed more anxiety. There were reported difficulties 
in communicating the results to family members, and the reactions of relatives were not always 
supportive. After testing, four couples had problems with reproductive decision-making. Four 
couples who had live-born children after testing reported concerns during infancy about the 
correctness of the results of prenatal diagnosis. Most couples did not regret the testing and, in 
general, the counselling was experienced positively, although some dissatisfaction was reported by 
five couples with regard to the (lack of) psychological support during pregnancy. Couples 
supported the idea of carrier screening in the general population, although various concerns were 
expressed, such as the difficult decisions that would have to be faced, and the fact that a negative 
screening test-result does not guarantee that the child is healthy. 
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Conclusions 
The screening study presented in this thesis has provided better insight into the desirability and 
feasibility of offering preconceptional carrier screening for CF in the general population. It has 
demonstrated that carrier testing offered to couples planning a pregnancy is possible: there was 
a positive attitude towards routinely offering preconceptional CF carrier screening, screening 
was feasible in terms of both logistics and organisation and target group accessibility, and 
participants are satisfied. The results give rise to the development of a more extensive 
screening study to answer the question whether implementation on a larger scale is also 
possible, and to find the best way of introducing a national programme for cystic fibrosis 
carrier screening in the Netherlands . 
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Cystic fibrosis (afgekort CF) is één van de meest voorkomende, ernstig verlopende, erfelijke 
aandoeningen in Nederland. De aandoening wordt gekenmerkt door terugkerende luchtweg-
infecties en spijsverteringproblemen. De verschijnselen worden veroorzaakt door een 
opeenhoping van abnormaal taai slijm. De ziekte wordt daarom ook wel ‘taaislijmziekte’ 
genoemd. CF is niet te genezen. Door betere behandelingsmethoden wordt ongeveer de helft 
van de patiënten nu ouder dan 34 jaar. CF is een autosomaal recessieve aandoening. Een kind 
krijgt alleen CF als zowel vader als moeder een CF mutatie heeft en zij dit beiden overdragen 
op hun kind. In Nederland heeft 1 op de 3600 pasgeborenen CF en is 1 op de 30 mensen drager 
van een CF mutatie. Dragers zijn zelf gezond. Indien beide ouders drager zijn (1 op de 900 
paren), heeft elk van hun kinderen een kans van 1 op 4 (25%) om CF te krijgen. In de meeste 
gevallen zijn patiënten met CF de eerste met deze aandoening in de familie en is de diagnose 
volkomen onverwacht. 
CF dragerschapscreening biedt mensen de mogelijkheid om na te gaan of zij CF drager 
zijn. Dragerschapscreening vóór de zwangerschap (preconceptioneel) biedt dragerparen alle 
beschikbare reproductieve mogelijkheden: paren kunnen het risico aanvaarden, afzien van het 
krijgen van kinderen, kiezen voor prenatale diagnostiek met eventuele zwangerschapsaf-
breking, gebruik maken van pre-implantatie genetische diagnostiek, kiezen voor zwangerschap 
met behulp van donorinseminatie of eiceldonatie, of adoptie.  
Het belangrijkste doel van deze studie was de wenselijkheid en haalbaarheid van het 
aanbieden van preconceptionele dragerschapscreening in Nederland te onderzoeken. Naast de 
evaluatie van een aanbod van screening (Hoofdstukken 5, 6, 7 en 8), zijn ook andere aspecten 
van een bevolkingsonderzoek op dragerschap voor CF belicht, namelijk: 
 De uitkomsten van CF dragerschapscreening programma’s die beschreven zijn in de 
literatuur (Hoofdstuk 2). 
 De houding van CF patiënten en ouders van een kind met CF ten aanzien van de 
verschillende reproductieve mogelijkheden en het testen op dragerschap (Hoofdstuk 3). 
 De ervaringen en beslissingen rond het krijgen van kinderen van paren waarbij bij beide 
partners prospectief (vóór de geboorte van een kind met CF) dragerschap ontdekt is binnen 
CF families (Hoofdstuk 4). 
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Wenselijkheid en haalbaarheid van preconceptionele CF dragerschapscreening  
De wenselijkheid en haalbaarheid van preconceptionele CF dragerschapscreening is 
onderzocht door mensen daadwerkelijk een CF dragerschaptest aan te bieden. De screening 
was gericht op paren met (toekomstige) kinderwens en is tussen mei 1997 en december 2000 
aangeboden in het midden-westen van Nederland. Het onderzoek is op vier verschillende 
manieren uitgevoerd, waarbij variatie is aangebracht in het uitnodigen en voorlichten van de 
doelgroep. Om de doelgroep te bereiken zijn personen (leeftijd 20-35 jaar) schriftelijk 
uitgenodigd ofwel door de Gemeentelijke Gezondheidsdienst (GGD) of door hun eigen 
huisarts om samen met hun partner deel te nemen aan de screening. Paren werden 
geïnformeerd ofwel via een 45 minuten durende voorlichtingsbijeenkomst op aangegeven 
tijden of zij werden verwezen naar hun huisarts om een afspraak te maken voor een consult. De 
vier scenario’s zijn uitgevoerd in verschillende geografische regio’s. Na de voorlichting zijn 
mondspoelsels afgenomen bij beide partners. Nadat van beide partners schriftelijke 
toestemming was ontvangen werd de DNA mutatieanalyse gestart. In eerste instantie werd één 
partner getest; de tweede partner werd alleen getest indien bij de eerste partner dragerschap 
was aangetoond. Vóór en na de voorlichting en zes maanden na het verkrijgen van de 
testuitslag is door de deelnemers een vragenlijst ingevuld. 
Van de 38.114 personen die uitnodigd waren voor screening, bleek ongeveer 20% een 
partner en kinderwens te hebben. Van deze groep varieerde de deelname afhankelijk van de 
wijze van voorlichting: via het huisartsconsult was de deelname hoger (25%) dan via de 
voorlichtingsbijeenkomst (10%). De wijze van uitnodigen, via GGD of huisarts, had geen 
invloed op het deelnamepercentage. Na de voorlichting gaven 559 paren (96%) toestemming 
voor het uitvoeren van de test. Herhaling van de uitnodiging na 1 jaar gaf nog een extra 
opkomst van 3%-7%. De consulterende huisartsen (n=18) hebben geen negatieve ervaringen 
gerapporteerd, maar 11 van hen vonden het, met name door de extra werklast, niet behoren tot 
hun takenpakket. Paren met kinderwens hadden in het algemeen een positieve houding ten 
aanzien van het aanbieden van dragerschapscreening in de bevolking: 69% van de niet-
deelnemers en 89% van de deelnemers was voorstander van het routinematig aanbieden van 
screening aan paren met kinderwens. Wat betreft de praktische uitvoerbaarheid en 
bereikbaarheid van de doelgroep bleek preconceptionele dragerschapscreening haalbaar.  
De belangrijkste door 150 paren opgegeven reden om niet op de uitnodiging voor 
screening in te gaan was dat zij geen tijd hadden om deel te nemen of het vergeten waren 
(48%). Van deze paren verwachtte 72% wel voordelen van de screening. In één van de 
scenario’s, waarbij paren uitgenodigd werden door hun huisarts om deel te nemen via een 
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voorlichtingsbijeenkomst, zijn 76 deelnemende en 53 niet-deelnemende paren vergeleken om 
na te gaan welke factoren gerelateerd zijn aan deelname. Deelnemers, vergeleken met niet-
deelnemers, verwachtten minder ongemak van deelname aan de screening, verwachtten meer 
voordelen en minder nadelige gevolgen van screening, hadden meer kennis over CF en een 
hogere score op de interne health locus of control schaal, ten opzichte van degenen die niet 
meededen. In het algemeen waren deze factoren sterker gerelateerd aan deelname wanneer 
beide partners dezelfde verwachtingen hadden. De resultaten suggereren dat het aanbieden van 
meer voorlichtingsbijeenkomsten, het geven van meer informatie over de betekenis van het 
dragerschap, en het vergroten van de publieke bekendheid met genetica, barrières voor 
deelname zou kunnen verlagen. 
Aan 108 deelnemende paren werd de mogelijkheid geboden te kiezen uit (a) een 
volledige testuitslag, inclusief het resultaat waarbij één partner drager is en de ander niet, of (b) 
een testuitslag waarbij zij alleen te horen kregen of zij beiden drager waren of niet; 94% koos 
voor (a). 
Er zijn in totaal 18 dragers gevonden; hun partners zijn negatief getest (geen drager). 
De dragerschapfrequentie in de onderzoekspopulatie was 1 op de 35. Na zes maanden is de 
impact van deelname aan screening onderzocht. Volledige resultaten zijn verkregen van 17/18 
dragers, 15/18 negatief geteste partners en 794 (73%) deelnemers met een negatief of geen 
testresultaat. Als beide partners positief getest zouden worden, geeft 36% aan waarschijnlijk af 
te zien van het krijgen van (meer) kinderen, 87% zou overwegen gebruik te maken van 
prenatale diagnostiek in geval van zwangerschap. Daarvan zou 68% zwangerschapsafbreking 
overwegen bij het diagnosticeren van een aangedaan kind (gerapporteerd vóór de testuitslag 
bekend was). 
Dragers rapporteerden geen invloed van de testuitslag op de beslissingen rond het 
krijgen van kinderen. Hoewel acht deelnemers, waaronder vier dragers, vermeldden zich zes 
maanden na de test zorgen te maken en zeven dragers aangaven zich minder gezond te voelen 
na de testuitslag, was de tevredenheid hoog: alle dragers, alle deelnemers die zich zorgen 
maakten, en  95% van alle overige deelnemers zouden opnieuw de beslissing tot deelname aan 
screening genomen hebben. In het algemeen zou 88% van de deelnemers andere paren 
aanraden zich ook te laten testen. Na zes maanden wist 62% van de deelnemers de testuitslag 
en de gevolgen ervan. Factoren geassocieerd met een correct begrip van het testresultaat waren: 
een positieve testuitslag, een goede kennis van CF na zes maanden, een hoog opleidingsniveau, 
deelname aan een voorlichtingsbijeenkomst, en gehoord van CF vóórdat de screening werd 
aangeboden.  
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De evaluatie van CF dragerschapscreening programma’s 
Pilot-studies voor CF dragerschapscreening die beschreven en gepubliceerd zijn tussen 1990 en 
2001, zijn geëvalueerd in het licht van belangrijke genetische screening criteria. In totaal zijn er 
13 studies over screening gedurende de zwangerschap en 7 studies over screenings-
programma’s gericht op individuen in de reproductieve leeftijd of paren met kinderwens 
geselecteerd. In het algemeen voldoet CF dragerschapscreening aan de primaire criteria waar 
genetische screening aan moet voldoen: 1) de ziekte is ernstig, goed gedefinieerd en niet te 
genezen, 2) er is een screening test beschikbaar en 3) deelnemers kunnen een beslissing nemen 
op basis van de testresultaten. Echter, de meer specifieke criteria voor de ontwikkeling van 
genetische screeningsprogramma’s zijn niet altijd in acht genomen. De meeste auteurs hebben 
zich geconcentreerd op deelname aan screening als belangrijke uitkomstmaat en minder op het 
nemen van een geïnformeerde beslissing. Begrip van de testuitslag, ongerustheid en 
tevredenheid van de deelnemers is eveneens uitgebreid onderzocht, minder aandacht is besteed 
aan de psychologische en sociale gevolgen van screening op lange termijn. 
 
Attitudes van CF patiënten en ouders van een kind met CF 
De gegevens zijn verkregen uit een Nederlandse studie naar de impact van CF op de medische, 
psychologische en sociale aspecten van het leven. Van twee groepen is de houding ten aanzien 
van de reproductieve mogelijkheden en het testen op dragerschap nagegaan: 287 volwassen 
patiënten met CF (>16 jaar) en 288 ouders van een kind met CF (<16 jaar). Daarnaast zijn bij 
de ouders de beslissingen en intenties rond het krijgen van eventuele volgende kinderen 
onderzocht. Om de geboorte van een kind met CF te voorkomen hebben de meeste ouders 
besloten geen kinderen meer te krijgen of gebruik te maken van reproductieve mogelijkheden, 
zoals prenatale diagnostiek. Prenatale diagnostiek werd gebruikt door 72% van de ouders en 
76% van ouders met kinderwens gaf aan van deze mogelijkheid gebruik te willen maken. Het 
voornemen van ouders om bij een volgende zwangerschap gebruik te maken van prenatale 
diagnostiek was gerelateerd aan de mate van religieuze overtuiging en was niet gerelateerd aan 
de ervaren ernst van de ziekte, de gezondheid van het kind met CF of toekomstverwachtingen 
wat betreft therapeutische mogelijkheden. Zowel ouders als volwassen CF patiënten waren 
meer terughoudend wat betreft het aborteren voor CF. De meerderheid van de ouders en 
volwassen patiënten steunden het dragerschaponderzoek binnen CF families. In het algemeen 
suggereren de resultaten dat ouders van kinderen met CF en volwassen patiënten, de 
reproductieve beslissingen van dragerparen die gevonden worden in screeningsprogramma’s 
zullen accepteren.  
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Persoonlijke ervaringen van CF dragerparen 
De ervaringen van CF dragerparen met de dragerschaptest en de invloed van het gevonden 
verhoogde risico op de beslissingen rond het krijgen van kinderen zijn beschreven met behulp 
van interviews met dragerparen die gevonden zijn binnen CF families en zelf geen kind met CF 
hebben. Van de 12 paren die gevonden zijn voor 1997 hebben 7 paren deelgenomen aan semi-
gestructureerde interviews en twee paren hebben een vragenlijst ingevuld. Het onderzoek werd 
twee tot acht jaar na het verkrijgen van de testuitslag uitgevoerd. De belangrijkste beslissing 
zich te laten testen was het verkrijgen van zekerheid. Bij twee paren twijfelde de huisarts aan 
het nut van de test. Na het horen van de uitslag rapporteerden de meeste paren dat zij erg 
geschrokken waren van de uitslag. De schok was groter voor vier paren die zwanger waren 
tijdens het doen van de test. Er werden problemen gerapporteerd met het verstrekken van 
informatie aan familieleden en de reacties van familieleden waren niet altijd ondersteunend. Na 
de test hadden vier paren problemen met het nemen van beslissingen rond het al dan niet 
krijgen van kinderen en het gebruik maken van prenatale diagnostiek. Vier paren die kinderen 
kregen na de test rapporteerden dat zij zich zorgen maakten over de juistheid van de resultaten 
van de prenatale diagnostiek. De meeste paren hadden geen spijt van de test en in het algemeen 
werd de counseling als zeer positief ervaren, hoewel er door vijf paren enige ontevredenheid 
gerapporteerd werd wat betreft (het ontbreken van) psychologische begeleiding tijdens de 
zwangerschap. Hoewel dragerparen het idee steunen om alle paren met kinderwens 
dragerschapscreening aan te bieden, werden verschillende bezwaren genoemd, zoals de 
moeilijke beslissingen die men zou moeten maken en het feit dat deelname aan screening niet 
kan garanderen dat het kind gezond is. 
 
Conclusies 
De screening studie, zoals beschreven in dit proefschrift, geeft inzicht in de wenselijkheid en 
haalbaarheid van preconceptionele screening op dragerschap van mutaties in het cystic fibrosis 
gen in Nederland. Daarbij is aangetoond dat CF dragerschapscreening bij paren met 
kinderwens mogelijk is. Dit blijkt uit de acceptatie van het aanbod van screening, de 
bereikbaarheid van de doelgroep, de praktische uitvoerbaarheid en de tevredenheid van de 
deelnemers. De resultaten van het onderzoek geven aanleiding tot het doen van een volgende 
stap; namelijk nagaan of de implementatie van preconceptionele screening op grotere schaal 
ook mogelijk is en wat de beste manier is om het screeningsprogramma te introduceren in 
Nederland. 
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Ik dacht: ik doe het gewoon. 
 
Maar zo gewoon was het helemaal niet! Het werd in alle opzichten een uitdaging en ik heb zoveel 
geleerd, haast jammer dat het voorbij is. In de loop van de tijd werd het ook wel duidelijk dat niet 
‘ik promoveer’ maar ‘wij promoveren’, en in gedachten werd het hoofdstuk Dankwoord steeds 
langer. Ik probeer het toch kort te houden.  
 
Ik denk dat het in de eerste plaats komt door mijn promotor, Leo ten Kate, dat alles zo prima is 
gegaan. Beste Leo, je bent voor mij een zeer belangrijke en kritische leermeester geweest in al 
die jaren. En hoewel je ideeën en tijdsplanning soms nóg optimistischer waren dan de mijne, 
moet ik zeggen dat je me daarmee zeker gestimuleerd hebt in het bolwerken van dit project. En 
waarschijnlijk komt het door onze roots (jij Groninger en ik Zeeuw) dat we elkaar prima 
verstaan.  
 
Hooggeleerde promotor van der Ploeg, beste Henk. Bedankt voor de gesprekken die we hebben 
gehad. Je had niet alleen oog voor het onderzoek, maar ook voor allerlei andere zaken die bij het 
promoveren komen kijken en die ik bijna zou vergeten.  
 
Inge Bramsen, ik vond het bijzonder prettig om samen met jou de stof te structuren. Je hebt me 
af en toe duidelijk op het juiste spoor weten te zetten. Heel erg bedankt! 
 
Ik wil alle deelnemers in de verschillende studies bedanken voor de moeite die zij hebben 
genomen om de vragenlijsten in te vullen of mee te werken aan de interviews. Zonder hen geen 
onderzoek. De medewerkers van de Nederlandse Cystic Fibrosis Stichting dank ik voor hun 
advies en betrokkenheid bij het onderzoek.  
 
Alle deelnemende huisartsen, en in het bijzonder de huisartsen van Uithoorn, wil ik hartelijk 
danken voor hun inzet. De GGD Amstelland- de Meerlanden dank ik voor de medewerking en 
voor het beschikbaar stellen van ruimtes voor het ‘stickeren’. Manita van Acker en Jolanda ten 
Brinke dank ik in het bijzonder. Jullie kunnen vast geen etiket meer zien! 
 
De leden van de begeleidingscommissie Herman Adèr en Henriëtte van der Horst wil ik 
bedanken voor de hulp bij de analyses en commentaar op de manuscripten.  
Loes Kooij, je inzet is uiteindelijk niet voor niets geweest, Bedankt! 
 
Gerard Pals, Hans Gille en andere medewerkers van VUmc DNA- en eiwitdiagnostiek dank ik 
voor alle hulp bij de uitvoering van de CF-testen en het beschikbaar stellen van het lab. Hans, 
dank voor je geduld, vooral het eerste jaar dat ik het lab onveilig maakte door zelf de analyses 
te doen. Ik zal nooit meer met een pipet over de gang zwaaien. Linda van Kempen, de 
mondspoelsels zijn voornamelijk door jou getest en je hebt daarvoor hard en accuraat gewerkt. 
Zonder jou was het allemaal niet gelukt! 
 
De (ex-)medewerkers van de afdeling klinische genetica en antropogenetica (Marieke, Francis, 
Charlotte, Martina, Agnies, JM, Theo, Maureen, Henri, Johan, et al.) wil ik danken voor de 
prettige werksfeer en natuurlijk vooral voor de gezelligheid. Ik ben de afgelopen jaren zeven 
keer van werkplek verhuisd. Voordeel is wel dat ik beide overkanten gezien heb en daardoor 
veel wandelgangen en collega’s heb gekregen. Een nadeel is wel dat velen nog steeds een doos 
of wat van mij in bewaring hebben (niks weggooien hoor!).  
 
All-round Ilse Mooij, je bent echt van goud! 
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Ik kwam en kom ook geregeld bij het EMGO, en wil daarom alle medewerkers en medecollega’s 
heel hartelijk bedanken voor de praatjes, discussies, borrels, dagjes-uit, financiële afhandelingen, 
pennen, computer-reparaties, etc. Mijn nieuwe baan bij de Sociale Geneeskunde is inmiddels in 
volle gang en daar heb ik het prima naar mijn zin! 
 
Ik heb veel zogenaamde ‘knip en plak steun’ gehad: assistenten, studenten, secretaresses, 
drukkers, en de jongens CDF. Het worden te veel namen om jullie allemaal te noemen. 
Daarom:…dank je wel!  
 
Iedereen die de moed heeft gehad bij mij in de bestelwagen te stappen om vervolgens de 
lieftallige assistente te zijn op de voorlichtingsavonden: bedankt, jullie zijn vreselijk dapper! 
 
Lieve Miranda en Anita, dank voor het aanhoren van het (jullie welbekende) aio-gezemel, ik 
stel voor dat we nu toch echt eens naar Emmen gaan. Antoine regelt het. 
 
Verder dank aan alle vrienden en vriendinnen voor jullie interesse in het onderzoek, de 
uitstapjes en afleiding. En sorry dat ik niet altijd lang kon blijven of de baby nog steeds niet 
heb bewonderd. Het gaat allemaal gebeuren (ja, ik kom ook voor je vakantiedia’s, de 
vastenavend, en de nieuwe dakkapel). 
 
Mijn lieve nymfen Guus en Arlette. Bij jullie vond ik alles wat ik nodig had: peptalk, etentjes 
met knoflook en wijn, films, veel lol en gezellige weekenden. Jullie zijn echt superwomen! 
 
Donald en Ineke (mijn pake en moeke), Sjoerd, Nancy en Aukje. Met jullie is het altijd lachen 
geblazen, vooral in en om het strandhuisje. Van je familie moet je het duidelijk hebben. 
 
En natuurlijk de oma’s, fijn dat jullie er zijn en dank voor jullie genen! 
 
Quinten, je bent mijn ticket to the tropics! Wat kan ik nou nog anders zeggen dan: LET’S GO ! 
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